Biomira zweiter Anlauf mit den biotherapeutischer Impfstoff BLP25 - 500 Beiträge pro Seite (Seite 6)

[versager69]

Antwort auf Beitrag Nr.: 22.166.578 von freetibet am 18.06.06 10:50:36

#2500

[philippf]

Biomira to explore pipeline development


NEW YORK (AFX) - Biomira Inc., (Nachrichten) a Canadian biotechnology company specializing in cancer treatments, said Tuesday it hired investment bank Janney Montgomery Scott to help explore its pipeline development options.

Terms of the agreement were not disclosed.

Biomira said it is making the move now that German-based Merck KGaA has taken over the Phase III study program for its Stimuvax cancer vaccine product, clearing the way for the company to seek out other opportunities.

Janney will be responsible for identifying in-licensing and acquisition opportunities and resources for targeted therapeutics. Biomira said it wants to focus on oncology products, and is looking for mid-stage drugs with option rights or a license to earlier-stage product candidates.

'Our goal is to complete our due diligence in the next few months and then be able to discuss our expanded pipeline more fully,' Biomira interim President and Chief Executive Edward Taylor said in a statement.

Biomira closed Monday at $1.07 on the Nasdaq.


Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

[philippf]

Biomira Retains Janney Montgomery Scott to Explore Pipeline Development Options



EDMONTON, June 20 /PRNewswire-FirstCall/ -- Biomira Inc. (Nachrichten) (TSX: BRA) today announced that it has retained Janney Montgomery Scott to help the Company explore pipeline development options.

Janney will work with Biomira to identify in-licensing and acquisition opportunities that are a natural fit with the Company's core competencies and resources in the development of innovative, targeted therapeutics that extend the quality and duration of patients' lives. Biomira is seeking mid-stage products with good safety and efficacy data, and option rights to or license earlier stage product candidates. The immediate focus is on oncology products.

In January, Biomira announced that its partner Merck KGaA of Darmstadt, Germany, would take full control of the phase 3 study program for its lead cancer vaccine product, Stimuvax(R) (formerly L-BLP25) with effect from March 1. Without the costs and risks associated with the future development of Stimuvax(R), Biomira's resources will now be deployed on the development of the follow-on vaccine L-BGLP40 and on other late pre-clinical and clinical product candidates to be acquired through in-licensing.

"With the phase 3 development program for Stimuvax(R) now being led by Merck KGaA, we are focusing our efforts and resources on building a comprehensive and diversified pipeline that will take advantage of our product development and clinical trial expertise," said Edward Taylor, Biomira's interim President and CEO. "Janney has extensive experience and understanding of the biotechnology space and has already started to identify promising opportunities for Biomira, which we are actively exploring. Our goal is to complete our due diligence in the next few months and then be able to discuss our expanded pipeline more fully. We look forward to updating the market on our progress in due course."

Stephen Hurly, Managing Director and Head of the Life Sciences Group at Janney, commented, "Biomira has strong proprietary immunology and organic chemistry technologies as well as excellent research, development, regulatory and clinical expertise which we believe make it an attractive partner for many other companies and products. We look forward to assisting Biomira with the important task of developing a high quality pipeline to complement its leading position in the cancer vaccine field."

[freetibet]

Merck KGaA: Entwicklung von Parkinson-Arzneimittel Sarizotan wird nicht weiter verfolgt
Westerburg, 23. Juni 2006 (aktiencheck.de AG) - Der Pharmakonzern Merck KGaA (ISIN DE0006599905/ WKN 659990)

Westerburg, 23. Juni 2006 (aktiencheck.de AG) - Der Pharmakonzern Merck KGaA (ISIN DE0006599905/ WKN 659990) teilte am Freitag mit, dass er nach Auswertung klinischer Studien der Phase III beschlossen hat, keinen Antrag auf Zulassung des Arzneimittels Sarizotan für die Indikation Dyskinesien bei fortgeschrittener Parkinson-Erkrankung einzureichen.

Wie der Konzern weiter bekant gab, haben die Studien (PADDY-1 und PADDY-2) die Ergebnisse aus Phase II bzw. präklinischer Studien nicht bestätigt. Vor diesem Hintergrund wurde entschieden, die Entwicklung von Sarizotan nicht weiter zu verfolgen.


Merck wird jetzt tierisch unter Druck stehen.
Hoffentlich gut für uns.

[donnerpower]

Merck Kgaa Artikel (23.06.06

http://www.pharmatimes.com/news/9100-Merck-KGaA-sarizotan.as…

The decision leaves a hole in Merck's near-term pipeline as sarizotan was one of just two new drugs in later-stage testing at the company, the other being cancer vaccine Stimuvax, which it acquired from Biomira earlier this year. The latter product is just starting a Phase III programme.

[freetibet]

Auf Hawaii wäre ich jetzt auch gern.

http://cancerconferences.com/conferences/thoracic/lcc/agenda…

11:45 AM betrifft uns.

[BULLE2004]

Ist eigentlich jemand noch investiert.
Charttechnisch ist der Weg nach unten absolut frei.

[freetibet]

http://www.primabiomed.com.au/projects/prodDocuments/Milesto…

[peter47]

Antwort auf Beitrag Nr.: 22.325.589 von BULLE2004 am 28.06.06 21:59:49

@All
Lebt ihr eigendlich noch???
Fragender Gruß Peter

[verdi2003]

Antwort auf Beitrag Nr.: 22.535.524 von peter47 am 12.07.06 07:24:13

Hallo Peter,

aber klar doch, mind. sind mehr als die Hälfte von uns noch am Leben

Grüße
verdi

[peter47]

Antwort auf Beitrag Nr.: 22.536.792 von verdi2003 am 12.07.06 09:19:34

@Verdi
ES LEBT !!!!!
VG Peter

[donnerpower]

Antwort auf Beitrag Nr.: 22.535.524 von peter47 am 12.07.06 07:24:13

Wir warten alle vor dem Sturm!

Jetzt kann es jeden Tag los gehen


Gruss

[peter47]

Antwort auf Beitrag Nr.: 22.551.663 von donnerpower am 12.07.06 22:22:39

Hi Donner
Heute knacken wir wohl die 1$ Marke
VG Peter

[freetibet]

Antwort auf Beitrag Nr.: 22.593.813 von peter47 am 14.07.06 16:30:14

@peter47
Warum so nervös? Das hatten wir doch schon mal.

Lt. yahoo-board sollen die nächsten Nachrichten
bezgl. Ph III erst im September kommen.

Schönes Wochenende !

[peter47]

Antwort auf Beitrag Nr.: 22.595.170 von freetibet am 14.07.06 17:29:41

@Free
Ich nixe nervös Nur leider im Mom net flüssig genung, um nachzukaufen
Schönes Wochenende

[BULLE2004]

Bei gutem Börsenumfeld gewinnt die Aktie nichts und bei schlechtem Umfeld verliert die Aktie überproportional!!
Meiner Meinung nach (leider) ein Finger weg von dieser Aktie da
ein Totalverlust möglich ist.

[wayne99]

Press Release Source: Biomira Inc.


Biomira Stimuvax(R) (L-BLP25) Prostate Cancer Study Results Published
Thursday July 20, 6:00 am ET


EDMONTON, July 20 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq Global Market:BIOM) (TSX:BRA - News), today announced publication of study results showing that Stimuvax®, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients, potentially delaying the need for initiation of androgen deprivation therapy (ADT). The study results were described in an article entitled "A Pilot Study of the Liposomal MUC1 vaccine BLP25 in Prostate Specific Antigen Failures After Radical Prostatectomy" that appears in the July 2006 issue of the Journal of Urology. PSA is a tumour marker used by physicians to detect prostate cancer, monitor treatment effects and guide medical management of men with this disease, rising levels being predictive of relapse and disease progression.
ADVERTISEMENT


The open-label phase 2 safety and efficacy trial, conducted at the Cross Cancer Institute in Edmonton, Alberta, enrolled 16 post-radical prostatectomy patients. Patients enrolled in the trial had undergone this surgery at least six months prior to study entry, but experienced rising PSA levels post-surgery, final measurements having increased at least 50 per cent above the lowest post-surgical level. The primary study endpoint was to determine if Stimuvax® could stabilize or decrease serum PSA in these men; secondary endpoints included safety and immune response measurements. Study treatment consisted of a primary and maintenance phase.

The primary treatment phase included a single dose of cyclophosphamide, used as an immunomodulator to enhance the potential activity of Stimuvax®, followed three days later by the first of eight weekly vaccinations. The maintenance phase followed, with the administration of vaccinations every six weeks for a maximum total of 15 doses over approximately one year.

While no decreases in PSA occurred during the study period, PSA stabilization occurred in 50 percent of patients at the end of the primary treatment phase, and was maintained in one patient at the end of the study. Another interesting outcome was a noted increase in the PSA doubling time, which was prolonged by more than 50 per cent in six men at the end of the trial, compared with the doubling time prior to vaccine treatment. These observations, along with favorable safety data, led the study's authors to conclude that immunotherapy with Stimuvax® may "impart a positive effect on the population tested", warranting further testing in controlled studies in a larger patient population. Dr. Scott A. North, the study's principle investigator, said, "Many men are placed on ADT, a therapy with significant side effects based on some pre-defined PSA level. Delaying the time to PSA level doubling may defer initiation of this treatment and spare patients the negative impact of the only therapy available to them for a longer period of time." He further commented that, "Since men with a longer PSA doubling time can expect longer survival than those with shorter times, a strategy to lengthen the time to doubling may favorably impact the disease."

PSA doubling time is defined as the time it takes for the PSA value to double. This is used to help predict the possibility of metastasis and make treatment options.

Biomira's interim president and CEO Edward Taylor, commenting on the paper's publication, said, "While we are not currently pursuing a prostate cancer application for Stimuvax®, the acceptance and publication of these clinical trial results in a leading medical journal support the potential value of cancer vaccine approaches to patients with few therapeutic options and our future plans for this product candidate, which include an upcoming phase 3 study in non-small cell lung cancer."

About Prostate Cancer

---------------------

The American Cancer Society states that prostate cancer is the most common type of cancer found in American men, other than skin cancer. The Society estimates that there will be about 234,460 new cases of prostate cancer in the United States in 2006. About 27,350 men will die of this disease. Prostate cancer is the third leading cause of cancer death in men, after lung cancer and colorectal cancer.

Stimuvax®

-----------

Formerly known as BLP25 Liposome Vaccine (L-BLP25), Stimuvax® is a synthetic MUC1 peptide vaccine. Stimuvax® incorporates a 25-amino acid sequence of the MUC1 cancer mucin, encapsulated in a liposomal delivery system. The liposome enhances recognition of the cancer antigen by the immune system and facilitates better delivery. Stimuvax® is designed to induce an immune response to cancer cells.

About Biomira

-------------

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.

Except for historical information contained herein, this release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include the risk that additional trials may not demonstrate the safety and efficacy required to satisfy the regulatory authorities; and dependence on the efforts of third parties, including suppliers and collaborators; dependence on intellectual property rights and the effectiveness thereof. The Company assumes no obligation to update any forward-looking statements.




--------------------------------------------------------------------------------
Source: Biomira Inc.

[wayne99]

6:05AM Biomira study shows Stimuvax could slow rising Prostate Specific Antigen levels in some post-surgical prostate cancer patients (BIOM) 0.97 :

Co announces announced publication of study results showing that Stimuvax could slow rising Prostate Specific Antigen levels in some post-surgical prostate cancer patients, potentially delaying the need for initiation of androgen deprivation therapy. P.S.A is a tumour marker used by physicians to detect prostate cancer, monitor treatment effects and guide medical management of men with this disease, rising levels being predictive of relapse and disease progression.

Briefing.com

[freetibet]

Antwort auf Beitrag Nr.: 22.805.970 von wayne99 am 20.07.06 13:25:40

Biomira Stimuvax (R) (L-BLP25) Prostatakrebs-Studie Resultate

veröffentlicht Donnerstag, die 20.,6. Juli: 00 morgens UND EDMONTON, 20. Juli /PRNewswire-FirstCall/ -

Biomira Inc. (Nasdaq globaler Markt: BIOM) (TSX: BRA - Nachrichten), die heute verkündete Publikation der Studie Resultate, die dieses Stimuvax®, früher bekannt als Impfstoff des Liposom-BLP25 oder L-BLP25 zeigen, konnten steigende Niveaus des Prostataspezifische Antigens (PSA) bei einigen postoperativen Prostatakrebspatienten verlangsamen, möglicherweise delaying die Notwendigkeit an der Einführung der Androgenentzugtherapie (ADT). Die Studie Resultate wurden in einem Artikel beschrieben, der „eine Versuchsstudie des liposomalen MUC1 Impfstoffs BLP25 Prostatain den spezifischen Antigen-Ausfällen nach radikalem Prostatectomy“ erlaubt wurde, der in der Juli 2006 Ausgabe des Journals von Urology erscheint. PSA ist eine Tumormarkierung, die von den ärzten benutzt wird, um Prostatakrebs, Monitorbehandlungeffekte zu ermitteln und medizinisches Management der Männer mit dieser Krankheit zu führen, die steigenden Niveaus, die vom Rückfall und von der Krankheitweiterentwicklung vorbestimmt sind. REKLAMEANZEIGE Der open-label Phase 2 Sicherheit und Wirksamkeitversuch, geleitet am Kreuzkrebs-Institut in Edmonton, Alberta, schrieb 16 Pfosten-radikale Prostatectomypatienten ein. Die Patienten, die im Versuch eingeschrieben wurden, hatten diese Chirurgie mindestens sechs Monate vor Studie Eintragung durchgemacht, aber steigende PSA Niveaus Pfostenchirurgie, die abschließenden Maße erfahren, die mindestens 50 Prozent über dem niedrigsten postoperativen Niveau erhöht wurden. Der Primärstudie Endpunkt war, festzustellen, wenn Stimuvax® Serum PSA in diesen Männern stabilisieren oder verringern könnte; Sekundärendpunkte schlossen Sicherheit und immunes Wartemaße ein. Studie Behandlung bestand aus einer Primär- und Wartung Phase. Die Primärbehandlungphase schloß ein Eindosen des Cyclophosphamids mit ein, verwendet als immunomodulator, die mögliche Tätigkeit von Stimuvax® zu erhöhen, folgte drei Tage später von der ersten von acht wöchentlichen Schutzimpfungen. Die Wartung Phase folgte, mit der Leitung von Schutzimpfungen alle sechs Wochen für eine Maximumgesamtmenge des überschusses mit 15 Dosen ungefähr ein Jahr. Während keine Abnahmen an PSA während der Studie Periode auftraten, trat PSA Ausgleichung in 50 Prozent Patienten am Ende der Primärbehandlungphase auf und wurde bei einem Patienten am Ende der Studie beibehalten. Ein anderes interessantes Resultat war eine notierte Zunahme des PSA Eilschritts, der durch mehr als 50 Prozent in sechs Männern am Ende des Versuches ausgedehnt wurde, verglichen mit dem Eilschritt vor vaccine Behandlung. Diese Beobachtungen, zusammen mit vorteilhaften Sicherheit Daten, führten die Autoren der Studie, festzustellen, daß Immunotherapy mit Stimuvax® „einen positiven Effekt auf die Bevölkerung zuteilen kann, die“ geprüft wird und in kontrollierten Studien in einer größeren geduldigen Bevölkerung weiter prüfen gewährleisten. Dr. Scott A. North, der Grundregelforscher der Studie, gesagt, „viele Männer werden auf ADT, eine Therapie mit den bedeutenden Nebenwirkungen gesetzt, die auf irgendeinem vorbestimmtem PSA Niveau basieren. Die Verzögerung der Zeit zur PSA Niveauverdoppelung kann Einführung dieser Behandlung und Ersatzpatienten aufschieben die negative Auswirkung der einzigen Therapie, die vorhanden ist zu ihnen während eines längeren Zeitabschnitts.“ Er kommentierte weiter, daß, „seit Männern mit einem längeren PSA Eilschritt längeres überleben als die mit kürzeren Zeiten erwarten kann, eine Strategie, um die Zeit zur Verdoppelung zu verlängern kann die Krankheit vorteilhaft auswirken.“ PSA Eilschritt wird definiert, wie die Zeit, die sie für den PSA Wert zum Doppelten dauert. Dieses wird verwendet, um zu helfen, die Möglichkeit von Metastasis vorauszusagen und Behandlungoptionen auszuüben. Präsident und CEO Edward Taylor Zwischenzeit Biomiras, kommentierend die Publikation des Papiers, sagten, „, während wir nicht z.Z. eine Prostatakrebsanwendung für Stimuvax® ausüben, die Annahme und Publikation dieser klinischen Proberesultate in einem führenden medizinischen Journal stützen den möglichen Wert der vaccine Annäherungen des Krebses zu den Patienten mit wenigen therapeutischen Wahlen und unseren zukünftigen Plänen für diesen Produktanwärter, die einschließen eine upcoming Phase 3 Studie im nicht-kleinen Zelle Lungenkrebs.“ Über Prostatakrebs --------------------- Die Amerikaner-Krebs-Gesellschaft gibt, daß Prostatakrebs die allgemeinste Art des Krebses gefunden in den amerikanischen Männern ist-, anders als Hautkrebs an. Die Gesellschaft schätzt, daß es ungefähr 234.460 neue Kästen Prostatakrebs in den Vereinigten Staaten 2006 gibt. Ungefähr 27.350 Männer sterben an dieser Krankheit. Prostatakrebs ist- die dritte führende Ursache des Krebstodes in den Männern, nach Lungenkrebs und colorectal Krebs. Stimuvax® ----------- Früher bekannt als Impfstoff des Liposom-BLP25 (L-BLP25), ist Stimuvax® ein synthetischer Impfstoff des Peptids MUC1. Stimuvax® enthält eine Reihenfolge der Aminosäure 25 des Krebs MUC1 mucin, eingekapselt in einem liposomalen Anlieferung System. Das Liposom erhöht Anerkennung des Krebsantigens durch das immune System und erleichtert bessere Anlieferung. Stimuvax® ist entworfen, um eine immune Antwort zu den Krebszellen zu verursachen. Über Biomira ------------- Biomira ist eine Biotechnologiefirma, die auf die Entwicklung der erfinderischen therapeutischen Annäherungen zum Krebsmanagement sich spezialisiert. Verpflichtung Biomiras gegenüber der Behandlung des Krebses konzentriert z.Z. auf die Entwicklung der synthetischen Impfstoffe und der Romanstrategien für Krebs Immunotherapy. Außer den historischen Informationen, die hierin enthalten werden, enthält diese Freigabe das Vorwärts-Schauen der Aussagen, die abhängig von Gefahren und Ungewißheiten sind, die tatsächliche Resultate veranlassen können, sich von den Resultaten materiell zu unterscheiden, die in den Vorwärts-schauenden Aussagen, besonders der Prozeß vom Entdecken besprochen werden und Drogen entwickeln und in den Handel bringen, die sicher und für Gebrauch als menschliche Therapeutik wirkungsvoll sind. Faktoren, die solch einen Unterschied verursachen können, schließen die Gefahr ein, daß zusätzliche Versuche möglicherweise nicht die Sicherheit und die Wirksamkeit zeigen können, die erfordert werden, um die Aufsichtsbehörden zu erfüllen; und Abhängigkeit auf den Bemühungen der dritten Parteien, einschließlich Lieferanten und Mitarbeiter; Abhängigkeit auf Rechten am geistigen Eigentum und der Wirksamkeit davon. Die Firma nimmt keine Verpflichtung an, alle mögliche Vorwärts-schauenden Aussagen zu aktualisieren. -------------------------------------------------------------------------------- Quelle: Biomira Inc.

[verdi2003]

hallo,
es hört sich gut an.
schön. wir haben geduld
schöne grüße an alle investierten!
verdi

[kurttilly]

... und schon steigt der Kurs in USA, die Umsätze ziehen an !!!!


Vielleicht kommt morgen bei uns auch Leben in die Bude; ich bin schon seit über 2 Jahren bei BIOM dabei: Lohnt sich das Warten???


mfg kurttilly

[freetibet]

Antwort auf Beitrag Nr.: 22.815.019 von kurttilly am 20.07.06 20:38:58

Das ist zwar eine gute Nachricht,
aber nicht DIE NACHRICHT !

Umsätze sind auch zu gering.
Der Kurs wird wieder absacken.

Ob sich das Warten für Dich lohnt weiß
ich nicht. Ich kann warten.

[MasaRatti]

Hallo,
melde mich nach einigen Monaten des Abwartens zurück - bin mal
unter 0,80 wieder mit an Bord !

Bis Ende August sind wir ja sicher mal wieder schlauer und Merck
rechnet ja bis Ende des Jahres mit dem Beginn der Phase III !

[kurttilly]

Hallo zusammen!

Wer ist denn auch noch in Biom investiert ???





http://www.finanznachrichten.de/nachrichten-2006-07/artikel-…



27.07.2006 12:04
Biomira Inc. Announces Second Quarter 2006 Results

EDMONTON, July 27 /PRNewswire-FirstCall/ -- Biomira Inc. (Nachrichten) (Nasdaq Global Market: BIOM) (TSX:BRA), a leading developer of innovative therapeutic approaches to cancer management, today reported financial results for the three and six months ended June 30, 2006.

"This has been a solid quarter for Biomira, with our lead product Stimuvax(R) continuing to make important progress toward the start of a phase 3 trial," said Edward Taylor, Biomira's interim President and CEO. "With Merck's greater involvement, we have turned our attention to bolstering the pipeline of products between Stimuvax(R) and BGLP40 Liposomal Vaccine (L-BGLP40) and we have already seen a number of promising opportunities, which would benefit from Biomira's expertise in moving products through all stages of development. We have also made cost containment a priority as we seek to maximize and reallocate our resources in the most appropriate fashion. We look forward to further significant product news in the second half of the year."Second Quarter Highlights - Lead cancer vaccine Stimuvax(R) is on track to enroll the first patient in a large, multi-national phase 3 trial in non-small cell lung cancer (NSCLC) by the end of the year. Biomira is finalizing the amendments to the existing supply and collaboration agreements with Merck KGaA of Darmstadt, Germany (Merck) for the future clinical development of Stimuvax(R). Merck and Biomira are in the process of preparing the protocol to commence a large scale trial that will likely involve approximately 1300 men and women with Stage III cancer in approximately 30 countries and 250 clinical trial sites. - In May, the Company announced that Dr. Alex McPherson would step down as President and CEO after a 15 year tenure. His position has been taken on an interim basis by Edward Taylor, the Company's Chief Financial Officer and Vice President, Finance and Administration. Dr. McPherson subsequently stepped down from the Board of Directors after 19 years of service. Mr. Taylor was also appointed to the Board of Directors. The Company is in the process of seeking a new President and CEO and potentially looking for new Board members with skills that would complement the current Board. While this can be a lengthy process, the Company has developed a strategic direction for moving forward, with the support of the Board of Directors. - In June, Biomira announced that it had retained Janney Montgomery Scott LLC (Janney) to help the Company explore pipeline development options. Janney is working with Biomira to identify in-licensing and acquisition opportunities that are a natural fit with the Company's core competencies and resources in the development of innovative, targeted therapeutics that extend the quality and duration of patients' lives. Biomira is seeking mid-stage products with good safety and efficacy data, and potentially option or licensing rights to earlier stage product candidates. The immediate focus is on oncology products. - The Journal of Urology recently published study results showing that Stimuvax(R) could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients, potentially delaying the need for initiation of androgen deprivation therapy (ADT). The study results were described in an article entitled "A Pilot Study of the Liposomal MUC1 vaccine BLP25 in Prostate Specific Antigen Failures After Radical Prostatectomy." PSA is a tumour marker used by physicians to detect prostate cancer, monitor treatment effects and guide medical management of men with this disease, rising levels being predictive of relapse and disease progression. The acceptance and publication of these clinical trial results in a leading medical journal support the potential value of cancer vaccine approaches to patients with few therapeutic options and our future plans for this product candidate, which include the upcoming phase 3 study in NSCLC. - Biomira's Synthetic Biologics Business Unit (SBBU) is in discussions with several companies, which are now performing due diligence on the synthetic adjuvants and compounds developed by the SBBU. The Company hopes to begin finalizing agreements in the coming year. - In May, Prima BioMed announced favourable results from its phase 2a study in ovarian cancer. Our agreement with Prima BioMed provides that we have the sole option to elect to either license the exclusive worldwide commercialization rights (excluding Asia, Australia and New Zealand), or only the North American region, for this product candidate, following conclusion of the phase 2a trial in ovarian cancer, or an option to simply maintain the current license that grants certain rights to Biomira technology to Prima BioMed. We will make that election following our review of the phase 2a clinical trial data later this year. - Pre-clinical work continues on the Company's third-generation product candidate, L-BGLP40. We believe the pre-clinical work will warrant moving into clinical trials in 2007 and we hope to find a partner to take over the clinical development in the coming year. Financial Update

Financial results for the six months ended June 30, 2006 reflect a consolidated net loss from operations of $9.8 million or $0.11 per share compared to $9.2 million or $0.12 per share for the same period in 2005. The increased net loss of $0.6 million in 2006 arises from lower revenues of $0.4 million, reduced investment and other income of $0.4 million and higher general and administrative expenses of $1.0 million, partially offset by decreased research and development expenditures of $0.9 million and marketing and business development expenses of $0.3 million. The increased net loss primarily relates to workforce reduction and exiting costs incurred in the first half of 2006, partially offset by a deferral of Stimuvax(R) manufacturing costs incurred in preparation for the planned Merck-led phase 3 trial in NSCLC expected to commence by the end of the year, and reduced clinical expenditures in anticipation of finalizing the amendments to the existing supply and collaboration agreements with Merck for the future clinical development of Stimuvax(R).

As at June 30, 2006, our cash and cash equivalents and short-term investments were $28.7 million compared to $21.4 million at the end of 2005, an increase of $7.3 million or 34%.

For a further discussion of the Company's financial results for the six months ended June 30, 2006, please refer to the Company's unaudited consolidated financial statements and the Company's Management Discussion&Analysis of Financial Condition and Results of Operations included in this report.

Biomira Inc.

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM).


mfg

kurttilly

[donnerpower]

Antwort auf Beitrag Nr.: 23.118.220 von kurttilly am 27.07.06 18:33:48

...Ich denke alle noch!

Das Spiel hatten wir schon mal..mit wenig Shares unter 1$ und dann mit der Blp25 News auf über 4$!

Geduld es kann sich nur noch um ein paar Wochen handeln..wo es in der Phase3 geht!


Fakt:Wer jetzt Aussteigt dem ist nicht mehr zu helfen!

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.206.680 von donnerpower am 29.07.06 14:03:47

...ach Donner du bist ein Träumer. Wer Börsenerfahrung hat, ist längst raus. Die, welche noch keine ausreichende Erfahrung haben, sammeln diese gerade.




Gruß Andreas

[BULLE2004]

Antwort auf Beitrag Nr.: 23.296.815 von wirdschonwerden am 03.08.06 12:31:31

muss Dir recht geben, viele hartgesottene haben mehr als 60% verlust und einige hier meinen noch immer dass mit biomira was wird. 4 Dollar ist meimer meinung utopisch.

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.297.906 von BULLE2004 am 03.08.06 13:48:27

@Bulle2004,

nun, großen erfolg kann man nur haben, wenn alle anderen falsch liegen. aber ich bin, wie in meinem beitrag nr. 1844 beschrieben an diesem tag (fast)raus aus biomira. konnte mit einem anderen wert meine 11€ct verlust/aktie, welche durch das investment in biomira entstanden sind, kompensieren, so dass nun genug kleingeld übrig ist, wieder ein paaaar euronen in biomira zu investieren. die storry ist prinzipiell noch immer intakt.
ich denke, dass die aktionäre hier in diesem fall als geldbeschaffungsvieh benutzt werden...und das sehr erfolgreich.

[donnerpower]

@wirdschonwerden

Ich bin kein Träumer nur ein Realist wer keine Geduld hat wird auch an der Börse nichts erreichen...bisher habe ich mit Biomira gut verdient , natürlich immer wieder Stop Los gesetzt.Habe zur Zeit nur eine kleine Position werde aber nächste Woche "gross" ausbauen!

Was kann man aktuell Falsch machen??? Biomira geht in die 3Phase und die Shares werden mindestens 30-50% steigen! Sollte 2007-2008 BLP25 zugelassen werden,gibt es ein fröhlichen Aktionär mehr!

Jeder der seinen!

WER IST SCHON MERCK

@ll

HALTEN

[donnerpower]

4 Dollar ist meimer meinung utopisch.




Man sieht wieviel Ahnung du über BLP25 hast!

[peter47]

@All
Na endlich mal wieder ein paar Lebenszeichen hier
Das ist ein gutes Zeichen, das es wieder aufwärts geht
Werde heute auch mal auf Einkaufstour gehen
Schönes Wochenende
VG Peter

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.305.773 von donnerpower am 03.08.06 22:19:46

Guten Morgen an Donner und all die anderen

Ich bin kein Träumer nur ein Realist wer keine Geduld hat wird auch an der Börse nichts erreichen

Da bin ich voll bei dir...


...bisher habe ich mit Biomira gut verdient ,

dann hättest du den Nobelpreis verdient!


habe zur Zeit nur eine kleine Position werde aber nächste Woche "gross" ausbauen!

So kann man es auch sagen, bist du Politiker? Du bist also sogut wie raus!


Was kann man aktuell Falsch machen??? B

man kann alles verlieren (aber das Risiko ist ja allen bekannt)


Biomira geht in die 3Phase und die Shares werden mindestens 30-50% steigen!

Toll 30%? dann haste wieder fast 1,20€! Toll was für ein Gewinn? Spätestens dann werden die dir den Nobelpreis wieder wegnehemen. bitte meinen beitrag Nr. 1844 oder war es 1845? beachten)

Sollte 2007-2008 BLP25 zugelassen werden,gibt es ein fröhlichen Aktionär mehr!


stimmt nicht, mindestens 2, nämlich mich!


HALTEN

Nicht halten, KAUFEN!



Gruß und schönes WE

[donnerpower]

Antwort auf Beitrag Nr.: 23.313.281 von wirdschonwerden am 04.08.06 09:55:22

@wirdschonwerden

wirdschonwerden

[BULLE2004]

Antwort auf Beitrag Nr.: 23.319.751 von donnerpower am 04.08.06 17:23:33

jeden Tag ein paar Prozente im Minus.

aber es wird schon werden

Viel Glück den Investierten, ihr könnt es wirklich
brauchen.

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.361.247 von BULLE2004 am 08.08.06 22:19:26

...ja in wenigen wochen kann ich, wenn der kurs so weiter verfällt, die Aktienmehrheit aus der Kaffeekasse kaufen.
nein mal im ernst, der kursverlauf resultierend aus nachrichtenlage und geschäftsgebaren vor allem gegenüber den shareholders ist sehr bedenklich.... eine erfolgreiche entwicklung schaut anders aus. es muß personen geben, die eine mögliche positive bilanz der andauernden tests vorher wissen (Vorstand, ärzte, andere direkt beteiligte)
aber der abgabedruck hält unvermindert an.......




Andreas

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.366.664 von wirdschonwerden am 09.08.06 12:27:29

ähhhh ........ ich berichtige meine Aussage: wenn der kursverfall so weittergeht kann ich am ende der woche die mehrheit erwerben.

Andreas

[peter47]

Antwort auf Beitrag Nr.: 23.372.103 von wirdschonwerden am 09.08.06 17:50:36

@Andreas
Jetzt reicht bald das Klimpergeld in der Hosentasche
VG Peter der ein schönes Wochenende wünscht.

[verdi2003]

So kann weiter gehen

Willkommen die 3Phase!

Euch alle Investierten eine schöne und erfolgreiche Woche wünsche ich

verdi

[seppel]

So, jetzt mal jeden Tag schön 10% rauf und schon sind wir in 7 Handelstagen bei 2US$

[peter47]

Antwort auf Beitrag Nr.: 23.444.426 von seppel am 14.08.06 20:10:21

@All
Langsam mit den "jungen Pferden" wäre zwar schön, jeden Tag 10% mehr, nur das war doch KEIN Umsatz in den USA, da sind wieder meine "Freunde" die "Hardcorezocker am Werke
VG Peter

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.452.038 von peter47 am 15.08.06 11:10:23

hallo an alle,

nun mal langsam, eine Schwalbe macht noch keinen Frühling!!! das ist nur die nächste Korrektur im Abwärtstrend......mehr nicht




Gruß Andreas, (den Finger in der Wunde, das Salz in der Hand)

[kurttilly]

... es tut sich was:


Eröffnung:0,93
Tageshoch/-tief:1,05 / 0,93
52W-hoch/-tief:2,00 / 0,85
Schlußkurs von:17.08.2006 1,05


gibt´s was neues????


mfg kurttilly

[kurttilly]

was war das vorhin eine Anzeige bei W???


jetzt wieder:

Eröffnung:0,93
Tageshoch/-tief: 1,00 / 0,93
52W-hoch/-tief:2,00 / 0,85
Schlußkurs von: 17.08.2006 02:00

gruß kurttilly

[wirdschonwerden]

oha,

was ist denn hier los? 4 tage in folge ohne verlusste? da muß wohl die übernahme noch etwas warten


Andreas

[BIOMIRA]

steigt ohne news ?
sieger an der börse ist der....der ohne nerven ständig ein kaufsystem hat.
tödlich ist ein blockinvest
ein kaufsystem ist genial

[BIOMIRA]

steigt weiter ohne news

nun ja, dann gebt gas da drüben

[seppel]

Haut doch ganz gut hin mit den täglichen 10% Da muss ich doch glatt mal ausrechnen, wann wir die 10US$ holen werden

@biomira: Gib uns doch mal ein paar Infos zu deinem Kaufsystem

[philippf]

Antwort auf Beitrag Nr.: 23.561.416 von seppel am 22.08.06 16:45:53

okay, irgendwer ne idee, was hier plötzlich los ist???

[verdi2003]

Antwort auf Beitrag Nr.: 23.561.695 von philippf am 22.08.06 16:59:25

hallo,

am besten die beiträgen von letzten wochen lesen, dann wüsst ihr weshalb der kurs steig.
es wurde auch zeit.
die positive nachrichten kommen auch bald.

viele grüße
verdi

[peter47]

Antwort auf Beitrag Nr.: 23.560.817 von BIOMIRA am 22.08.06 16:13:43

nun ja, dann gebt gas da drüben
Na, gestern haben die Amis wenigstens mal ein wenig aufs Gas gedrückt
VG Peter

[MasaRatti]

Hi Leute,

kommt gut, wie gesagt Ende August

[yoppu]

die Umsätze ziehen auch langsam an.
Allerdings ist gerade da noch viel Luft nach oben!
10$ will ich sehen!

[seppel]

Bei 10% jeden Tag sind wir bald alle gaaaaaaaaant reich *hehe*



Sind doch nur noch 30 Handelstage bis zu den 20 US$

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.575.566 von seppel am 23.08.06 12:16:45

Hallo seppel arbeitest du bei der BILD- Zeitung?


Andreas

[seppel]

Hallo Andreas,

noch nicht, aber ne gute Idee.

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.580.054 von seppel am 23.08.06 16:29:00

wenn deine vorhersage eintrifft, ernenne ich dich zum börsenseniorgott.

[BIOMIRA]

das kaufsystem ist so einfach wie die börse

suche die ANGST der marktteilnehmer und kaufe den ANGSTAHSEN die teile ab.
wichtig ist, dass es keine KLITSCHE ist.

ich habe jeden monat ca. 1000 E in BIOM investiert ohne dabei mit der wimper zu zucken.

fallende kurse sind dabei ein geschenk.

bei 10E wird verkauft

[BIOMIRA]

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.585.151 von BIOMIRA am 23.08.06 21:56:10

Hallo BIOMIRA,

deine Erkenntnisse sind mindestens so alt wie die Börse! Das Problem an der Sache ist die Phsyche der Teilnehemer. Es ist halt schwierig gegen den Strom zu schwimmen und sein sauer verdientes Geld in jeden Tag fallende Kurse hineinzuinvestieren.

Aber was sollen uns die Aufzeichnungen bzw. Abbildungen der tektonischen Bewegungen der Erdkruste sagen?In welchem Zusammenhang stehen diese zu Börse? oder sind das Gehirnaktivitäten wärend eines Geschlechtsaktes?

Gruß an alle, Andreas

[BIOMIRA]

Antwort auf Beitrag Nr.: 23.589.378 von wirdschonwerden am 24.08.06 09:56:35

gehirn an der börse ist SCHÄDLICH
ein AFFE zum beispiel, kauft zu tiefen kursen, da er es billig findet
ein dummes SCHAF kauft immer
ein schlauer FUCHS kauft ---->NIE ,da er den optimalen kaufpunkt erwischen will und DIESEN nicht findet.

daher nicht zu viel DENKEN, immer nachkaufen, wenn man denkt----die anderen retten ihr geld

beispiel ALLIANZ bei 40 E, weltuntergangsstimmung im jahr 2003, monat märz

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.603.504 von BIOMIRA am 24.08.06 21:59:23

Morgen BIOMIRA,

jetzt, da ich deinen beitrag gelesen habe, bin ich restlos wach und habe wieder lebensmut gefasst. ich dachte bis dato mein gehirn/persönlichkeit ist durch die börse geschädigt....aber nun.

aber ich kann dir trotzdem trost spenden: nichts ist so krank, das es nicht wenigstens als abschreckendes beispiel genutzt werden kann


zitat:

gehirn an der börse ist SCHÄDLICH und
ein AFFE zum beispiel, kauft zu tiefen kursen,


ohne Worte

[verdi2003]

Nachricht vom 29.08.2006 | 12:10 57 mal gelesen

Merck KGaA investiert 190 Mio. Euro in neue biopharmazeutische Anlage
Darmstadt (aktiencheck.de AG) - Der Pharmakonzern Merck KGaA (ISIN DE0006599905/ WKN 659990) will an seinem
Leser des Artikels: 57


Darmstadt (aktiencheck.de AG) - Der Pharmakonzern Merck KGaA (ISIN DE0006599905/ WKN 659990) will an seinem Hauptsitz in Darmstadt eine biopharmazeutische Produktionsanlage errichten. Dies teilte der im MDAX notierte Konzern am Dienstag mit.

Private Equity
Investieren wie die Profis und bis zu 12% Rendite pro Jahr sichern - Info hier!Steuervorteil Rürup Rente
Sichere Rente mit Steuervorteil für Selbstständige. Hier gratis Angebot!Private Krankenversicherung
Leistungen hier kostenlos vergleichen und in einen günstigeren Tarif wechseln!
In der neuen Anlage soll die neueste Generation biologischer Wirkstoffe zur Krebsbehandlung hergestellt werden. Die Produktion soll voraussichtlich im Jahr 2010 beginnen. Hauptprodukt der neuen Anlage wird zunächst der monoklonale Antikörper Erbitux (Cetuximab) zur Behandlung von Darm-, Kopf- und Halskrebs sein. Insgesamt sollen rund 190 neue hoch qualifizierte Arbeitsplätze entstehen. Das Investitionsvolumen wurde auf rund 190 Mio. Euro beziffert.

Die Aktie von Merck KGaA notiert aktuell mit einem Minus von 0,08 Prozent bei 76,65 Euro. (29.08.2006/ac/n/d)


Wertpapiere des Artikels:
Merck KGaA

[freetibet]

Biomira Appoints Robert Kirkman President and CEO
Wednesday August 30, 8:00 am ET
Christopher Henney Named Chairman


EDMONTON, Aug. 30 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced the appointment of Robert L. Kirkman, MD, as President and Chief Executive Officer. Dr. Kirkman was also elected to the Board of Directors. In addition, the Company announced that Christopher Henney, PhD, has been named Chairman of the Board. Drs. Kirkman and Henney will commence their duties on September 5, 2006.

Dr. Kirkman was formerly Acting President and CEO of Xcyte Therapies, Inc of Seattle, WA, which concluded a merger with Cyclacel Pharmaceuticals, Inc., in March 2006. From 2004-2005, Dr. Kirkman was Chief Business Officer and Vice President at Xcyte, where he played a significant role in the Company's initial public offering and led business development and strategic planning activities.

From 1998 to 2003, Dr. Kirkman was Vice President, Business Development and Corporate Communications at Protein Design Labs, where he had a broad range of responsibilities, including expansion of PDL's pipeline through in-licensing, mergers and acquisitions. From 1981 to 1998, Dr. Kirkman worked at the Brigham and Women's Hospital in Boston, MA as a surgeon and subsequently as Chief, Division of Transplantation. His research demonstrating that antibodies directed against the IL-2 receptor would prolong allograft survival was instrumental in the approval of Zenapax® for the prevention of renal transplant rejection. Dr. Kirkman has a BA in Economics from Yale University and an MD from Harvard Medical School.

Dr. Christopher Henney has been elected Chairman of Biomira. Dr. Henney joined the Board of Directors in March 2005 and is the co-founder of three major publicly-traded U.S. biotech companies, Immunex, ICOS and Dendreon. Dr. Henney was Chairman and CEO of Dendreon from 1995 to 2004. He is Chairman of SGX Pharmaceuticals and Vice-Chairman of Cyclacel Pharmaceuticals. He has a PhD in experimental pathology from the University of Birmingham, England.

Biomira also announced that Robert Blair has been reappointed to the Board of Directors. "We are glad that Bob Blair has agreed to give us the benefit of his long experience as a prior member of Biomira's Board," said Dr. Henney.

"I am very pleased to be joining Biomira at this exciting time in the evolution of the Company," said Dr. Kirkman. "With the responsibility for the future clinical development of Biomira's lead cancer vaccine, Stimuvax®, now in the hands of our collaborator, Merck KGaA, I look forward to the promise and challenge of expanding and diversifying the pipeline. I am delighted with the opportunity to work with Chris Henney again, and we are committed to building a leading cancer therapeutics company."

Dr. Henney added, "The Board of Directors has fully endorsed a strategy of growth through the acquisition or in-licensing of additional cancer therapeutics. Bob Kirkman and I will be aggressively seeking promising new products to add to the pipeline, both for internal development and future partnering activities."

Mr. Eric Baker, the outgoing Chairman of the Board, will remain on the Board. He commented, "These two key appointments strengthen Biomira's leadership as the Company moves to expand its focus and build new value for the shareholders. Dr. Kirkman brings extensive business and scientific expertise which will be invaluable to the company going forward. We are also delighted that Dr. Henney has agreed to succeed me as Chairman, increasing his activities in business development in partnership with Dr. Kirkman."

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, trial reviews and analyses and regulatory reviews, the safety and efficacy of the product, and the ability to identify and partner with owners of possible products through in-licensing arrangements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct or that the Company will have sufficient resources to fund clinical trials. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.




--------------------------------------------------------------------------------
Source: Biomira Inc.

[DausendUndMehr]

Antwort auf Beitrag Nr.: 23.684.415 von freetibet am 30.08.06 14:51:51

Danke

Schau mer mal ... ob das der Grund für die Trendwende war und ob diese sich jetzt fortsetzt

[wirdschonwerden]

Hallo MasaRatti,

in deinem Beitrag vom 23.08.2006 hattest Du ganz dick News für Ende August angekündigt. Was ist denn nun? Haste nur geraten? Oder meinste das nächste Jahr?



Andreas

[MasaRatti]

Antwort auf Beitrag Nr.: 23.754.771 von wirdschonwerden am 04.09.06 12:12:32

Servus,
weiß nicht was Du willst, bis Ende August gibt es einen neuen
CEO, der Abwärtstrend wurde gebrochen und jetzt
warten wir noch alle auf konkrete Nachrichten zur Phase3, was
sind schon ein paar Tage oder Wochen, bisher läuft doch alles
nach Plan... und 20% Kursgewinn in ein paar Wochen ist ja
auch nicht schlecht, oder ?

[wirdschonwerden]

Antwort auf Beitrag Nr.: 23.765.407 von MasaRatti am 05.09.06 07:32:32

.....20% Kursgewinn ist gut gesagt bzw. gerechnet. aber was meinst du sagen die, welche bei 2€ eingestiegen sind?



Gruß Andreas

[donnerpower]

Antwort auf Beitrag Nr.: 23.773.781 von wirdschonwerden am 05.09.06 16:53:55

@andreas

warte doch einfach mal ab..wenn die 3Phase bekannt gegeben wird läuft alles ganz von alleine! Dann kannst du heulen..denn wenn du zu diesen Kursen nicht nach gekauft hast!

[MasaRatti]

Joh,
sieht so aus, als brauchen wir doch etwas mehr Geduld für
die Phase 3, denn sonst hätten wir bestimmt schon früher
etwas erfahren. Jetzt wohl doch erst gegen Jahresende, oder
kommt doch noch eine Überraschung, der Kurs spricht jedoch
Bände !!!

[freetibet]

Antwort auf Beitrag Nr.: 23.912.750 von MasaRatti am 13.09.06 17:13:29

Hallo,
Jahresende wird überall prognostiziert (yahoo-board, BIOM Q&A).
Die Rallye im Nov./Dez. hatten wir doch schon zweimal.
Finde ich einen guten Zeitpunkt.

Wenn Du es genau wissen willst, musst Du Merck anrufen.

[freetibet]

Merck übernimmt Serono für 10,6 Milliarden Euro
Drittgrößter Biotech-Konzern der Welt wechselt Besitzer - Gemeinsame Biotech-Sparte in der Schweiz
AP 21.09.2006 13:09

Das Serono Biotech Center in Corsier-sur-Vevey, Schweiz. (AP Photo/Keystone, Andree-Noelle Pot)
Darmstadt/Genf - Der deutsche Pharmakonzern Merck kauft das Schweizer Biotechnologieunternehmen Serono für rund 10,6 Milliarden Euro (16,6 Milliarden Schweizer Franken). Wie Merck am Donnerstag berichtete, zahlt das Darmstädter Unternehmen für den drittgrößten Biotechnologiekonzern der Welt pro Aktie 1.100 Schweizer Franken (692 Euro). Eine entsprechende Vereinbarung sei mit der Serono-Eigentümerfamilie Bertarelli getroffen worden, die ihren 64,5-Prozent-Anteil verkaufen wolle.

Allen übrigen Anteilseignern, mit Ausnahme von Serono-Aktionären in den USA, will Merck ein Angebot in gleicher Höhe machen. Nach Angaben des Darmstädter Konzerns kamen Merck und Serono 2005 gemeinsam auf einen Umsatz von 7,7 Milliarden Euro, davon 3,6 Milliarden Euro im Geschäft mit Biopharmazeutika. «Zusammen mit dem Management und den Mitarbeitern von Serono wollen wir ein weltweit führendes biopharmazeutisches Unternehmen mit globaler Marktpräsenz, hoch entwickelter Biotech-Produktion und starkem Wachstum schaffen», sagte Merck-Chef Michael Römer.

Das Forschungsbudget der um Serono erweiterten Merck werde sich auf eine Milliarde Euro belaufen, sagte Römer. Dies sichere die Zukunft von Merck für das 21. Jahrhundert. Serono-Eigentümer Ernesto Bertarelli erklärte, das größte Potenzial des vereinigten deutsch-schweizerischen Unternehmens liege in den Bereichen Neurologie und Krebsforschung. Zusammen mit Serono werde Merck zu einem gewichtigen Akteur im internationalen Pharmageschäft. Dem Zusammenschluss müssen die Kartellbehörden noch zustimmen.

Wie der Darmstädter Konzern berichtete, sollen die biopharmazeutischen Aktivitäten von Merck und Serono in einer eigenen Gesellschaft mit Sitz in Genf zusammengeführt werden. Die Übernahme werde durch Barmittel, Darlehen, eine Anleihe sowie eine Kapitalerhöhung in Höhe von zwei bis 2,5 Milliarden Euro finanziert. An der Kapitalerhöhung werde die Merck-Familie sich mit bis zu einer Milliarde Euro beteiligen. Die Transaktion soll Anfang 2007 abgeschlossen sein. Der erweiterte Merck-Konzern wird künftig rund 35.000 Mitarbeiter weltweit beschäftigen.

Verkauf von Serono überraschend
Der Verkauf von Serono kommt überraschend, da Bertarelli im April dieses Jahres noch erklärt hatte, dass er die Suche nach einem Käufer abgebrochen habe. Die Angebote seien ungenügend gewesen und er wolle dem Konzern zu Wachstum durch Akquisitionen verhelfen. Im November 2005 hatte der drittgrößte Biotechnologiekonzern der Welt bekannt gegeben, dass für die Zukunft auch Alternativen zum Alleingang gesucht würden. Serono ist gemessen am Umsatz hinter Genentech und Amgen der weltweit drittgrößte Biotechnologie-Konzern und gemessen an der Börsenkapitalisierung die Nummer 6.

Merck hatte im März versucht, den Berliner Pharmakonzern Schering für 14,6 Milliarden Euro zu übernehmen, war jedoch vom Konkurrenten Bayer überboten worden. Im Rahmen des Tauziehens um Schering erwarb das Darmstädter Familienunternehmen selbst rund 42 Millionen Schering-Papiere, die Merck im Juni an Bayer verkaufte und so einen Extragewinn von 400 Millionen Euro einstrich.

Serono hatte Ende Juli dieses Jahres einen Halbjahresgewinn von 369,2 Millionen Dollar ausgewiesen. Der Umsatz verbesserte sich im ersten Halbjahr 2006 um 6,9 Prozent auf 1,367 Milliarden Dollar. Der Absatz des Multiple-Sklerose-Medikaments Rebif stieg im Vorjahresvergleich um 11,2 Prozent auf 688,5 Millionen Dollar; Rebif steuert nun 56,3 Prozent zum Produktumsatz bei.

(AP)

[freetibet]

Biomira Inc. Announces U.S. $100 Million Shelf Registration
Wednesday September 27, 6:00 am ET


EDMONTON, Sept. 27 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that it has received final clearance from the applicable Canadian regulatory authorities with respect to a U.S. $100 million shelf prospectus filed in specified Canadian jurisdictions. Biomira concurrently filed a shelf registration statement in the United States on Form F-10, which was effective upon filing in definitive form. The shelf registration became effective in both countries on September 26, 2006.
"Biomira is approaching an important transition as we look to acquire or in-license additional cancer therapeutics to expand our pipeline," commented Dr. Robert Kirkman, President and CEO. "This shelf registration will provide us with the flexibility to obtain financing efficiently, as market conditions allow, to support both internal development and future partnering activities."

The shelf prospectus will be effective for approximately 25 months. The terms of any offering under the shelf prospectus will be established at the time of the offering and will be described in a prospectus supplement filed at that time.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.


This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected
in forward-looking statements, including those predicting the
potential expansion of our pipeline and the ability to identify
and partner with owners of possible products through in-licensing
or out-licensing arrangements as well as the availability of future
financing on acceptable terms under the shelf registration statement.
Although the Company believes that the forward-looking statements
contained herein are reasonable, it can give no assurance that the
Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary
statement.
--------------------------------------------------------------------------------
Source: Biomira Inc.

[bernie55]

Antwort auf Beitrag Nr.: 24.231.949 von freetibet am 27.09.06 14:38:47

News & Analysis: Biotech

Biomira May Sell Securities

By Althea Chang
TheStreet.com Staff Reporter
9/27/2006 9:51 AM EDT


Drug developer Biomira (BIOM - news - Cramer's Take) has received regulatory clearance for a $100 million shelf registration to help fund its cancer drug research and expand its pipeline.

"This shelf registration will provide us with the flexibility to obtain financing efficiently, as market conditions allow, to support both internal development and future partnering activities," said Dr. Robert Kirkman, Biomira's president and CEO.

The company filed a shelf registration statement in the U.S. and received final approval from Canadian regulators. The registration became effective Tuesday.

The shelf prospectus will be effective for around 25 months, and the terms of any offering under it will be established at the time of the offering, Biomira said.

Shares were trading 2.9% higher at $1.05 in premarket trading Wednesday.


http://www.thestreet.com/_tscs/newsanalysis/biotech/10311495…

[wirdschonwerden]

Antwort auf Beitrag Nr.: 24.252.646 von bernie55 am 28.09.06 08:50:48

nachrichten zum thema

quelle: handelsblatt

In mehreren lukrativen Segmenten des Arzneimittelgeschäfts verschärft sich der Wettbewerb durch neue Wirkstoffe. So hat der amerikanische Biotech-Konzern Amgen in den USA gerade eine Zulassung für sein Krebsmittel Vectibix erhalten – und will damit dem Krebsmittel von Merck Konkurrenz machen........

nNun sollte BIOMIRA den finger ziehen, sonst geraten sie unter die räder (so wie der Kurs)

Andreas

[freetibet]

Antwort auf Beitrag Nr.: 24.402.446 von wirdschonwerden am 04.10.06 17:41:48

Amgen erhält FDA-Zulassung für Krebsmedikament "Vectibix"
Donnerstag 28. September 2006, 09:00 Uhr

NEW YORK (Dow Jones)--Die Amgen Inc, Thousand Oaks, hat von der US-Gesundheitsbehörde FDA die Zulassung für ihr Krebsmedikament "Vectibix" erhalten. Wie das US-Biotechnologieunternehmen am Mittwoch mitteilte, soll das Medikament Anfang bis Mitte Oktober erhältlich sein. Der Preis werde circa 20% unter dem Preis anderer Medikamente dieser Kategorie liegen. Vectibix wird bei fortgeschrittenem Darmkrebs eingesetzt, bei dem eine Chemotherapie ohne Wirkung geblieben ist.

Analysten von William Blair & Co rechnen 2006 mit Vectibix-Umsätzen von 10 Mio USD. Für 2007 erwarten sie Umsätze von 211 Mio USD. Amgen konkurriert mit Vectibix gegen Anzeige

das Krebsmedikament "Erbitux" der ImClone Systems Inc, das von der Bristol-Myers Squibb Co vermarktet wird. Die FDA hatte den kommerziellen Einsatz von Erbitux gegen Darmkrebs 2004 genehmigt.

Die Überprüfung von Vectibix wurde im Juni als dringlich eingestuft, nachdem sich bei Patienten das Tumorwachstum nach Einnahme des Medikaments verlangsamt und sich in einigen Fällen die Größe des Krebstumors verkleinert hatte.

- Von Erica Owen, Dow Jones Newswires; [phone], [e-mail] DJG/DJN/kla/brb


Konzentrieren wir uns doch lieber auf Lungenkrebs!

[freetibet]

Upcoming Events 2006

October 18, 2006-October 19, 2006

San Francisco BIO InvestorForum 2006
"The BIO InvestorForum is attended by public and private biotechnology investors and will profile top life science growth companies in 2006 as well as those poised to join ght growth "watch list" in 2007," according to the BIO organization. BIO InvestorForum will take place at the Palace Hotel in San Francisco, October 18-19, 2006.

We will confirm our time slot once the program has been further developed.

November 6, 2006-November 8, 2006

Palace Hotel, New York, NY Rodman and Renshaw 8th Annual Healthcare Conference
Biomira will be a presenter at the upcoming Healthcare Conference. Once our meeting time is known we will update this information.

www.biomira.com

[wirdschonwerden]

Antwort auf Beitrag Nr.: 24.472.267 von freetibet am 07.10.06 18:27:34

hallo zusammen,

bin ja mal gespannt wann der erste "nun wir werden alle reich, ich habs ja schon immer gesagt, beitrag?" kommt.
nur so vor den hintergrund, dass wir schon 2 tage ohne kursverlusste leben müssen


Andreas

[BIOMIRA]

Antwort auf Beitrag Nr.: 24.565.103 von wirdschonwerden am 11.10.06 18:58:47

die kommen bei 10E mit ziel DAUSEND

[BIOMIRA]

da gibt es aber INSIDER die was wissen
der kurs steigt total sauber und ohne stress und große aufmerksamkeit

würde mich nicht wundern der KNALL kommt bald

[donnerpower]

Antwort auf Beitrag Nr.: 24.565.103 von wirdschonwerden am 11.10.06 18:58:47

ich habs ja schon immer gesagt

[BIOMIRA]

Antwort auf Beitrag Nr.: 24.567.055 von BIOMIRA am 11.10.06 20:26:27

und wie es nallen kann, dass sehen wir im großen überblick

[BIOMIRA]

Antwort auf Beitrag Nr.: 24.567.061 von donnerpower am 11.10.06 20:26:36

donner... deine und aber auch meine geduld wird sich auszahlen

hab fett dazugekauft, da ich an die zulassung FEST HALTE

gruß
biom

[verdi2003]

Hallo Gemeinde,

es sieht gut aus mit BIOMIRA.
Euch allen eine schöne Herbstzeit wünsche ich

Grüße
verdi

[BIOMIRA]

Antwort auf Beitrag Nr.: 24.706.442 von verdi2003 am 18.10.06 18:15:30

dir und ALLEN longs viele viele %-te



insider kaufen da in die steigenden kurse hinein

[kurttilly]

Hallo an alle Biomira-Fans!


Unsere Geduld wird sich auszahlen!


Hat man schon was gehört?



Upcoming Events 2006

October 18, 2006-October 19, 2006

San Francisco BIO InvestorForum 2006
"The BIO InvestorForum is attended by public and private biotechnology investors and will profile top life science growth companies in 2006 as well as those poised to join ght growth "watch list" in 2007," according to the BIO organization. BIO InvestorForum will take place at the Palace Hotel in San Francisco, October 18-19, 2006.

We will confirm our time slot once the program has been further developed.




mfg kurttilly

[minadon]

AP
Volume Spikes: ABPI SIGA BIOM AMRN VIGN
Thursday October 19, 12:47 pm ET
Shares of Accentia Biopharmaceuticals Surge on Extraordinary Volume on Drug Study


NEW YORK (AP) -- The following companies were showing unusually heavy volume in trading Thursday on the Nasdaq around noon. Higher-than-normal volume can indicate increased activity by institutions such as mutual funds and insurance companies. Upward stock movement on such volume can show increased confidence among investors, while selling can signal further downward pressure on a stock.
ADVERTISEMENT


Shares of Accentia Biopharmaceuticals Inc. traded on extraordinarily heavy volume after the Tampa, Fla.-based drug developer said a new study showed its BiovaxID formula sent follicular non-Hodgkins lymphoma following chemotherapy into long-lasting remission in 80 percent of patients.

Nearly 3.1 million shares of Accentia Biopharmaceuticals changed hands by noon, dwarfing the typical daily trading volume of 33,803 shares. The stock rose 47.9 percent to $4.26.

Siga Technologies Inc., a New York-based biotechnology company, said it is selling 2 million shares of its stock for $4.54 per share, or a total of $9 million, and the announcement sent the company's shares into accelerated trading.

By noon, investors exchanged more than 5.6 million Siga shares, almost seven times the average daily trading volume. The stock fell about 6 percent to $4.28.

Shares of Biomira Inc., a Canadian biotechnology researcher, traded with unusually heavy volume. More than 1.7 million of the company's shares had changed hands by noon, compared with daily trading volume of 229,720 shares.

There was no apparent cause for the heightened trading. No analysts released research on the company, and Biomira hasn't issued any news since September.

Amarin Corp., a London-based neuroscience company, said it found buyers for $18.7 million of its shares in a private sale. The company will sell 9 million shares to investors for $2.09 per share, representing a 15 percent discount to Wednesday's closing price.

While in a typical day only 144,738 Amarin shares are traded, the news spurred investors to buy and sell more than 1 million shares by noon. The stock fell 8.5 percent to $2.25.

Shares of Vignette Corp. traded heavily after the Austin, Texas-based Internet applications software maker reported third-quarter profit nearly tripled on higher sales.

Investors bought and sold nearly 1.4 million shares by noon, compared with average daily trading volume of 198,074 shares. The stock rose nearly 8 percent to $15.

[BIOMIRA]

chart sieht wirklich gut aus

stochastic und macd auf long gesprungen

wird ja auch zeit
unter 10€ wird nicht verkauft

[BIOMIRA]

im "großen überblick" kann man sehen, dass noch viel platz nach oben ist, die richtige party geht erst los

[bernie55]

Antwort auf Beitrag Nr.: 24.728.341 von BIOMIRA am 19.10.06 20:08:03

....die richtige party geht erst los

.. heute zumindest schon mit 2.741.341 gehandelte Aktien ein Anfang der Party...

[BIOMIRA]

Antwort auf Beitrag Nr.: 24.731.293 von bernie55 am 19.10.06 22:22:11

die umsätze

[MasaRatti]

Wenn das mal kein netter Wochenabschluss ist !

Happy W-end

[DausendUndMehr]

[schmacki]

Na ja,erst mal abwarten ob das kein Strohfeuer war!
Hoffentlich hau'n Sie erst bei 5Dollar neue Aktien raus.

[BULLE2004]

Antwort auf Beitrag Nr.: 24.739.992 von schmacki am 20.10.06 13:21:00

war wohl doch ein strohfeuer.

[gehtsjetztendlich]

morgen wird der Kurs bei 1,53€ stehen - hab ich zumindest gestern nacht geträumt.......

[verdi2003]

@gehtsjetztendlich

schöner traum

ich hoffe, er geht bald in erfüllung!

grüße
verdi

[schmacki]

Press Release Source: Biomira Inc.

Biomira Announces Acquisition of ProlX Pharmaceuticals
Tuesday October 31, 8:00 am ET
- Company to Host Conference Call at 11:00 a.m. ET -

EDMONTON, Oct. 31 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) announced today that it has acquired ProlX Pharmaceuticals Corporation, of Tucson, Arizona, and Houston, Texas, a privately-held biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. ProlX is developing small-molecule drugs that inhibit redox and cell-survival signaling proteins.

ADVERTISEMENT
The acquisition will give Biomira a broadly-based portfolio of oncology products, including one product candidate expected to enter phase 3 by year end (Stimuvax®), one product expected to enter phase 2 in the current quarter (PX-12), and two products expected to begin clinical trials over the next 6 to 12 months, as well as several additional pre-clinical candidates.

"The acquisition of ProlX is a transformative event for Biomira, expanding and diversifying our pipeline of cancer therapies in development," said Robert L. Kirkman, M.D., President and CEO. "The combined programs will give us products in several phases of clinical development directed against multiple targets, diversifying risk while retaining our focus on the treatment of solid tumors. This is a major step toward our goal of building a leading oncology franchise."

Lynn Kirkpatrick, Ph.D., President and CEO of ProlX, who will join Biomira as Chief Scientific Officer, noted, "ProlX has built a diversified pipeline of novel drugs through structural design and targeted combinatorial chemistry, based on our research on targets which regulate cancer cell growth and cell death. I am delighted to be joining with Biomira and excited by the opportunity this transaction creates to accelerate the development of our drugs."

Promptly following closing Biomira will pay U.S. $3 million in cash and approximately 17,878,000 shares of Biomira common stock (subject to certain resale restrictions) in return for all of the outstanding stock of ProlX. In addition, and subject to applicable regulatory requirements, there may be up to three future payments based on the achievement of specified milestones. A payment in Biomira common stock (with registration rights) of U.S. $5 million is due upon the initiation of the first phase 3 trial of a ProlX product. Another payment in Biomira common stock (with registration rights) of U.S. $10 million is due upon regulatory approval of a ProlX product in a major market. Finally, under certain circumstances, ProlX shareholders may also receive a share of revenue from a potential collaboration agreement for a ProlX product in a specified non-oncology indication.

ProlX Products in Development

PX-12 is an inhibitor of thioredoxin. Increased thioredoxin levels in cancer cells have been linked to the aggressive proliferation of solid tumors, including colon, lung, and gastric cancers. PX-12 is currently being evaluated in a phase 1b trial in patients with advanced gastrointestinal cancers. A randomized phase 2 trial comparing two dose levels of PX-12 in patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine containing regimen is expected to start in the current quarter. An initial phase 1 trial involving 38 patients with advanced metastatic cancer showed that PX-12 was well tolerated and produced a decrease in plasma concentrations of thioredoxin that was significantly correlated with increased patient survival. Seven of the 38 patients achieved stable disease of up to 322 days.

PX-478 is an inhibitor of hypoxia inducible factor-1a (HIF-1a), a protein responsible for initiating the process of tumor blood vessel growth, or angiogenesis. PX-478 is the first direct inhibitor of this protein to be described. PX-478 is effective when delivered orally, and has shown marked tumor regressions and growth inhibition in model systems across a range of cancers, including ovarian, renal, prostate, colon, pancreatic, and breast cancer. PX-478 is in late stage pre-clinical development and is expected to begin its first clinical trial in the first half of 2007.

PX-866 is an inhibitor of the phosphatidylinositol-3-kinase (PI-3-kinase)/PTEN/Akt pathway, an important survival signaling pathway that is activated in many types of human cancer. PI-3-kinase is over expressed in a number of human cancers, especially ovarian, colon, head and neck, urinary tract, and cervical cancers, where it leads to increased proliferation and inhibition of apoptosis. The PI-3-kinase inhibitor PX-866 induces prolonged inhibition of tumor PI-3-kinase signaling following both oral and intravenous administration and has been shown to have good in vivo anti-tumor activity in human ovarian and lung cancer, as well as intracranial glioblastoma, tumor models. PX-866 is in late pre-clinical development.

PX-316 is the first in a new class of chemical inhibitors of Akt-mediated survival signaling, has shown anti-tumor activity in animal models of colon and breast cancer, and is undergoing more extensive pre-clinical development.

Stimuvax®

Formerly known as BLP25 Liposome Vaccine (L-BLP25), Stimuvax® is a synthetic MUC1 peptide vaccine. Stimuvax® incorporates a 25-amino acid sequence of the MUC1 cancer mucin, encapsulated in a liposomal delivery system. The liposome enhances recognition of the cancer antigen by the immune system and facilitates better delivery. Stimuvax® is designed to induce an immune response to cancer cells. In a phase 2b trial conducted by Biomira in patients with Stage IIIb and IV non-small cell lung cancer, the median survival in the subset of patients with locoregional Stage IIIB disease was 30.6 months for patients receiving Stimuvax, compared with 13.3 months for patients in the control arm. A phase 3 trial of Stimuvax in patients with Stage III non-small cell lung cancer is expected to begin by year end. The trial will be conducted by Merck KGaA of Darmstadt, Germany, under terms of a licensing arrangement with Biomira.

About ProlX

ProlX Pharmaceuticals Corporation is a private biotechnology company located in Tucson, AZ and Houston, TX, dedicated to the discovery of novel therapies for the treatment of cancer. The Company's small molecule drug pipeline and discovery efforts target redox and survival signaling pathways.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.

Conference Call

Biomira will host a conference call to discuss the acquisition of ProlX at 11:00 a.m. ET today, October 31, 2006. The conference call will be broadcast live on the Internet on the Company's website, www.biomira.com and at: http://phx.corporate-ir.net/playerlink.zhtml?c=78683&s=wm&e=… The call will be archived through November 30, 2006.

This release may contain forward-looking statements, including the anticipated benefits of the acquisition, expectations regarding the development and timing of clinical trials in relation to acquired products, development of our product pipeline and related diversification of risk, building a leading oncology franchise, potential new employees resulting from the acquisition and possible future payments related to the acquisition agreement. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of the products, and the possibility of future payments. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct or that the Company will have sufficient resources to fund clinical trials. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Source: Biomira Inc.

[verdi2003]

hallo schmacki!

das ist eine gute meldung.
der kurs wird weiter steigen

viele grüße
verdi

[ollihat]

Das mit der Kurssteigerung hängt ganz davon ab, was die neuen vereinten Partner entwickeln können; vordergründig gibt es mal erst ca. 18 Mio zusätzliche Biomira Shares!

[DausendUndMehr]

Antwort auf Beitrag Nr.: 25.048.214 von ollihat am 31.10.06 20:51:51

wo steht da was von zusätzlichen (neuen) Shares

[DausendUndMehr]

SK 1.26$ +7,69%

[freetibet]

Merck to conduct cancer vaccine trials in India
C H Unnikrishnan / Mumbai November 01, 2006

The German drug multinational, Merck KGaA, which received the Indian marketing approval for its head and neck cancer drug Erbitux last month, is planning to conduct its first cancer vaccine trials in India.

The company will start the trials of this therapeutic vaccine-Stimuvax, being developed for non-small cell lung cancer (NSCLC), by early next year at six centres in the country, said Wayne Paterson, regional head of Oncology Asia Pacific, Merck.

“We are currently in the process of deciding the drug trial portfolios, number of patients to be enrolled for the study and also the locations of trial centres in the country,” Paterson said adding that since Merck had identified India as one of the important geographies in its global R&D map, it would continue investing in the country for drug development activities.

Stimuvax (L-BLP 25) is the first therapeutic vaccine from Merck’s oncology portfolio and the first of this kind treatment for non-small cell lung cancer in the world.

Merck KGaA had earlier said that over 1,300 patients with stage III unresectable disease from more than 140 centres in North America and Europe would be recruited for the NSCLC trial.

The major component of Stimuvax is the synthetic human MUC I protein consisting of a 20-amino acid tandem repeat sequence on its extracellular domain that is highly antigenic. MUC I is expressed on normal epithelial tissue as well as NSCLC tumour cells, but on tumours it is abnormally glycated and therefore able to trigger an immune response.

The World Health Organisation estimated that over 900,000 new NSCLC cases of lung cancer were diagnosed worldwide in 2000. In India, most cases present to the physician in advanced stages when chemotherapy is the only available option.

Lung cancer is a major cause of cancer mortality, accounting for 20 per cent of cancer deaths worldwide. The survival statistics are dismal with an average 5-year survival of 14 per cent in the US, 10 per cent in Europe, India, China, and the developing countries.

The multinational company, which has an annual R&D budget of over $ 1 billion, has been working on oncology as one of its important research portfolios and currently it has about five very advance stage oncology leads in its broad oncology pipeline.

www.business-standard.com

[sdiver]

Hier die Übersetzung.

erck, um Krebs-Impfproben in Indien C H Unnikrishnan / Mumbai am 1. November 2006 Das deutsche Rauschgift multinational, Merck KGaA zu führen, der die indische Marktbilligung für seinen Kopf und Hals-Krebs-Rauschgift-Erbitux im letzten Monat erhielt, plant, seine ersten Krebs-Impfproben in Indien zu führen. Die Gesellschaft wird die Proben mit diesem therapeutischen Impf-Stimuvax anfangen, für nichtkleinen Zelllungenkrebs (NSCLC), bis zum Anfang nächsten Jahres an sechs Zentren im Land entwickelt werden, sagten Wayne Paterson, regionales Haupt Oncology von Asien der Pazifik, Merck. " Wir sind zurzeit im Prozess, die Rauschgift-Probe-Mappen, Zahl von Patienten zu entscheiden, um für die Studie und auch die Positionen von Probe-Zentren im Land eingeschrieben zu werden," sagte Paterson das Hinzufügen, dass da Merck Indien als eine der wichtigen Erdkunden in seiner globalen R*D-Karte identifiziert hatte, es würde fortsetzen, ins Land für Rauschgift-Entwicklungstätigkeiten zu investieren. Stimuvax (L-BLP 25) ist der erste therapeutische Impfstoff von der oncology Mappe von Merck und der ersten von dieser freundlichen Behandlung für nichtkleinen Zelllungenkrebs in der Welt. KGaA von Merck hatte früher gesagt, dass mehr als 1.300 Patienten mit der Bühne III unresectable Krankheit von mehr als 140 Zentren in Nordamerika und Europa für die NSCLC Probe rekrutiert würden. Der Hauptbestandteil von Stimuvax ist der synthetische menschliche MUC ich das Protein-Bestehen aus einem 20-Aminosäuren-Tandem wiederholt Folge auf seinem extracellular Gebiet, das hoch antigenic ist. MUC ich werde auf dem normalen epithelischen Gewebe sowie den NSCLC Tumor-Zellen, aber auf Tumoren ausgedrückt, das ist anomal glycated und deshalb fähig, eine geschützte Antwort auszulösen. Die Weltgesundheitsorganisation schätzte ein, dass mehr als 900.000 neue NSCLC Fälle des Lungenkrebses weltweit 2000 diagnostiziert wurden. In Indien präsentieren die meisten Fälle dem Arzt in fortgeschrittenen Stufen, wenn Chemotherapie die einzige verfügbare Auswahl ist. Lungenkrebs ist eine Hauptursache der Krebs-Sterblichkeit, für 20 Prozent von Krebs-Todesfällen weltweit verantwortlich seiend. Die Überleben-Statistiken sind mit einem durchschnittlichen 5-jährigen Überleben von 14 Prozent in den Vereinigten Staaten, 10 Prozent in Europa, Indien, China, und den Entwicklungsländern düster. Die multinationale Gesellschaft, die ein jährliches R*D Budget von mehr als 1 Milliarde $ hat, hat an oncology als eine seiner wichtigen Forschungsmappen gearbeitet, und zurzeit hat es ungefähr fünf sehr Fortschritt-Bühne oncology führt in seiner breiten oncology Rohrleitung. www.business-standard.com

Gruß sdiver

[freetibet]

Die Zahlen zum III.Quartal

http://www.biomira.com/news/main/?id=926006

[BIOMIRA]

[primaabzocker]

[kurttilly]

Hallo zusammen!

Wie schon im August beschrieben:

Geduld ist angesagt, und vielleicht werden wir jetzt bald belohnt werden.

Umsätze in an der NASDAQ steigen schon seit einigen Tagen an; warum ist bei uns in D fast kein Handel???


Nicht mehr viele investiert???


mfg kurttilly

[cyberhai]

Antwort auf Beitrag Nr.: 25.179.510 von kurttilly am 06.11.06 18:11:10

Hallo kurttilly,

ich bin mit einer kleinen Pos. investiert. Die Aktie ist bei uns nicht so bekannt bzw. viele deutsche Investoren kaufen lieber direkt in den USA. Dass in Deutschland fast kein Handel stattfindet ist daher bedeutungslos. Bin in einigen US-Biotechs investiert und es findet relativ wenig bis teilweise gar kein Handel in Deutschland statt...

Gruß Cyberhai

[kurttilly]

Hallo cyberhai!

Vielen Dank für die rasche Antwort;

bin natürlich bei meinem ersten direkten Kauf an der US-Börse richtig reingefallen:

hatte damals 555 Nutrition21 geordert, bekam sie auch promt, gedoch in jeweils 5 Käufe à ca. 110 St.! Hab´dabei 5 x Ordergebühren bezahlt.

Deshalb kaufe ich nur noch in D; oder gibt´s ne andere Möglichkeit, die das ausschließt?

Danke!

kurttilly

[cyberhai]

Antwort auf Beitrag Nr.: 25.180.117 von kurttilly am 06.11.06 18:43:56

Ich hatte mal ca. 10 Teilausführungen, die Bank hatte sich allerdings kulant gezeigt und mir einen Teil der Gebühren erstattet. Du kannst Teilausführungen verhindern, wenn "all or none" beim Orderzusatz angeklickt wird, so ist das jedenfalls bei der Comdirect. Falls Du das machst, solltest Du aber auf jeden Fall ein Limit eingeben. Das Limit vor allem bei ungewöhnlichen Stückzahlen etwas höher ansetzen, damit auch gerade jemand bereit ist, seine Aktien an Dich zu verkaufen...

[kurttilly]

Hallo cyberhai!

Vielen Dank!


mfg kurttilly

[DausendUndMehr]

[BIOMIRA]

hi @ALL

hier mal ein beispiel, wie schnell es gehen kann









die longs mußten auch NERVEN lassen und wurden nun fett belohnt


ich bleibe in BIOM bis 10 dollar

[seppel]

@Biomira: Ich bis 20US$

[freetibet]

November 7, 2006

Palace Hotel, New York, NY Rodman and Renshaw 8th Annual Healthcare Conference
Biomira will be a presenter at the upcoming Healthcare Conference. Our presentation is scheduled for 4:15 p.m. Eastern time on Tuesday, November 7, 2006.

Our presentation will be Web cast. You may view the Web cast at:

http://www.wsw.com/webcast/rrshq10/biom

[philippf]

Wie viele Biomiraner lesen hier denn noch aktiv mit?
Hand hoch!

Ich mach mal den Anfang - immerhin die halbe Stückzahl von vor 2 Jahren hab ich noch...

[bernie55]

Antwort auf Beitrag Nr.: 25.205.883 von philippf am 07.11.06 22:30:21

..Yepp...immer noch dabei, aber bisher noch keine verkauft....erst dann, wenn es sich $$$$$$ mäßig lohnt.....

[bernie55]

Antwort auf Beitrag Nr.: 25.186.239 von freetibet am 07.11.06 08:17:44

http://www.wsw.com/webcast/rrshq10/biom/


....die Präsentation vom 7.11 06 kann man sich hier noch einmal anschauen....

[schmacki]

Antwort auf Beitrag Nr.: 25.205.883 von philippf am 07.11.06 22:30:21

Bin auch noch an Bord!
Glaube an eine Zulassung von Stimuvax.

[kurttilly]

Hi Biomira-Fans!


Unsere Biomira steigt weiter an !!!!

Wer ist noch dabei ????


gruß kurttilly

[philippf]

Antwort auf Beitrag Nr.: 25.606.869 von kurttilly am 22.11.06 21:41:45

Ich bin noch dabei...
Aber ich sehe hier weniger einen Anstieg als eher ein Pendeln :-)

[seppel]

Da könnte ja unser Chart Spezi mal wieder nen Update machen, aber im 1-Jahres-Chart sieht es so aus, dass die 1.4 und 1.5US$ wichtige Marken sind. Wenn die erst mal überwunden werden, dann ...

[Vaio]

Auch noch an Bord und warte auf steigende Kurse ...

Gruß
Vaio

[donnerpower]

Habt noch etwas Geduld..es kann sich nur noch um Tage handeln!

[seppel]

Na, das sieht doch langsam ganz gut aus

Gestern schon über 400.000 Stück gehandelt und aktuell bei 1.47US$ schon über 200.000 nach 25 Minuten Handelszeit

[KnigRollo]

hi seppel,

wo kriegt man den realtime kurse aus den usa ??? kostenlos wenns geht ?? Danke

[mape9]

Antwort auf Beitrag Nr.: 25.771.004 von KnigRollo am 28.11.06 16:21:20

jeden tag 2-4% unauffällig super

[gehtsjetztendlich]

habe jetzt erste Position zu 1,16€ verkauft - Rest bleibt im Depot
Habe lange genug warten müssen.....

[seppel]

Antwort auf Beitrag Nr.: 25.771.004 von KnigRollo am 28.11.06 16:21:20

@KnigRollo: Ich hab mich bei http://www.advfn.de/ angemeldet. Dort kannst du kostenlos (15Minuten zeitverzögert) ne Watchlist anlegen. Für 10Euro/Monat kannst du auch USA Realtime dazubuchen.

[philippf]

Antwort auf Beitrag Nr.: 25.772.163 von mape9 am 28.11.06 16:56:45

Wobei man sagen muss, dass die Umsätze in D nahezu lächerlich sind...

[ruden]

Antwort auf Beitrag Nr.: 25.771.004 von KnigRollo am 28.11.06 16:21:20

Kostenlose Realtimekurse:

http://realtime.bigcharts.com/chart.asp?%20type=100style=45&…

--> hinten Kürzel eint´ragen z.B. "biom"

aber nicht weitersagen und viel Spass weiterhin!

[ruden]

Antwort auf Beitrag Nr.: 25.775.043 von philippf am 28.11.06 18:25:14

Hey Philipp,

noch auf dem Planeten Tätig?

r

[donnerpower]

@ll

Kennen wir den Verlauf nicht alle

ich denke kurzfristig ein Anstieg bis 1,60$ und danach dürften wir die News sehen!

[philippf]

Antwort auf Beitrag Nr.: 25.775.206 von ruden am 28.11.06 18:30:18

Hi Rüdi!
Ja - Biomira hat noch nicht die richtige Kurve eingeschlagen, damit ich mich in der Karibik zur Ruhe setzen kann :-)

Wie läuft's in der Textilindustrie?

Gruß,
Philipp

[bernie55]

Antwort auf Beitrag Nr.: 25.787.091 von philippf am 29.11.06 08:37:49

Ja - Biomira hat noch nicht die richtige Kurve eingeschlagen, damit ich mich in der Karibik zur Ruhe setzen kann :-)



..tja, Philipp...dann sagst du einfach mal Bescheid, wann es soweit ist.....denn....

....You`ll never walk ( fly ) alone.....


Grüße bernie55

[BIOMIRA]

Antwort auf Beitrag Nr.: 25.791.115 von bernie55 am 29.11.06 12:01:21

Biomira cleared in Canada, U.S. for US$100 mln shelf filing
Print
Disable live quotes
RSS
Digg it
Del.icio.us
By Robert Daniel
Last Update: 6:22 AM ET Sep 27, 2006


TEL AVIV (MarketWatch) -- Biomira Inc., (BIOM :
biomira inc com
News , chart, profile, more
Last: 1.480.00-0.01%
10:43am 11/29/2006
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
BIOM1.48, 0.00, 0.0% ) (CA:BRA :
biomira inc com
News , chart, profile, more
Last: 1.68-0.01-0.59%
10:42am 11/29/2006
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
CA:BRA1.68, -0.01, -0.6% ) the Edmonton, Alberta, biotech company developing cancer therapeutics, said it received Canadian regulatory clearance for a US$100 million shelf registration with the U.S. Securities and Exchange Commission. The filing is thus effective in both countries. The company plans to use the funds to expand its pipeline by acquiring or licensing new cancer therapies. The filing is effective for 25 months, with the terms of any offering to be set when the securities are offered, Biomira said. End of Story

[minadon]

Antwort auf Beitrag Nr.: 25.799.073 von BIOMIRA am 29.11.06 16:58:43

Kann mir das bitte mal jemand in deutsch erklären?
DANKE

[BULLE2004]

Antwort auf Beitrag Nr.: 25.800.048 von minadon am 29.11.06 17:31:31

auf jeden Fall wird in Amerika wieder abgeladen.
Vielleicht nun doch eine gute Nachkaufchance?

[BULLE2004]

Antwort auf Beitrag Nr.: 25.806.054 von BULLE2004 am 29.11.06 20:25:14

Der Rückgang geht auch heute weiter, vielleicht sollte man noch warten bis die 1,20 Dollar erreicht sind.

[primaabzocker]

Biomira Biomira Biomira

[KnigRollo]

@all
könnte biomira unmittelbar nach einer erfolgreich beendeten phase II Studie zugelassen werden ?
Diese daten stehen doch an ??

oder sind die schon in phase III ?

woher (aus welcher studie) kam vor einigen jahren diese meldung mit den hervorragenden überlebensdaten ??

[donnerpower]

Antwort auf Beitrag Nr.: 25.854.890 von KnigRollo am 01.12.06 15:08:03

Ja sie könnten vorzeitig zugelassen werden..Ergebnisse fehlen noch von der PhaseIIb..dieses Jahr soll PhaseIII folgen wo man aber hauptsächlich noch weitere Krebsarten mit Blp25 testen will!

Zulassung für Canada ist beantragt !

PhaseIII führt Merck jetzt persönlich[und finanziert) da die Daten mehr als erwartet waren und man die Anwendungsreihe ausbreiten will!

[KnigRollo]

ok, und merk hat doch irgendwelche rechte sich noch gekrallt.

irgendwelche vertriebsrechte ? was war das noch genau ??

[philippf]

Antwort auf Beitrag Nr.: 25.859.117 von KnigRollo am 01.12.06 16:48:38

Wenn ich's richtig in Erinnerung habe, hat Merck die Vertreiebsrecht für die USA und den Rest der Welt.

Ursprünglich haben Biomira und Merck sich die Recht für USA und Kanada geteilt, dann hat BIOM aber den US-Anteil abgetreten (gegen Lizenzzahlungen). Zum Teilen bleiben jetzt nur noch die Kanada-Rechte übrig...

[bonDiacomova]

Antwort auf Beitrag Nr.: 25.800.048 von minadon am 29.11.06 17:31:31

Du hast ne

[donnerpower]

Antwort auf Beitrag Nr.: 25.859.117 von KnigRollo am 01.12.06 16:48:38

Canada wird geteilt..der Rest der Welt hat Merck die Rechte.

Das bedeutet Biomira bekommt etwa Lizenzzahlungen von Merck..diese betragen im üblichen etwa 10-12%.

Das Potential wird über 750Mio geschätzt.

Biomira hat keine Kosten..Merck übernimmt den ganzen Marketing,Verkäufe und die Kosten für weitere Versuche wie z.B. andere Krebsarten durch wo auch noch eventuell ein Umsatz später von xxxMio mit zurechnen ist.

Im ganzen kann hier für das kleine Unternehmen wie Biomira ein ordentliche Stange Geld im Jahr zusammen kommen..man beachte Merck führt die Versuche auf anderen Eben weiter und Biomira kann ihre weiteren vielversprechende Produte voran treiben die sich in verschieden Phasen schon befinden!

[primaabzocker]

Herzlichen Glückwunsch zum Geburtstag !!!!!
Biomira Biomira Biomira
100 US

[KnigRollo]

danke euch

[freetibet]

Alles zurück auf Start !!

[wachholder]

Hallo,

das könnte der Aktie am Montag einen Schub verleihen.

http://www.clinicaltrials.gov/ct/show/NCT00409188?order=1

Man beachte das Erfassungsdatm 07. Dezember 2006, d.h bald dürfte die Phase III Studie beginnen und eine entsprechende Presseerklärung veröffentlicht werden.

Wer weiß, wann die Meilensteinzahlung von Merck fällig ist und wie hoch sie ist?

wachholder

[mfierke]

hat keiner die news gesehen

[Zok2007]

Antwort auf Beitrag Nr.: 26.124.804 von mfierke am 12.12.06 14:22:38

ja doch aber keiner intresiert es woll..!!!

[bernie55]

December 12, 2006 - 8:00 AM EST

Biomira receives special protocol assessment from the FDA for Phase III trial of Stimuvax for non-small cell lung cancer

EDMONTON, Dec. 12 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today announced that it has reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for the planned Phase III clinical trial of Stimuvax(R) for the treatment of non-small cell lung cancer (NSCLC). The SPA agreement between Biomira and the FDA concerns the design of the Phase III trial and outlines definitive clinical objectives and data analyses considered necessary to support regulatory approval of Stimuvax. The trial will be conducted by Merck KGaA under terms of a licensing arrangement with Biomira.

The planned Phase III trial is a multi-center, randomized, double-blind placebo controlled trial of Stimuvax in patients with unresectable Stage III non-small cell lung cancer. The trial is expected to enroll approximately 1,300 patients in over 250 centers in approximately 30 countries. The primary endpoint of the trial is overall survival in patients receiving Stimuvax compared to those receiving placebo.

"This trial builds upon the encouraging results seen in Biomira's Phase IIb trial of Stimuvax in patients with stage IIIB and IV non-small cell lung cancer," said Robert L. Kirkman, M.D., President and CEO of Biomira. "In that trial, the median survival in the subset of patients with locoregional Stage IIIB disease was 30.6 months for patients receiving Stimuvax, compared with 13.3 months for patients in the control arm. The Phase 3 trial will seek to extend and confirm these results in patients with both Stage IIIA and IIIB locoregional disease."

"Completion of the SPA agreement with the FDA is an important step in the clinical development of Stimuvax," continued Dr. Kirkman. "We look forward to the initiation of this Phase III trial by the end of this year."

Stimuvax(R)

Formerly known as BLP25 Liposome Vaccine (L-BLP25), Stimuvax(R) is a synthetic MUC1 peptide vaccine. Stimuvax(R) incorporates a 25-amino acid sequence of the MUC1 cancer mucin, encapsulated in a liposomal delivery system. The liposome enhances recognition of the cancer antigen by the immune system and facilitates better delivery. Stimuvax(R) is designed to induce an immune response to cancer cells.

About Lung Cancer

In 2005, approximately 172,000 new cases of lung cancer were diagnosed in the U.S. Approximately 163,000 people are estimated to have died of this disease in the U.S. alone in 2005. NSCLC accounts for approximately 75 to 80 per cent of all primary lung cancers. At the time of diagnosis, only 25 per cent of patients are potentially curable by surgery.

Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, trial reviews and analyses and regulatory reviews, and the safety and efficacy of the product. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct or that the Company will have sufficient resources to fund clinical trials. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.



Source: Canada NewsWire (December 12, 2006 - 8:00 AM EST)

News by QuoteMedia
www.quotemedia.com

[bernie55]

Antwort auf Beitrag Nr.: 26.125.215 von bernie55 am 12.12.06 14:40:44

http://app.quotemedia.com/quotetools/popups/story.jsp

[bernie55]

Antwort auf Beitrag Nr.: 26.125.215 von bernie55 am 12.12.06 14:40:44

...vorbörslich aktuell 1,67 USD - 1,70 USD....

[DausendUndMehr]

Antwort auf Beitrag Nr.: 26.124.804 von mfierke am 12.12.06 14:22:38

keine Angst, sind alle noch da

[bonDiacomova]

Antwort auf Beitrag Nr.: 26.125.215 von bernie55 am 12.12.06 14:40:44

das "gehoert" imho auch unterstrichen

The primary endpoint of the trial
is overall survival in patients receiving Stimuvax
compared to those receiving placebo.

[KnigRollo]

About 1,300 patients will be enrolled to confirm if Stimuvax allows patients with Stage III non-small cell lung cancer to live longer. Non-small cell lung cancer is the most common form of the disease, accounting for about 75 percent of lung cancers. Stage III lung cancer occurs when the disease has spread beyond the lungs to the lymph nodes.

Das ist nicht hoch genug zu bewerten....
In a midstage clinical trial, lung cancer patients given Stimuvax survived an average of 30.6 months, compared with the average 13.3 months of those patients given a placebo.

[philippf]

Antwort auf Beitrag Nr.: 26.127.330 von KnigRollo am 12.12.06 16:00:13

??? das ist doch nix Neues ???

[BIOMIRA]

unter 10 dollar verkaufe ich nicht

[verdi2003]

was ist passiert?

[philippf]

Antwort auf Beitrag Nr.: 26.153.493 von verdi2003 am 13.12.06 16:18:34

das vielleicht?
http://biz.yahoo.com/prnews/061213/to464.html?.v=11
Biomira announces U.S. $13 million financing
Wednesday December 13, 9:36 am ET

EDMONTON, Dec. 13 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that it has arranged a financing of approximately U.S. $13 million, before deducting placement agent fees and expenses, with Rodman & Renshaw, LLC of New York acting as exclusive placement agent. In connection with this financing, Biomira intends to file shortly in Canada a prospectus supplement to its September 26, 2006 Base Shelf Prospectus and in the United States a prospectus supplement to its September 26, 2006 F-10 Registration Statement. The financing is expected to close within the next few days and is subject to regulatory approval.

The Company will be offering up to 9,629,650 units, each unit consisting of one common share and 0.20 of a warrant, at an issue price of U.S. $1.35. In addition, approximately 96,000 compensation warrants, having similar terms to the purchaser warrants, will be issued to the placement agent.

Each warrant will entitle the holder thereof to purchase one common share at an exercise price of U.S. $1.86. The warrants will have a 48-month term, from the date the financing closes, and a no-exercise period of six months.

Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

This release contains forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting or discussing the timing of the closing of the financing, the filing of regulatory documents and receipt of regulatory approvals related to the financing and the satisfaction of other conditions to closing of the transaction. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Source: Biomira Inc.

[seppel]

Ja, das ist die aktuelle Meldung. Anstatt so eine Finanzierung vor so einer guten Meldung wie gestern gestartet wird, macht man es im Anschluss. Beim Management von BIOM könnte man glatt denken, die wollen den Preis der Aktien unten halten

[DausendUndMehr]

Sauerei


und die Insider traden sich wie immer die Taschen voll

[BULLE2004]

Absolute Verarschung der Aktionäre.

[gehtsjetztendlich]

und gerade gab`s ein block-trade von 110000 zu 1,22$.....

[freetibet]

Guten Tag,

nachdem Biomira im Herbst an der Rodman&Renshaw Veranstaltung
teilgenommen hatte, mußte man doch damit rechnen.
Warum sollten die sonst dahin gehen ?

Hier mal wieder etwas positives:

http://www.primabiomed.com.au/projects/prodDocuments/Treatme…

[freetibet]

Unsere wichtigste Seite z.Z.

http://www.clinicaltrials.gov/ct/show/NCT00409188?order=4

[versager69]

Antwort auf Beitrag Nr.: 26.449.235 von freetibet am 24.12.06 10:09:17

Press Release Source: Biomira Inc.


Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer now open for patient enrollment
Tuesday January 2, 8:00 am ET


EDMONTON, Jan. 2 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that the global Phase III clinical trial, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax® (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC) is open for patient enrollment. The trial is being conducted by Merck KGaA of Darmstadt, Germany, ("Merck") and its U.S. affiliate EMD Pharmaceuticals, Inc. under the provision of a collaboration agreement between Biomira and Merck. Biomira is entitled to a milestone payment upon enrollment of the first patient in the Phase III trial, which is anticipated to occur in January 2007.
ADVERTISEMENT





Enrollment in the trial, which is expected to include more than 1,300 patients in approximately 30 countries, is now open to patients in 12 countries, including the U.S., and will subsequently expand to additional countries. Currently, there are no approved maintenance therapies for patients responding to first-line treatment for unresectable stage III NSCLC.

About the START Trial

The START trial is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum based radio-chemotherapy. The study has been designed considering scientific advice from the European Medicines Agency (EMEA/CHMP) and has been agreed upon with the U.S. Food and Drug Administration (FDA) through a Special Protocol Assessment (SPA). Data from a randomized phase IIb trial described below encouraged the initiation of the Phase III program.

For more information on the START trial, or to find a participating center and eligibility criteria, log on to www.StimuvaxSTART.com or www.clinicaltrials.gov.

About Stimuvax

Stimuvax is an innovative cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. MUC1 is over expressed on many cancers such as lung cancer, breast cancer and colorectal cancer. Stimuvax is thought to work by stimulating the body's immune system to identify and destroy cancer cells expressing MUC1.

A randomized Phase IIb trial was conducted in 171 patients with stage IIIb and IV NSCLC with response or stable disease after first line therapy. While the overall study results were not statistically significant, in the randomization stratum of patients with stage IIIb locoregional disease, Stimuvax showed a median survival of 30.6 months versus 13.3 months in the control group - an improvement of 17.3 months. In the Phase IIb trial, side effects were primarily limited to mild-to-moderate flu-like symptoms, GI disturbances, and mild injection site reactions.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

This press release contains forward looking statements, including, without limitation, statements related to payments Biomira expects to receive; the therapeutic and commercial potential of Stimuvax and other drug candidates in Biomira's pipeline; future clinical development plans; the details of the clinical trials; and the anticipated future size of the market for Stimuvax. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Stimuvax, and the possibility of future payments. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.




--------------------------------------------------------------------------------
Source: Biomira Inc.

[freetibet]

Und noch eine !!


Phase II clinical trial of Biomira's PX-12 in patients with advanced pancreatic cancer now open for patient enrollment
Tuesday January 2, 8:00 am ET


EDMONTON, Jan. 2 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that the Phase II clinical trial of PX-12 in patients with advanced pancreatic cancer is open for enrollment. PX-12 is a proprietary small molecule designed to inhibit the activity of thioredoxin (Trx-1), a protein that regulates a number of cancer-related pathways. Biomira anticipates that the first patient in the trial will be treated in January 2007.

The randomized, open-label Phase II trial will evaluate two dose levels of PX-12 in patients with advanced pancreatic cancer whose tumors have progressed while being treated with gemcitabine or gemcitabine-containing regimens. Up to 80 patients are expected to be enrolled in the trial at three centers in the United States: the Virginia G. Piper Cancer Center in Scottsdale, Arizona; the University of Arizona Cancer Center, Tucson; and the University of Texas M.D. Anderson Cancer Center in Houston. The United States National Cancer Institute (NCI) is partially funding the trial under a Clinical Trials Agreement with the Translational Genomics Research Institute (TGen). The principal investigator for the trial is Daniel D. Von Hoff, MD.

"Trx-1 is known to control diverse molecular pathways that contribute to the growth, survival and drug resistance of many cancers," said D. Lynn Kirkpatrick, Ph.D., Biomira's Chief Scientific Officer. "By inhibiting Trx-1, PX-12 may have utility in a variety of cancer indications, including pancreatic cancer, an aggressive malignancy for which there are limited treatment options and significant unmet medical needs."

About PX-12

PX-12 is an irreversible inhibitor of thioredoxin (Trx-1), a protein that regulates many transcription factors including hypoxia inducible factor (HIF)-1 alpha, vascular endothelial growth factor (VEGF) and activator protein 1 (AP-1). These factors play a critical role in cancer cell growth, survival and resistance to chemotherapy. Increased thioredoxin levels in cancer cells have been linked to the aggressive proliferation of solid tumors, including colon, lung, and gastric cancers. PX-12 has successfully completed Phase I safety evaluation and is currently being studied in a Phase IB trial for the treatment of gastrointestinal cancers. An initial Phase I trial involving 38 patients with advanced metastatic cancer showed that PX-12 was well tolerated and produced a decrease in plasma concentrations of thioredoxin that was significantly correlated with increased patient survival. Seven of the 38 patients achieved stable disease of up to 322 days.

About the Translational Genomics Research Institute (TGen)

The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, is focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research. For more information go to www.tgen.org.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward Looking Statements

This press release contains forward looking statements, including, without limitation, statements related to the therapeutic and commercial potential of PX-12 and other drug candidates in Biomira's pipeline; future clinical development plans; the details of the clinical trials; and the anticipated future size of the market for PX-12. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Biomira's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability of the company to successfully conduct clinical trials for PX-12 and other drug candidates; the uncertainty of the U.S. Food and Drug Administration (FDA) approval process and other regulatory requirements; and the therapeutic and commercial value of Biomira's drug candidates. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[seppel]

Na, das sieht doch schon mal ganz gut aus:

Aktuell: 1.61$ in Kanada = 1.04 Euro

[ollihat]

Antwort auf Beitrag Nr.: 26.640.263 von seppel am 02.01.07 18:38:06

Inzwischen sind es 1.70 can$

[gans35]

Antwort auf Beitrag Nr.: 26.643.544 von ollihat am 02.01.07 21:12:11

Hallo ollihat,
kannst du bitte mal den Link für den Kurs aus Canada reinstellen?! Vielen Dank!
Gruß gans35

[versager69]

Antwort auf Beitrag Nr.: 26.643.653 von gans35 am 02.01.07 21:17:12

http://www.tsx.com/HttpController?GetPage=QuotesLookupPage&D…

[ollihat]

Antwort auf Beitrag Nr.: 26.643.653 von gans35 am 02.01.07 21:17:12

Also Kollege versager hat das ja schon erledigt:

nur für die Schnellen: TSX.COM
Dasd Kürzel von Biomira ist dort : BRA

[gans35]

Antwort auf Beitrag Nr.: 26.643.997 von ollihat am 02.01.07 21:34:58

Herzlichen Dank! Hat geklappt! Schaue mir sonst den Kurs in NY an.
Noch allen Biomira-Fans viel Glück im neuen Jahr und insbesondere für die Kursentwicklung von biom!
Gruß gans35

[US336]

http://www.pharmaceutical-business-review.com/article_news.a…

[freetibet]

Biomira Reaches Cancer Drug Milestone
Wednesday January 3, 10:06 am ET
Biomira Shares Rise After Reaching Cancer Drug Milestone for Start of Clinical Trial


NEW YORK (AP) -- Shares of Biomira Inc. surged Wednesday after the Canadian biotech drugmaker said it is entitled to an undisclosed milestone payment from its partner, the German drug maker Merck KGaA, for beginning a late stage clinical trial for Stimuvax.


Biomira shares rose 13 cents, or 11.4 percent, to $1.27 in morning trading on the Nasdaq. The stock has traded between 85 cents and $2 over the past 52 weeks.

The Phase III clinical trial will study the cancer vaccine Stimuvax as a treatment in patients with advanced non-small cell lung cancer that cannot be removed through surgery. The trial will be run by Merck and its U.S. affiliate EMD Pharmaceuticals. Biomira expects the milestone payment sometime in January.

Biomira anticipates the clinical trial will enroll more than 1,300 patients in about 30 countries.

Separately, Biomira said it is enrolling patients in a mid-stage clinical trial for its PX-12 cancer drug for advanced pancreatic cancer. The company expects to enroll the trial's first patient this month. PX-12 is a small molecule intended to inhibit a protein that regulates the activity of cancer cells.

[freetibet]

@donnerpower

-gesperrt- ??

Gute Besserung !

[seppel]

Tja, damit hat sich leider bewahrheitet, was einige User in den USA bereits am Montag kritisiert hatten: Die IR-Abteilung bei Biomira hat mal wieder grandios versagt. Anstatt die Meldung gestern zu veröffentlichen, macht man das am Montag, wo der wichtigste Handelsplatz geschlossen ist. Allein durch die ungünstige Bekanntgabe der Kapitalerhöhung und der aktuellen Meldung hat man 50-60% Kursplus verschenkt

[philippf]

Antwort auf Beitrag Nr.: 26.671.734 von seppel am 04.01.07 13:05:33

Ich denke, die müssen das an dem Tag veröffentlichen, wo es für den Börsenhandel relevant ist. Und wenn an dem Tag nur bei uns – nicht in Amerika – gehandelt wird, ist das zwar ärgerlich – aber vermutlich nicht zu ändern.

[seppel]

Nun, das sehen einige anders: Die Kapitalerhöhung hätte man auch einige Tage vor der guten News im Dezember veröffentlichen können. Dann wäre der Kurs niemals auf 1.1 US$ gefallen. Wir waren einen Tag vorher immerhin Spitze bei 1.70 US$. Die neue News hätte auch am 3.1. kommen können, denn immerhin entscheiden Merk und Biomira ja, ab wann sie die Pateinten für Phase III auswählen. Ich bin mir fast sicher, dass wir ohne diese Fehler schon bei 2 US$ wären.

[freetibet]

Antwort auf Beitrag Nr.: 26.673.757 von seppel am 04.01.07 15:08:45

@seppel

Man kann sagen was man will,
es ist einfach nur ein Trauerspiel.

Da bin ich jetzt schon auf die Art und Weise der
möglichen Zulassungsmeldung gespannt.

Beste Grüsse
freetibet

[bernie55]

Antwort auf Beitrag Nr.: 26.676.362 von freetibet am 04.01.07 17:01:21

...unprofessioneller und diletanttischer kann es wirklich nicht mehr werden....

....ich hoffe , dass wir mal positiver überrascht werden und dass sich dieses dann auch im Kurs niederschlägt.....

.... let`s hope together....

[versager69]

Antwort auf Beitrag Nr.: 26.676.747 von bernie55 am 04.01.07 17:20:03

völlig untergegangen ist doch auch der start von phase2
PX-12
hat hier biomira noch alle vermarktungsrechte??

[seppel]

Kaum auszudenken, wenn man die beiden sehr guten nachrichten am 3.1. und 4.1. nacheinander veröffentlicht hätte

Nun gut, wir sind ja alle leidgeprüfte Biomler und dadurch auch fürs richtige Leben abgehärtet

Kurze Google-Übersetzung zu PX-12:

EDMONTON, 2. Jan. 2007 Biomira Inc. (Nasdaq: BIOM) hat heute verkündet, daß der Phase II klinische Versuch von PX-12 bei Patienten mit vorgerücktem pankreatischem Krebs für die Einschreibung geöffnet ist. PX-12 ist ein eigenes, kleines Molekül, das entworfen wurde, um die Tätigkeit von Thioredoxin (Trx-1), ein Protein zu hemmen, das eine Anzahl von, mit Krebs in Verbindung stehenden Bahnen, reguliert. Biomira nimmt vorweg, daß der erste Patient im Versuch im Januar 2007 behandelt wird. Der randomisierte, open-label Phase II Versuch wertet zwei Dosisniveaus von PX-12 bei Patienten mit vorgerücktem pankreatischem Krebs aus. Es werden dabei bis zu 80 Patienten erwartet, die sich an dem Versuch an 3 Stationen in den Vereinigten Staaten einschreiben werden: die Virginia G. Pfeifer-Krebs-Station in Scottsdale, Arizona; die Universität der Arizona-Krebs-Station, Tucson und die Universität Texas M.D. Anderson der Krebs-Station in Houston. Das nationale Krebs-Institut (NCI) finanziert teilweise den Versuch unter einer klinischen Vereinbarung mit dem Translational Genomics Forschungsinstitut (TGen).

Der Hauptforscher für den Versuch ist Daniel D. Von Hoff, MD. "Trx-1 ist bekannt dafür, verschiedene molekulare Bahnen, die zum Wachstum, Überleben und Widerstand von Krebs führen, zu steuern" sagte D. Lynn Kirkpatrick, Ph.D., Biomiras wissenschaftlicher Verantwortlicher. "...durch das Hemmen von Trx-1 kann PX-12 Möglichkeiten aufzeigen, eine Vielzahl der Krebsanzeigen, einschließlich pankreatischen Krebs zu behandeln."

Über PX-12
PX-12 ist ein irreversibles Hemmnis von Thioredoxin (Trx-1), von Protein, das viele Übertragungfaktoren, einschließlich durch Induktion erhältlichen Faktor der Hypoxie (HIF), reguliert - 1 Alpha, von endothelial Wachstumgefäßfaktor (VEGF) und von Aktivatorprotein 1 (AP-1). Diese Faktoren spielen eine kritische Rolle im Krebszelle Wachstum, dem überleben und dem Widerstand zur Chemotherapie. Erhöhte thioredoxin Niveaus in den Krebszellen sind mit der konkurrenzfähigen starken Verbreitung der festen Tumoren, einschließlich Doppelpunkt, Lungenflügel und gastrische Krebse verbunden worden. PX-12 hat erfolgreich Phase I Sicherheit Auswertung durchgeführt und wird z.Z. in einem Phase IB Versuch für die Behandlung der gastro-intestinalen Krebse studiert. Eine Ausgangsphase I Probe, 38 Patienten in vorgerückten metastatic Krebs mit einbeziehend, zeigte, daß PX-12 gut zugelassen wurde und produzierte eine Abnahme an den Plasmakonzentrationen von thioredoxin, das erheblich mit erhöhtem geduldigem überleben aufeinander bezogen wurde. Sieben der 38 Patienten erzielten beständige Krankheit von bis 322 Tagen.

Über das Translational Genomics Forschungsinstitut (TGen)
Das Translational Genomics Forschungsinstitut (TGen), eine gemeinnützige (c) (3) Organisation 501, wird auf sich entwickelnde frühere Diagnose und intelligentere Behandlungen gerichtet. Translational genomics Forschung ist auffangen das Einsetzen der erfinderischen Fortschritte ein verhältnismäßig neues, die aus dem menschlichen Genom-Projekt entstehen und sie an der Entwicklung der Diagnose anwenden, der Prognosen und der Therapien für Krebs, der neurologischen Störungen, des Diabetes und anderer komplizierter Krankheiten. Forschung TGens basiert auf personifizierter Medizin und den Institutplänen, um seine Ziele durch robuste und Krankheit-fokussierte Forschung zu erreichen. Zu mehr Information zu www.tgen.org gehen.

(Quelle: www.biomira.com)

[seppel]

Hi Biomler,

habe mal eine Email an die IR von Biomira geschickt. Hier die Antwort auf 2 meiner Fragen:


(2) Can you already measure, how high the milestone payment of Merck KGaA will be and when this takes place about?

The amount of the milestone payment is a fixed number, but the amount has not been disclosed. The payment will be made when the first patient is enrolled in the Phase III trial of Stimuvaxx.

(3) Are the capital increase (U.S. $13 million financing), communicated at 12-13-2006, already final and/or when will this be in final?

The financing was successfully completed in 2006.


Werde mich noch erkundigen, ob PX-12 zu 100% noch in der Hand von BIOM ist.

[smartinick]

Antwort auf Beitrag Nr.: 26.695.916 von seppel am 05.01.07 17:25:05

Hallo allerseits!

Das folgende hat mein rss-reader gestern aus den tiefen des netzes gefischt - für mich sieht das wieder mal als grund für einen weiteren kursverfall aus:

(http://www.newsrx.com/articles/423776.html)
Biomira announces $13 million financing

January 14th, 2007

(NewsRx.com) -- Biomira, Inc., (BIOM, BRA) announced that it has arranged a financing of approximately $13 million, before deducting placement agent fees and expenses, with Rodman & Renshaw, LLC of New York acting as exclusive placement agent.

In connection with this financing, Biomira intends to file shortly in Canada a prospectus supplement to its September 26, 2006 Base Shelf Prospectus and in the United States a prospectus supplement to its September 26, 2006 F-10 Registration Statement. The financing is expected to close within the next few days and is subject to regulatory approval.

The company will be offering up to 9,629,650 units, each unit consisting of one common share and 0.20 of a warrant, at an issue price of $1.35. In addition, approximately 96,000 compensation warrants, having similar terms to the purchaser warrants, will be issued to the placement agent.

Each warrant will entitle the holder thereof to purchase one common share at an exercise price of $1.86. The warrants will have a 48-month term, from the date the financing closes, and a no-exercise period of 6 months.

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

This article was prepared by NewsRx editors from staff and other reports. Copyright 2007, NewsRx.com.

[dannyrose]

Pressestimmen:
http://news.bbc.co.uk/2/hi/health/6249489.stm
http://www.pharmabiz.com/article/detnews.asp?articleid=37094
http://www.pharmaceutical-business-review.com/article_news.a…" target="_blank" rel="nofollow ugc noopener">http://www.pharmaceutical-business-review.com/article_news.a…

Ich bin schon einige Jahre dabei, lese sporadisch hier und auf
http://messages.finance.yahoo.com/mb/biom" target="_blank" rel="nofollow ugc noopener">http://messages.finance.yahoo.com/mb/biom

Mein Zeithorizont geht in Richtung 2015.

Gruß an alle Investierten
dannyrose

[bonDiacomova]

Antwort auf Beitrag Nr.: 26.906.622 von smartinick am 14.01.07 11:48:22

jungedie da haste Dir fuer Dein 1. posting
aber ordentlich zeit gelassen

Deine einschaetzung :
" - für mich sieht das wieder mal
als grund für einen weiteren kursverfall aus: "

teile ich nicht...
der vk der aktien ---> 1.35 $
liegt doch ueber dem akt. boersenkurs...
die warrants liegen bei 1.86 $ - ist doch o.k.

saludos bd

[smartinick]

Antwort auf Beitrag Nr.: 26.911.503 von bonDiacomova am 14.01.07 15:39:08

naja, die frage ist wann biom das selbst herausbringt...? wohl dann wenn der kurs bei 1,6 steht... dann sind die 1,35 schlechter und wir gehen wieder runter... wenn man von biomiras bisheriger unfähigkeit was pressemeldungen betrifft auf diese meldung schliest... wird es sicher am ende was negatives...

erster post und zeit gelassen... naja, bisher hab ich nur gelurked - gesucht und gelesen...

[bonDiacomova]

Antwort auf Beitrag Nr.: 26.919.642 von smartinick am 14.01.07 21:26:13

zitat smartinick :

naja, die frage ist wann biom das selbst herausbringt...?

zitat ende

---

# 2687 von smartinick :

Biomira, Inc., (BIOM, BRA) announced :

The financing is expected to close within the next few days...
... and is subject to regulatory approval.
---

# 2686 von seppel :

3) Are the capital increase (U.S. $13 million financing), communicated at 12-13-2006,
already final and/or when will this be in final?

The financing was successfully completed in 2006.

---

ich denke es ist schon gezeichnet
und nur noch die "approvation" fehlt

saludos bd

[seppel]

Antwort auf Beitrag Nr.: 26.906.622 von smartinick am 14.01.07 11:48:22

Hi smartinick. Das ist quasi wortwörtlich die Finanzierung vom 13.12.06. Also nix neues. Die Finanzierung vom 13.12.06 ist laut der IR von BIOM bereits abgeschlossen. Somit sollte nun eher die 1.35US$ als Ziel anvisiert werden. Im Januar sollte auch die genaue Höhe der Meilensteinzahlung von Merck KgaA bekannt gegeben werden.

Man darf also gespannt und leicht optimistisch die nächsten Wochen erwarten

[seppel]

dannyrose: Übrigens sind deine gesetzten Links sehr interessant. Die sollte sich jeder mal durchlesen.

Sätze, wie "Merck KGaA also plans to investigate the use of Stimuvax for other types of cancer." lassen ja auf einiges hoffen

[smartinick]

Antwort auf Beitrag Nr.: 26.934.633 von seppel am 15.01.07 14:15:18

Hallo Seppel!

wobei das ja in der vergangenheit schon öfter in berichten von biomira erwähnt wurde - man wolle blp-25/stimuvax auch auf die anwendung bei anderen krebsarten hin abklopfen...

lG, Martin.

[freetibet]

Eric Baker retires from Biomira's Board of Directors
Monday January 22, 8:00 am ET

EDMONTON, Jan. 22 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that Eric E. Baker retired from the Company's Board of Directors on January 19, 2007. Mr. Baker had been a member of the Board since 1985 and served as Chairman until September 2006. He also served over the years as a member of various committees of the Board, including most recently, the Executive Compensation Committee.
Christopher S. Henney, Ph.D., DSc, Chairman of Biomira's Board of Director said "It has been a pleasure to work with Eric. He has been a valuable resource to Biomira for more than 20 years and his services have been an asset to the Company. On behalf of Biomira's Board of Directors and the Company's management team, I wish Eric well in his future endeavors."

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.


BIOMIRA INC. 2011 - 94 St. Edmonton, AB, Canada T6N 1H1
Tel: [phone] Fax: [phone]
http://www.biomira.com

[KnigRollo]

hallo an alle,

kann mir irgend jemand mal erklären, warum ein wert wie biomira mit stimuvax ein derartiges mauerblümchen dasein führt. wann ist mit einem ende der begonnenen phase III zu rechnen ?
überlebensvorteil einfach nur sensationell !!


das meint der "forschungsminister" der merck
Elmar Schnee: I think we wouldn’t be in oncology if we did not think that we can get to a global position. Roche is an extremely interesting example. If you looked 10 years ago, Roche was nowhere; even as a company there were questions. They have obviously done some brilliant deals, like the Genentech model which they use. Roche is a dominant player currently in oncology, however, we think we also have a very nice pipeline lined up, apart from Erbitux, which we still believe will be a highly attractive drug. Also in competing against drugs from Roche or also staying its mark against new arrivals, we have a product like Stimuvax (BLP25), which could be the first therapeutic cancer vaccine. We know how to develop drugs, which we have proven with Erbitux; BMS and ImClone together were not successful and needed our information to get FDA approval. If we play our cards right, we could really have a global position and be an innovator in the arena.



andererseits steigt dieser kack mit schlechterem wirkprofil...

without words...
Die News für die Antisoma-Aktie würden seit der Kaufempfehlung von "Hot Stocks Europe" nicht abreißen: Für die beiden viel versprechenden Krebspräparate AS1404 und AS1411 habe das Unternehmen noch in 2006 weitere positive Forschungsergebnisse bei der Behandlung von Lungenkrebs und Leukämie präsentiert. Daraufhin habe Antisoma Mitte Dezember ohne Probleme GBP 26,3 Mio. bei institutionellen Investoren einkassiert, die Kapitalerhöhung sei sogar deutlich überzeichnet gewesen.

[freetibet]

Antwort auf Beitrag Nr.: 27.298.433 von KnigRollo am 30.01.07 16:21:42

Guten Abend,

hier hast Du alle Daten:

http://www.clinicaltrials.gov/ct/show/NCT00409188?order=1

Wichtig ist, dass wir einen Fast-Track Status haben.
Es kann also auch schneller gehen.

Interessant ist, dass bereits sämtliche domains für Stimuvax
gekauft sind.
Es wird also, wahrscheinlich von Merck Kgaa, bald die Werbetrommel
gerührt. Merck will schließlich Geld verdienen.

Wenn Biomira mal eine ordentliche PR macht und sich
dann Analysten für die Firma interessieren, dann werden
wir auch Kurssprünge sehen.
Ansonsten musst Du bis 2011 durchhalten.

[philippf]

Antwort auf Beitrag Nr.: 27.298.433 von KnigRollo am 30.01.07 16:21:42

Ich glaube das Hauptproblem bei BIOM ist im Moment, dass nahezu gar keine Pressearbeit stattfindet und deswegene logischerweise niemand mehr von BIOM Notiz nimmt...

[freetibet]

Biomira to present at the BIO CEO & Investor Conference 2007
Thursday February 8, 8:00 am ET


EDMONTON, Feb. 8 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the BIO CEO & Investor Conference 2007 at 2:15 pm EST on February 14th in New York City.

The presentation is planned for a live webcast and can be accessed at:

www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BIOM&item_…

Biomira intends to make a recording of the webcast available on the Biomira website approximately one hour after completion of the presentation. The presentation will be archived for 90 days.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[bernie55]

Analysis: Vaccine market to top $23B
By STEVE MITCHELL
UPI Senior Medical Correspondent

WASHINGTON, Feb. 9 (UPI) -- The global vaccine market is expected to top $10 billion this year and $23.8 billion by 2012, according to an analyst report released Friday.

. . . . . . . . . . .

Prostate cancer will also be a significant opportunity. Cell Genesys' Gvax and Dendreon's Provenge will lead this area, which is anticipated to be worth $3.2 billion by 2012.

Another top runner is Merck KGaA's lung-cancer vaccine Stimuvax, which is expected to generate $699 million in sales by 2012, Carlson said.


http://www.upi.com/HealthBusiness/view.php?StoryID=20070209-…

[donnerpower]

Antwort auf Beitrag Nr.: 27.572.181 von bernie55 am 10.02.07 11:44:23

[freetibet]

Ich bin ja mal gespannt ob die neue Führung heute so etwas
wie Aufbruchstimmung verbreiten kann.
Irgendwann muß es ja mal losgehen.

[freetibet]

worldwide rights to the commercialisation of CVacT
Tuesday, 13 February 2007, 12:25 pm
Press Release: Prima BioMed

Prima BioMed successfully negotiates licence variation with Biomira Inc to secure worldwide rights to the commercialisation of CVacTM
Key Points:


Prima BioMed (“Prima”) has successfully negotiated a variation to the License and Development Agreement with Biomira Inc. (“Biomira”)


Prima secures worldwide commercialisation rights for the Mucin-1 antigen for dendritic cell (DC) based therapies. Mucin-1 is the therapeutic target for Prima’s lead product candidate, CVacTM


Prima now has the opportunity to pursue the development of CVacTM for worldwide registration and marketing. CVacTM’s first target indication is ovarian cancer


The worldwide market for ovarian cancer was estimated at US$1.9 billion in 2006. The same market in Australia and New Zealand has been estimated at A$100 million


Milestone and royalty payments payable to Biomira under the Licence and Development Agreement have been reduced as part of the variation.

Tuesday 13 February 2007, Melbourne, Australia: Prima BioMed Limited (ASX:PRR) (“Prima”) today announced that it has successfully negotiated a variation of its Licensing and Development Agreement (“Licence”) with Biomira Inc. (NASDAQ: BIO; TSX:BRA) (“Biomira”). The variation confirms that Prima has worldwide commercialisation rights to the key tumour based antigen, Mucin-1, for the use in dendritic cell-based cancer therapies. Mucin-1 is an antigen expressed on a variety of solid tumours. The variation allows Prima to pursue the development of CVac™ with an internationally focused clinical development program.

The License, signed in March 2004, granted Prima worldwide access to Mucin-1 for use with the CVac™ platform technology. The License also granted Biomira an option, expiring 120 days post completion of the phase IIa clinical trial, to commercialise CVac™ outside of Australia and New Zealand (ANZ). The variation of the Licence confirms that Biomira will not be exercising the option, as the program no longer fits strategically with its portfolio of small molecule drugs and synthetic vaccines.

Mr Eugene Kopp, Executive Chairman of Prima said, “Licensing Mucin-1 from Biomira has been a critical step in the development of our CVac™ technology. Prima is now in a stronger position to develop an internationally competitive immunotherapy-based oncology product. We now have certainty that we can access markets beyond just Australia and New Zealand.”

Under the varied License, milestone payments and royalty obligations owed to Biomira by Prima have been reduced.

The final Phase IIa trial results for CVac™ are due to be released this quarter. Biomira has not assessed the statistical package or the Clinical Study Report being generated by Prima’s clinical research organisation.

Whilst successful development and/or commercialisation of CVac™ cannot be assured due the inherent risks associated with drug development, Prima is approaching the development of this product with enthusiasm. This variation to the License allows Prima to pursue a clinical development plan that aligns with an international product registration process rather than the previously stated ANZ only strategy.

[bernie55]

PREMARKET http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

08:49 $ 1.22 2,000
08:35 $ 1.22 8,520
08:35 $ 1.22 1,180
08:35 $ 1.20 200
08:35 $ 1.20 1,300
08:35 $ 1.20 50,000
08:32 $ 1.22 300
08:28 $ 1.22 1,900
08:28 $ 1.22 335
08:27 $ 1.22 100
08:26 $ 1.23 7,765
08:25 $ 1.22 900
08:21 $ 1.22 1,000
08:21 $ 1.23 5,000
08:21 $ 1.23 500
08:19 $ 1.19 1,500
08:18 $ 1.20 4,220
08:17 $ 1.22 100
08:17 $ 1.22 420
08:17 $ 1.22 780
08:17 $ 1.20 500
08:16 $ 1.22 1,000
08:16 $ 1.22 500
08:16 $ 1.22 500
08:16 $ 1.22 2,500
08:15 $ 1.21 1,000
08:14 $ 1.19 1,000
08:14 $ 1.19 500
08:06 $ 1.14 3,800

[bernie55]

Rodman & Renshaw, LLC initiated research coverage of Biomira, Inc. (NASD: BIOM) with a Market Outperform Rating and a 12-month price target $3.00.

Navdeep Jaikaria, Ph.D., Senior Biotechnology Analyst, issued the report.


http://www.investorvillage.com/smbd.asp?mb=2982&pt=qn

[freetibet]

Biomira Rodman & Renshaw initiates Mkt Outperform. Target $3. Rodman and Renshaw initiates BIOM with an Outperform and a $3 tgt saying their analysis of BIOM shares leads us to conclude that current valuations are not reflective of the value proposition provided by the potential of Stimuvax, a cancer vaccine in Phase III trials, which has demonstrated impressive results in patients with stage IIIB non-small cell lung cancer, and Biomira's promising pipeline. The firm believes that patients could be enrolled quickly in this trial, which they forecast could be completed by 1H08, with potential release of top-line data in 1H09, and a potential BLA filing/approval in 2010.
www.briefing.com

@bernie
Ich wollte nur die Zeitetappen bis zur Zulassung noch mit einfügen.

Na ja, 3$ hatten wir ja schon ein paar Mal.

Könnte ruhig langsam zweistellig werden.

[DausendUndMehr]

[schmacki]

Solange sich hier nichts tut,könnt Ihr ja mal BNC anschauen,kann ne Rakete werden!

[minadon]

Press Release Source: Biomira Inc.


First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
Monday February 26, 8:00 am ET


EDMONTON, Feb. 26 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that the first patient has been enrolled in the global Phase III clinical trial, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax® (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). The trial is being conducted by Merck KGaA of Darmstadt, Germany, ("Merck") and its U.S. affiliate EMD Pharmaceuticals, Inc. pursuant to the terms of a collaboration between Biomira and Merck. The collaboration arrangement provides that Biomira is entitled to receive a milestone payment from Merck upon enrollment of the first patient in this trial. As per the terms of the collaboration, the amount of the milestone is not being disclosed.
ADVERTISEMENT


"Enrolling the first patient in this Phase III trial is a major step forward for Biomira's therapeutic vaccine technology and represents an important milestone toward our goal of commercializing important new cancer therapies," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "To our knowledge, this is the first Phase III trial of a therapeutic vaccine in unresectable stage III NSCLC, which, if successful, would offer new hope for patients with limited options."

Dr. Kirkman added, "In 2007 we expect to make additional progress in advancing our clinical pipeline. The Phase II trial of PX-12 in patients with advanced pancreatic cancer is ongoing and we expect to bring PX-478 into clinical development at mid-year. With this progress, we are building a diverse clinical portfolio of innovative potential cancer therapies, and moving closer to realizing the value of our vaccine and small-molecule platforms."

According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in both men and women worldwide with approximately 80 percent of lung cancer cases classified as NSCLC. Further, only about 15 percent of people diagnosed with NSCLC survive this disease after five years. For most patients with NSCLC, current treatments provide limited success.

Enrollment in the START trial, which is expected to include more than 1,300 patients in approximately 30 countries, is now open to patients in the U.S. where the first randomization has occurred. It is expected that enrollment will subsequently expand to additional countries. Currently, there are no approved maintenance therapies for patients responding to first-line treatment for unresectable stage III NSCLC.

About the START Trial

The START trial is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum based chemo-radiotherapy. The study has been designed considering scientific advice from the European Medicines Agency (EMEA/CHMP) and has been agreed upon with the U.S. Food and Drug Administration (FDA) through a Special Protocol Assessment (SPA). Data from a randomized Phase IIb trial described below encouraged the initiation of the Phase III program.

For more information on the START trial, or to find a participating center and eligibility criteria, log on to www.nsclcstudy.com or www.clinicaltrials.gov.

About Stimuvax

Stimuvax is an innovative cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. MUC1 is over expressed on many cancers such as lung cancer, breast cancer and colorectal cancer. Stimuvax is thought to work by stimulating the body's immune system to identify and destroy cancer cells expressing MUC1.

A randomized Phase IIb trial was conducted in 171 patients with stage IIIb and IV NSCLC with response or stable disease after first line therapy. While the overall study results were not statistically significant, in the randomization stratum of patients with stage IIIb locoregional disease, Stimuvax showed a median survival of 30.6 months versus 13.3 months in the control group - an improvement of 17.3 months. In the Phase IIb trial, side effects were primarily limited to mild-to-moderate flu-like symptoms, GI disturbances, and mild injection site reactions.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward Looking Statements

This press release contains forward looking statements, including, without limitation, statements related to milestone payments Biomira may expect to receive; the therapeutic and commercial potential of Stimuvax® and other drug candidates in Biomira's pipeline; future clinical development plans; the details of the clinical trials; and the anticipated future size of the market for Stimuvax. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Stimuvax, and the possibility of future milestone payments. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.




--------------------------------------------------------------------------------
Source: Biomira Inc.


Email Story
Set News Alert
Print Story






Sponsor Results
Mortgage Rates Near 40-Year Lows
$310K loan for $999/mo. Think you pay too much? Calculate new payment.
www.lowermybills.com
Become a Child Crisis Partner
Your $20 pledge helps one child after another escape lives of horror.
www.worldvision.org

(What's This?)



Related Quote
BIOM 1.20 +0.02 News
View Detailed Quote
Delayed 20 mins
Providers - Disclaimer


Related News Stories
· InPlay: Biomira says first patient enrolled in Stimuvax Phase III clinical trial in patients with non-small cell lung cancer - Briefing.com (8:06 am)
· Coverage initiated on Biomira by Rodman & Renshaw - Briefing.com (Thu Feb 15)
· Biomira to present at the BIO CEO & Investor Conference 2007 - PR Newswire (Thu Feb 8)
· Eric Baker retires from Biomira's Board of Directors - PR Newswire (Mon Jan 22)
More...

--------------------------------------------------------------------------------

· By industry: Biotechnology






Top Stories
· Wall Street Mostly Higher on M&A Deals - AP (10:17 am)
· Oil Prices Rise Above $61 a Barrel - AP (8:31 am)
· Greenspan Warns of Likely U.S. Recession - AP (8:34 am)
· TXU Agrees to $32B Sale to Buyout Firms - AP (9:49 am)
More...

--------------------------------------------------------------------------------

· Most-viewed articles




RSS Feeds
Add headlines to your
personalized My Yahoo! Page
( About My Yahoo! and RSS )

BIOM Headlines
My Yahoo RSS Biotechnology Headlines
My Yahoo RSS More Finance RSS Feeds

[BULLE2004]

Auf zu neuen Tiefstkursen, für mich ist Biomira ein glasklarer Verkauf.

[donnerpower]

[donnerpower]

[freetibet]

Biomira's Clinical Trial: Impetus To Sell
Posted on Feb 26th, 2007 with stocks: BIOM

Wall Street Mayhem submits:This morning Biomira (BIOM) announced that the first patient has been enrolled in a global Phase III clinical trial assessing the efficacy and safety of Stimuvax for treatment of non-small cell lung cancer. The trial is being conducted by Merck KGaA and its US affiliate EMD Pharmaceuticals. This event entitles Biomira to receive a milestone payment from Merck, but the amount of the milestone is not being disclosed at this time.

This is the event we were looking for and although this event did not have a large effect on the share price, we sold our shares this morning. Stimuvax looks like a promising drug and we will consider buying Biomira shares again in the future, but for now we don’t see any short term catalysts for Biomira so we will watch from the sidelines.

The next important event for Biomira will be either a new SEC filing or the next quarterly earnings announcement. One of these events will give investors the chance to find out the amount of the milestone payment by examining Biomira’s financial statements. This milestone payment amount is important because it could also shed some light on the royalty payment percentages Biomira would receive if Stimuvax is approved

http://biotech.seekingalpha.com/article/28053

[philippf]

Biomira restates U.S. GAAP note disclosure for non-cash charges

Print
3/2/2007 8:03:00 AM

EDMONTON, March 2 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today announced that it is restating its United States generally accepted accounting principles ("U.S. GAAP") reconciliation note in its financial statements due to a recent interpretation by the United States regulatory authorities of the U.S. accounting rules contained in the Statement of Financial Accounting Standards ("SFAS") 133, Accounting for Derivative Instruments and Hedging Activities which determines the current U.S. accounting treatment of the Company's share purchase warrants.

The Company reports in accordance with Canadian generally accepted accounting principles ("Canadian GAAP") and provides note disclosure in its financial statements with respect to a reconciliation of Canadian GAAP to U.S. GAAP. Under Canadian GAAP, the Company's share purchase warrants are classified as equity and recorded at their fair value on issuance. The interpretation under U.S. GAAP requires that when a company's share purchase warrants have an exercise price denominated in a currency other than a company's functional currency, those share purchase warrants must be classified as liabilities at their fair value with any changes in fair value being included in the calculation of U.S. GAAP earnings. In these circumstances, a loss (gain) would be recorded by a company when the value of the share purchase warrants increases (decreases).

As a result of this interpretation, the Company will include a restatement of comparative figures in the U.S. GAAP note included in its financial statements for the year ended December 31, 2006.

The Company's previously reported financial results under Canadian GAAP remain unchanged. These are non-cash charges for U.S. GAAP purposes only that do not impact the Company's operations or cash flows.

This restatement only pertains to the Company's U.S. GAAP reconciliation note disclosure, due to mark-to-market losses/gains arising from the fair value of these share purchase warrants and the classification of the warrants as liabilities under U.S. GAAP. The effect of the restatement under U.S. GAAP is as follows: a decrease in net loss of $3.1 million for the year ended December 31, 2002, a decrease in net loss of $1.5 million for the year ended December 31, 2003, an increase in net loss of $0.3 million for the year ended December 31, 2004, a decrease in net loss of $4.7 million for the year ended 2005, an increase in liabilities of $0.5 million as at December 31, 2005 and a decrease in shareholders' equity of $0.5 million as at December 31, 2005. For the year ended December 31, 2006, the Company will include in its U.S. GAAP note disclosure as a reconciling item a reduction of $4.4 million in losses related to the change in the fair value of share purchase warrants during the year. At the time that the Company's share purchase warrants are exercised, the value of the warrants will be reclassified to shareholders' equity within the Company's U.S. GAAP note.

The Financial Accounting Standards Board ("FASB") has initiated a project to determine the accounting treatment for convertible debt with elements of foreign currency risk. This project is expected to provide further U.S. GAAP guidance in respect of accounting for share purchase warrants.

[philippf]

Antwort auf Beitrag Nr.: 28.068.153 von philippf am 02.03.07 14:15:39

Achso... stammt von www.biomira.com

[MasaRatti]

Moin zusammen,
die Marktkapitalisierung von Biomira unter 100 Millionen zur Zeit,
wäre das nicht auch eine Möglichkeit für Merck hier tätig zu werden,
wie ist denn die Aktionärsstruktur, kann man ohne weiteres Biomira
übernehmen ! Sollte die Phase 3 gut verlaufen würde das doch Sinn
machen, man hätte alle Vermarktungsrechte und die Produktion von
Stimuvax komplett !
Gibt es eigentlich Meilensteinzahlungen demnächst ?
Meine Einschätzung wieder eine klare Einstiegsmöglichkeit !

[philippf]

Antwort auf Beitrag Nr.: 28.157.962 von MasaRatti am 07.03.07 06:40:26

Soweit ich weiß, soll es eine Meilensteinzahlung für den ersten Patienten in Phase 3 geben.
Allerdings ist die Höhe unbekannt.

[freetibet]

Biomira to present at two upcoming investor conferences

Print
3/7/2007 8:03:00 AM
EDMONTON, March 7 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.

The first presentation is scheduled to take place at the Cowen & Co. 27th Annual Health Care Conference at 9:30am EDT on March 15th in Boston. The second presentation is scheduled to take place at the Invest Northwest Investor and CEO Forum at 4:40pm EDT on March 20th in Seattle. A live webcast is planned for each presentation and can be accessed at www.biomira.com.

Biomira intends to make a recording of each webcast available on the Biomira website approximately one hour after completion of the presentation. The Company intends to archive each presentation for 90 days.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

SOURCE Biomira Inc.
-0- 03/07/2007
/CONTACT: Investor and Media Relations Contact: Stephanie H. Seiler,
Ph.D., Gemini BioProjects LLC, [phone], [e-mail]/

[donnerpower]

Antwort auf Beitrag Nr.: 28.166.708 von freetibet am 07.03.07 15:38:44

Ich hoffe die bringen später nicht noch mehr Shares auf den Markt

[minadon]

Antwort auf Beitrag Nr.: 28.193.640 von donnerpower am 08.03.07 22:01:53

Biomira reports Full year and Fourth Quarter 2006 Financial Results
Thursday March 8, 4:00 pm ET


EDMONTON, March 8 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today reported financial results for the year and quarter ended December 31, 2006. All results are in Canadian dollars.
ADVERTISEMENT



Net loss for the year ended December 31, 2006, was $17.8 million or $0.19 per basic and diluted share, compared with $19.0 million, or $0.24 per basic and diluted share in 2005. The decrease in net loss resulted from decreased clinical expenditures as a result of transferring the development program for Stimuvax® to Merck KGaA of Darmstadt Germany ("Merck") effective March 1, 2006, partly offset by increased general and administrative expenses related to changes in accounting for stock-based compensation and charges due to reduction in workforce. Revenue from operations for the year ended December 31, 2006 was $4.5 million, compared with $4.4 million in the prior year.

Expenses for the year ended December 31, 2006, were $24.1 million, compared with $24.5 million for the prior year. Research and development expenses decreased from $16.9 million in 2005 to $13.8 million in 2006, primarily as a result of reduced clinical expenditures with the transfer of responsibility for the clinical development of Stimuvax to Merck. This was offset by an increase in G&A expenses from $6.3 million in 2005 to $8.7 million in 2006. This increase was primarily attributable to changes in the expensing of stock options with the adoption of a new accounting policy in 2006, a non-cash expense, and with costs related to workforce reductions and employee exiting.

Net loss for the quarter ended December 31, 2006 was $4.3 million or $0.04 per basic and diluted share, compared with $4.4 million or $0.05 per basic and diluted share for the comparable period in 2005. Revenue from operations was $1.3 million, compared with $1.1 million for the comparable period in 2005. Expenses for the quarter were $6.7 million, compared with $6.0 million for the comparable period in 2005.

As of December 31, 2006, Biomira's cash, cash equivalents and short term investments were $33.0 million, compared to $21.4 million at the end of 2005, an increase of $11.6 million, or 54%. Major contributors to the net change included $31.9 million in net financing proceeds, offset by $15.6 million used in operations and $4.3 million used in the acquisition of ProlX Pharmaceuticals Corporation ("ProlX").

Financial Guidance

Biomira believes the following financial guidance to be correct as of the date provided. We are providing this guidance as a convenience to investors, and we assume no obligation to update it.

For 2007, we expect our research and development expenses to increase significantly, primarily as a result of increased manufacturing and process development activities for Stimuvax for the Phase 3 trial being conducted by Merck, and of increased development activity for the small molecules drugs we acquired with the acquisition of ProlX. We expect these expenses to be offset by increased funding from Merck, which is required to purchase Stimuvax from Biomira, by milestone payments we anticipate receiving from Merck, one for the enrollment of the first patient in the Phase 3 trial and another for the signing of the final amended collaboration and supply agreements, and by grant funding available to our ProlX subsidiary. The net result is that we anticipate that our cash used in operations for 2007 will be between $14 million and $16 million dollars. As a result, we believe that Biomira currently has sufficient cash resources to last into the second half of 2008.


Business Update

Key Achievements in 2006 included:
- Completing a Special Protocol Agreement (SPA) with the U.S. Food and
Drug Administration related to the Phase 3 trial of Stimuvax in
patients with non-small cell lung cancer. The SPA concerns the design
of the Phase 3 trial and outlines definitive clinical objectives and
data analyses considered necessary to support regulatory approval of
Stimuvax.
- Transferring the U.S. IND for Stimuvax to Merck, which enabled Merck
to initiate the Phase 3 trial.
- Appointing Robert L. Kirkman M.D. as President and Chief Executive
Officer and D. Lynn Kirkpatrick, Ph.D. as Chief Scientific Officer.
- Acquiring ProlX Pharmaceuticals Corporation. The acquisition brought
in a portfolio of small molecule compounds with significant potential
in the treatment of various cancers. Diversification of Biomira's
pipeline through the acquisition is expected to increase the
Company's opportunities for clinical and commercial success.
- Raising $31.9 million in net financing proceeds. These financial
resources are expected to support aggressive advancement of multiple
product development programs.

Key Achievements to date in 2007 include:
- Initiation of the Phase 3 trial of Stimuvax in patients with non-
small cell lung cancer by Merck. Enrollment of the first patient in
this trial, which occurred in February 2007, triggered a milestone
payment to Biomira of U.S. $2.5 million, before associated payments
to third parties of approximately U.S. $0.5 million. In addition,
Biomira has the responsibility for the manufacture of Stimuvax and
has been successfully manufacturing for the Phase 3 trial.
- Initiation of the Phase 2 trial of the thioredoxin inhibitor PX-12 in
patients with advanced pancreatic cancer resistant to gemcitabine or
a gemcitabine-containing regimen.

Conference Call and Webcast
Biomira's management will discuss the Company's fourth quarter and full year 2006 financial results as well as general business updates during a conference call beginning at 1:30 p.m. PT/ 4:30 p.m. ET today, Thursday, March 8, 2007. To listen to a webcast of the discussion, visit www.Biomira.com.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements

In order to provide our investors with an understanding of our current results and future prospects, this release may contain statements that are forward looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements represent Biomira's intentions, plans, expectations and beliefs with respect to research and development expenses, the use and adequacy of cash resources, the successful integration of ProlX, the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of our products, the possibility of future payments from Merck and the availability of grant funding for our ProlX subsidiary and are based on our experience and our assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the adequacy of financing and reserves on hand; currency exchange rate fluctuations; changes in general accounting policies, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in Canada on SEDAR and the United States on U.S. EDGAR. Biomira does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Biomira, including a copy of our Annual Information Form and Proxy Circular filed annually at the end of March, can be found on SEDAR at www.sedar.com and U.S. EDGAR at www.sec.gov.




Biomira Inc.
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)

-------------------------------------------------------------------------
Three Months Ended Year Ended
December 31 December 31
-------------------------------------------------------------------------
2006 2005 2006 2005
-------------------------------------------------------------------------
REVENUE
Contract research
and development $ 1,170 $ 977 $ 4,172 $ 3,842
Licensing revenue from
collaborative
agreements 50 52 207 207
Licensing, royalties,
and other revenue 43 86 135 328
-------------------------------------------------------------------------
1,263 1,115 4,514 4,377
-------------------------------------------------------------------------
EXPENSES
Research and
development 3,287 4,455 13,838 16,907
General and
administrative 2,615 1,441 8,661 6,295
Marketing and business
development 153 12 666 965
Amortization 602 106 897 376
-------------------------------------------------------------------------
6,657 6,014 24,062 24,543
-------------------------------------------------------------------------
OPERATING LOSS (5,394) (4,899) (19,548) (20,166)
Investment and
other income 424 226 1,039 795
Interest expense (2) (1) (11) (2)
-------------------------------------------------------------------------
LOSS BEFORE INCOME
TAXES (4,972) (4,674) (18,520) (19,373)
-------------------------------------------------------------------------
INCOME TAX RECOVERY:
Current 524 286 524 348
Future 174 - 174 -
-------------------------------------------------------------------------
698 286 698 348
-------------------------------------------------------------------------
NET LOSS $(4,274) $(4,388) $(17,822) $(19,025)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
BASIC AND DILUTED LOSS
PER SHARE $(0.04) $(0.05) $(0.19) $(0.24)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
WEIGHTED AVERAGE
NUMBER OF COMMON
SHARES OUTSTANDING 102,800 78,660 91,900 78,660
-------------------------------------------------------------------------
-------------------------------------------------------------------------


Biomira Inc.
Consolidated Balance Sheets Data
(in thousands)
(unaudited)

-------------------------------------------------------------------------
December 31, December 31,
2006 2005
-------------------------------------------------------------------------
Cash position $33,037 $21,415
-------------------------------------------------------------------------
Total assets $79,099 $24,263
-------------------------------------------------------------------------
Total long-term liabilities $13,378 $1,147
-------------------------------------------------------------------------
Shareholders' equity $61,417 $20,063
-------------------------------------------------------------------------
Common shares outstanding 116,915 78,817
-------------------------------------------------------------------------





--------------------------------------------------------------------------------
Source: Biomira Inc.


Email Story
Set News Alert
Print Story






Related Quote
BIOM 1.10 +0.01 News
View Detailed Quote
Delayed 20 mins
Providers - Disclaimer


Related News Stories
· Q4 2006 Biomira Earnings Release - After Market Close - CCBN (Thu Mar 8)
· Biomira to present at two upcoming investor conferences - PR Newswire (Wed Mar 7)
· Canada's Biomira to restate some US GAAP results - at Reuters (Fri Mar 2)
· Biomira announces March 8th webcast of its fourth quarter and full year 2006 financial results conference call - PR Newswire (Fri Mar 2)
More...

--------------------------------------------------------------------------------

· By industry: Biotechnology






Top Stories
· Gates, Buffett Top Billionaires Ranking - AP (12:14 am)
· EADS Reports $1.01 Billion Loss in 4Q - AP (2:20 am)
· Express Scripts Expects FTC Questions - AP (12:11 am)
· Aeon, Daiei to Announce Capital Tie-Up - AP (1:20 am)
More...

--------------------------------------------------------------------------------

· Most-viewed articles



Inside Yahoo! Finance
Today's Markets
· Earnings Calendar
· Upgrades/Downgrades
· Most Actives
· Stock Screener




RSS Feeds
Add headlines to your
personalized My Yahoo! Page
( About My Yahoo! and RSS )

BIOM Headlines
My Yahoo RSS Corporate Earnings Headlines
My Yahoo RSS Biotechnology Headlines
My Yahoo RSS More Finance RSS Feeds




--------------------------------------------------------------------------------

[philippf]

Antwort auf Beitrag Nr.: 28.196.508 von minadon am 09.03.07 08:29:13

Key Achievements to date in 2007 include:
- Initiation of the Phase 3 trial of Stimuvax in patients with non-
small cell lung cancer by Merck. Enrollment of the first patient in
this trial, which occurred in February 2007, triggered a milestone
payment to Biomira of U.S. $2.5 million, before associated payments
to third parties of approximately U.S. $0.5 million. In addition,
Biomira has the responsibility for the manufacture of Stimuvax and
has been successfully manufacturing for the Phase 3 trial.

[freetibet]

Biomira "market outperform"

Friday, March 09, 2007 6:15:01 AM ET
Rodman & Renshaw

NEW YORK, March 9 (newratings.com) - Analysts at Rodman & Renshaw maintain their "market outperform" rating on Biomira Inc (BIOM.NAS). The target price is set to $4.

In a research note published this morning, the analysts mention that the company has reported its 4Q net losses per share in-line with the estimates. Biomira had a capital reserve of C$33 million at the end of 2006, the analysts say. The enrolment of the company’s START trial for the Stimuvax drug in NSCLC is expected to be completed by 1H08 and the drug is likely to be approved by the FDA in 2010, Rodman & Renshaw adds.


Nach einem Monat das Kursziel um 1$ erhöht.
Warten wir mal auf den nächsten Monat.

[freetibet]

DNDN in premarket

BIOM profitiert, aber wie lange ?

[donnerpower]

Noch habe ich Zeit

[donnerpower]

[philippf]

ich freu mich schon über den Kurs-Anstieg... Aber dann war es nur eine Mini-Order...

[verdi2003]

hallo donnerpower,

wir haben zeit.

viele grüße
verdi

[philippf]

Stuttgart auf 1,91???

(Bid und Ask wieder gesunken inzwischen leider)

Hätte zu dem Preis aber auch noch welche abzugeben :-)

[DausendUndMehr]

Antwort auf Beitrag Nr.: 28.671.822 von philippf am 05.04.07 09:44:05

ich hoffe dass sich da nicht ein Kleinanleger einfach nur vertippt hat

aber zu dem Preis geben wir alle was ab

[philippf]

Antwort auf Beitrag Nr.: 28.673.939 von DausendUndMehr am 05.04.07 11:28:59

Würde eher vermuten, dass da jemand unlimitiert eine Kauf-Order eingestellt hat (vermutlich auch ein armer Kleinanleger).

[BULLE2004]

Antwort auf Beitrag Nr.: 28.673.939 von DausendUndMehr am 05.04.07 11:28:59

Zu diesem Preis gebe ich kein Stück her.
Ich will mindesten 200% Gewinn.

[donnerpower]

@ll

Achtung die Amis gehen jetzt alle in Biomira rein..hier will keiner den Anstieg wie bei DNDN verpassen

Sehe sogar ein höheres Potential wenn es die 3Phase weiterhin so positiv verläuft!


Phase III läuft seit Dezember 2006 !



Dank guter Überlebensdaten erste Phase-III-Studie mit Krebsimpfstoff Stimuvax®

Anfang 2006 erwarb Merck die exklusiven Rechte zur Entwicklung und Vermarktung von Stimuvax® (L-BLP25) auch in den USA und erweiterte damit das bestehende Lizenz­abkommen mit dem kanadischen Unternehmen Biomira. In Kanada teilen sich Merck und Biomira weiterhin die Rechte. Merck übernimmt die administrative und finanzielle Gesamtverantwortung für die Entwicklung und Vermarktung des Krebsimpfstoffs und entrichtet Lizenzzahlungen an Biomira. Stimuvax® ist ein innovativer Krebsimpfstoff, der eine Immunantwort gegen Krebszellen auslöst, die MUC1 exprimieren – ein Protein, das in vielen Tumoren vorkommt. Stimuvax® wird derzeit zur Behandlung des nichtkleinzelligen Lungenkarzinoms entwickelt. Lungenkrebs ist weltweit die Krebs-Todesursache Nummer 1. Jedes Jahr werden fast 1,2 Millionen Fälle neu diagnostiziert – rund drei Viertel davon sind nichtkleinzellige Lungenkarzinome. Aufgrund der erfreulichen Über­lebensdaten einer klinischen Studie der Phase IIB werden wir eine Studie der Phase III beginnen.

http://www.merck.de/servlet/PB/menu/1647250/index.html


Merck KGaA und Biomira prüften allerdings Möglichkeiten, in anderen Ländern eine schnelle Marktzulassung zu erreichen. Bisher hatten Merck und Biomira eine Vermarktung von BLP25 erst ab 2008 geplant.

Sogar ein höheres Potential

Daneben erwägt Merck auch Studien zum Einsatz von Stimuvax® [L-BLP25] bei anderen Krebsarten.

[[KERN]Codex]

Jetzt wirds doch noch was

[yoppu]

Antwort auf Beitrag Nr.: 28.717.427 von [KERN]Codex am 08.04.07 20:32:28

da hat wohl jemand die Zahlen nicht gelesen...

[donnerpower]

Antwort auf Beitrag Nr.: 28.717.427 von [KERN]Codex am 08.04.07 20:32:28

Jetzt kann ich auch noch warten

[donnerpower]

[donnerpower]

[BULLE2004]

Schaut interessant aus in den nächsten Wochen.

[yoppu]

Na die Umsätze sind recht überzeugend!
Das erinnert mich irgendwie an den April 2003

[frani60]

nichts verpassen gelle

[freetibet]

Biomira selects PX-866 as clinical development candidate and presents promising preclinical data at AACR
Monday April 16, 8:00 am ET
-IND filing expected by end of 2007-


EDMONTON, April 16 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that it has selected PX-866 as its next clinical development candidate. PX-866 is an inhibitor of the phosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer, including glioblastoma. Preclinical data presented this past weekend at the American Association of Cancer Research (AACR) annual meeting demonstrate that PX-866 has activity in an intracranial model of glioma.

"The preclinical data for PX-866, including those presented at AACR, are very promising and warrant advancing this small molecule compound to clinical development," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "The data presented this weekend are particularly compelling, as they provide evidence of PX-866 activity in an intracranial model of glioma, a disease that accounts for 77 percent of all malignant brain cancers and is refractory to conventional therapies. We are in the process of completing preclinical studies designed to support the expected filing of an investigational new drug (IND) application for PX-866 later this year. Expanding and advancing our clinical pipeline is a key priority for Biomira, and we are on track to have four programs in clinical development by the end of 2007."

Preclinical data presented at AACR by Dr. Dimpy Koul of The University of Texas M. D. Anderson Cancer Center (MDACC) (Abstract #278) showed that PX-866 treatment resulted in growth inhibition in three different glioma cell lines. The magnitude of the inhibition depended on the status of PTEN in the cell lines, with PTEN-negative cells showing greater sensitivity to PX-866. Treatment with PX-866 inhibited activation of AKT and other downstream targets of PI3K. A dose-dependent increase in autophagy, a type of programmed cell death, was observed and PX-866 also inhibited invasive and angiogenic capabilities of cultured glioma cells. In animals, PX-866 inhibited subcutaneous tumor growth by 84 percent after 4 weeks of oral dosing and increased median survival of animals with intracranial tumors. The authors conclude that PX-866 is a highly promising PI3 kinase inhibitor in glioblastomas and other tumors with aberrant PTEN/PI3K expression, which include advanced ovarian, breast and prostate cancers, as well as lung and head and neck cancers.

Dr. Koul and colleagues at MDACC conducted the studies in collaboration with Dr. Lynn Kirkpatrick, Biomira's Chief Scientific Officer, under a grant from the U.S. National Institutes of Health.

About PX-866

PX-866 is an inhibitor of the phosphatidylinositol-3-kinase (PI3 kinase)/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. PI3 kinase is overexpressed in a number of human cancers, especially ovarian, colon, head and neck, urinary tract, and cervical cancers, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). In preclinical studies, PX-866 has been shown to induce prolonged inhibition of tumor PI3 kinase signaling following both oral and intravenous administration. The compound also has been shown to have good in vivo anti-tumor activity in tumor models of human ovarian and lung cancer, as well as intracranial glioblastoma.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the pre-clinical and clinical development of PX-866; the therapeutic and commercial potential of PX-866; the filing of an investigational new drug application for PX-866 and the timing thereof; and future clinical development plans. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes", "anticipates", "plans", "expects", "will", "intends", "potential", "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the clinical development of PX-866; the therapeutic and commercial potential of PX-866; the filing of an investigational new drug application for PX-866 and the timing thereof, and future clinical development plans. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[BIOMIRA]

wieder ein beispiel wie es kommt, positives resultat bei phase 3
bei der fda zulassung kommt der nächste sprung

[freetibet]

http://www.biomira.com/news/main/?id=991769

[psycho214]

Featured Links


Stock Price
News Releases
Upcoming Events
Privacy Statement

News and Events
Biomira Inc. announces first quarter 2007 results

Print
4/26/2007 4:03:00 PM
EDMONTON, April 26 /PRNewswire-FirstCall/ - Biomira Inc. (NASDAQ:BIOM) (TSX:BRA) today reported a consolidated net loss from operations of $5.4 million or $0.05 per basic and diluted share for the three months ended March 31, 2007, compared to $5.8 million or $0.07 per basic and diluted share for the same period in 2006. Revenue was $0.2 million for the 2007 first quarter, compared with $0.4 million for the year earlier quarter. Total operating expenses were $6.7 million for the quarter ended March 31, 2007, compared with $6.4 million for the same quarter in 2006. All results are in Canadian dollars.

The increase in operating expenses in the first quarter of 2007 compared with the first quarter of 2006 primarily resulted from an increase in amortization expense and marketing and business development expense of $0.8 million and $0.4 million respectively, partially offset by a reduction in research and development expense of $1.0 million. The increase in amortization expense relates to the intangible assets acquired in the acquisition of ProlX Pharmaceuticals Corporation in October 2006, and the increase in marketing and business development expense relates to workforce reduction costs in the first quarter of 2007. The decrease in research and development expense primarily relates to reduced clinical and development expenditures as a result of transitioning the responsibility for the clinical development and regulatory activities for Stimuvax(R) to Merck KGaA of Darmstadt, Germany ("Merck KGaA") during 2006, and related workforce reductions undertaken during 2006.

As at March 31, 2007, our cash and cash equivalents and short-term investments were $28.7 million compared to $33.0 million at the end of 2006, a decrease of $4.3 million. Major contributors to the net change included $3.3 million used in operations, $0.5 million used in payment of accrued business acquisition and share issuance costs, and $0.5 million used in the purchase of intangible assets. Netted against cash used in operations was the receipt of a milestone payment to Biomira of $2.9 million as the result of the enrollment of the first patient in the global phase 3 Stimuvax clinical trial. This milestone payment has been recorded as deferred revenue and is being recognized as revenue on a straight-line basis over the remaining patent life of the Stimuvax product.

The increase in inventory to $3.7 million at March 31, 2007, from $1.3 million at December 31, 2006, reflects increased Stimuvax manufacturing activities as a result of the commencement of the Merck KGaA-led phase 3 trial of Stimuvax in non-small cell lung cancer initiated in the first quarter of 2007.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements

In order to provide our investors with an understanding of our current results and future prospects, this release may contain statements that are forward looking. These forward-looking statements represent Biomira's intentions, plans, expectations and beliefs and are based on our experience and our assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including those predicting adequacy of financing and reserves on hand; currency exchange rate fluctuations; changes in general accounting policies; and general economic factors. Although we believe that any forward-looking statements that may be contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in Canada and the United States, including the risk factors described in our 2006 Annual Report.

Additional Information

Additional information relating to Biomira, including a copy of our Annual Information Form, Form 40-F and Proxy Circular, can be found on SEDAR at www.sedar.com and U.S. EDGAR at www.sec.gov.


Biomira Inc.
Consolidated Statements of Operations
(expressed in thousands of Canadian dollars, except share and per share
amounts)
(unaudited)
Three Months Ended
March 31
2007 2006
-------------------------------------------------------------------------
REVENUE
Contract research and development $ 116 $ 324
Licensing revenue from collaborative
agreements 74 55
Licensing, royalties, and other revenue 11 1
-------------------------------------------------------------------------
201 380
-------------------------------------------------------------------------
EXPENSES
Research and development 2,989 3,956
General and administrative 2,243 2,130
Marketing and business development 560 218
Amortization 862 106
-------------------------------------------------------------------------
6,654 6,410
-------------------------------------------------------------------------
OPERATING LOSS (6,453) (6,030)
Investment and other income 358 237
Interest expense (1) (7)
-------------------------------------------------------------------------
LOSS BEFORE INCOME TAXES (6,096) (5,800)
INCOME TAX RECOVERY:
Future 737 -
-------------------------------------------------------------------------
NET LOSS $ (5,359) $ (5,800)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
BASIC AND DILUTED LOSS PER SHARE $ (0.05) $ (0.07)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
WEIGHTED AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING 116,915,338 85,864,809
-------------------------------------------------------------------------
-------------------------------------------------------------------------



Biomira Inc.
Consolidated Balance Sheets Data
(expressed in thousands)
(unaudited)
March 31 December 31
2007 2006
-------------------------------------------------------------------------
Cash and short-term investments $ 28,707 $ 33,037
Inventory $ 3,689 $ 1,287
Total assets $ 75,878 $ 79,099
Deferred revenue (current and non-current) $ 3,887 $ 1,036
Total long-term liabilities $ 15,212 $ 13,378
Shareholders equity $ 56,477 $ 61,417
Common shares outstanding 116,915 116,915
-------------------------------------------------------------------------
-------------------------------------------------------------------------

(CAD $1.00 = USD $0.87)

SOURCE Biomira Inc.
-0- 04/26/2007
/CONTACT: Investor and Media Relations Contact: Stephanie Seiler, Ph.D.,
Gemini BioProjects LLC, [phone], [e-mail]/
(BRA. BIOM)

CO: Biomira Inc.
ST: Alberta
IN: MTC BIO HEA SPM
SU: ERN

-30-

DH
-- TO490 --
5304 04/26/2007 16:00 EDT http://www.prnewswire.com

[freetibet]

Seite 2 :

http://www.thestreet.com/_yahoo/newsanalysis/biotech/1035468…

[freetibet]

Biomira to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
Tuesday May 8, 8:00 am ET


EDMONTON, May 8 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference at 3:35pm CEST/9:35am EDT/6:35am PDT on Monday, May 14th in Monte Carlo, Monaco.

The presentation is planned for a live webcast and can be accessed at:

http://www.wsw.com/webcast/rrshq11/biom

and at the Biomira website (www.biomira.com).

Biomira intends to make a recording of the webcast available on the Biomira website approximately one hour after completion of the presentation. The presentation will be archived for 90 days.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[MasaRatti]

Morgen zusammen,
so Merck hat ja jetzt wieder etwas Cash hinzu bekommen, rechnet
eigentlich jemand damit, das Merck KgaA evtl. Biomira über-
nehmen könnte, oder ist das völlig ausgeschlossen !!!
Würde doch irgendwie auch Sinn machen!

Netten Tag

[philippf]

Ich glaube Merck braucht gar nicht übernehmen, schließlich haben die schon so gut wie alle Vermarktungsrechte...

[donnerpower]

Antwort auf Beitrag Nr.: 29.296.135 von MasaRatti am 14.05.07 08:07:55

...ausgeschlossen!

Das in Verträgen immer vornherein abgesichert ..wenn du dir andere Firmen anschaust wo mit Merck zusammen Projekte entwickelt wurden gab es nie eine Übernahme

gruss

[freetibet]

Guten Abend,

schon wieder ist ein Jahr rum und es ist ASCO - Zeit.

Nur, dieses Jahr interessiert es niemanden.

http://www.asco.org/portal/site/ASCO/menuitem.9fef35ee4eaf51…

[freetibet]

Glaxo Starts Lung-Cancer Test in Race With Merck KGaA (Update4)

By Andrea Gerlin

June 18 (Bloomberg) -- GlaxoSmithKline Plc, the world's second-largest drugmaker, plans to enroll the first patient in a trial of its lung-cancer vaccine, the largest late-stage study of a treatment for the disease, in September.

The company, reeling from a report linking its Avandia diabetes drug to heart attacks, presented data on its vaccine and other cancer treatments to analysts and investors in London. Executives discussed the potential of the breast cancer drug Tykerb and a new kidney cancer medicine, Moncef Slaoui, Glaxo's chairman of research and development, said in a conference call with reporters today.

Glaxo is racing Germany's Merck KGaA to produce the first lung-cancer vaccine. The $35 billion market for cancer treatments will double by 2010, according to the research firm IMS Health Inc. of Fairfield, Connecticut. Glaxo fell behind in the development of a vaccine to prevent cervical cancer, after a rival product won approval last year.

``Big pharma is really getting into this,'' said Christian Ottensmeier, a doctor at the U.K.'s Southampton University Hospital, who is conducting studies of the lung cancer vaccines. ``They see the opportunity because the data is now showing these vaccines will work.''

The shots may prevent the most-common form of the lung disease, called non-small cell lung cancer, from relapsing and enable patients to live longer by helping their immune systems recognize and destroy cancer cells.

Glaxo has lined up test centers and is training workers for the start of the phase III trial of the vaccine, known as MAGE- A3, early in September at 400 centers in 37 countries. The study will follow 2,270 people with early lung cancer for 10 years after they have surgery and receive the shot. Initial results are expected in 2012.

Share Decline

Shares of London-based Glaxo have fallen 9.8 percent since a May 21 article in the New England Journal of Medicine linked Avandia to an increased risk of heart attacks. The diabetes treatment was Glaxo's second-best selling product last year, bringing in $3 billion. Of the 34 analysts following Glaxo and tracked by Bloomberg, 14 rate the company a ``buy,'' with 10 rating it a ``hold'' and 10 rating it a ``sell.''

Glaxo shares fell 6 pence, or 0.5 percent, to close at 1,320 pence in London.

Cancer Deaths

Lung cancer kills about 1.3 million people worldwide each year, more than any other cancer, according to the Geneva-based World Health Organization. Currently, 85 percent of lung cancer patients die within five years, one of the lowest survival rates.

Data on the vaccine ``is highly suggestive that this will work'' and help people live longer, Ottensmeier said in an interview.

An earlier trial's data, presented at a conference in Chicago this month, showed the vaccine reduced the relapse risk by 27 percent in 182 people with early non-small cell lung cancer after surgery. The cancer recurred in 31 percent of those who received the vaccine, compared with 43 percent who got a placebo.

Merck, based in Darmstadt, Germany, began enrolling 1,300 patients with advanced and inoperable non-small cell lung cancer after chemo-radiotherapy in a late-stage trial of its Stimuvax vaccine in February. Stimuvax induces the immune system to fight cancer cells in which a gene called MUC-1 is present, including some lung cancers.

Merck Trial

A mid-stage study of 171 patients with advanced forms of the disease, according to Merck, found that those with less advanced cancers who received Stimuvax lived 31 months, compared with 13 months for those who got a placebo. Merck KGaA, which isn't related to U.S.-based Merck & Co., bought worldwide rights to the vaccine from developer Biomira Inc. of Edmonton, Canada.

``These companies don't engage in such large phase III trials unless they have some level of confidence that this is an attractive product,'' said Denise Anderson, head of health-care sector research at Landsbanki Kepler in Zurich.

Anderson doesn't recommend clients invest heavily in companies based on their cancer vaccine efforts because of the high risk and past missteps. She cited Dendreon Corp. shares' 65 percent drop in May after U.S. regulators rejected its prostate cancer vaccine.

The Glaxo vaccine is only useful in tumors with MAGE-A3, about 35 percent to 50 percent of non-small cell lung cancers and about 70 percent of skin cancers, company scientist Patrick Therasse said in an interview. It fights cancer by stimulating a patient's white blood cells to target tumor cells that express MAGE-A3 and by providing antibodies to protect against further attack.

Little Success

Researchers have been seeking cancer vaccines for 25 years, with U.S. and European regulators approving only the one to prevent cervical cancer and another to prevent hepatitis B, which is linked to liver cancer. Merck and ImClone Systems Inc. dropped efforts to develop a vaccine for advanced small-cell lung cancer after trials didn't show a survival benefit in 2004.

``Immunotherapeutics are most likely to be successful in patients with small amounts of disease,'' said Johan Vansteenkiste, an internal medicine professor at Belgium's Catholic University Leuven who conducts trials of Glaxo's lung cancer vaccine. ``They're unlikely to be successful against large tumors and much more likely to work in a setting with minimal residual disease.''

The companies are betting that a vaccine that works against a cancer may have broader effects. Other studies of the MAGE-A3 vaccine are focusing on its possible use in multiple myeloma and skin, prostate, bladder and head and neck cancers. Stimuvax may also have applications in breast and colon cancer.

``To be able to get rid of a cancer with that sort of an approach is really a revolution,'' Philippe Monteyne, Glaxo's head of global vaccine development, said. ``It is a major shift. You open the door to a completely new field.''

To contact the reporter on this story: Andrea Gerlin in London [e-mail]

Last Updated: June 18, 2007 11:57 EDT

[bernie55]

ALLGEMEINE INFOS zur Zulassung neuer Arzneien


22.06.2007 - 09:28 Uhr

FTD: Das kann ja heiter werden

Die Zulassung neuer Arzneien ist für die Pharmabranche längst keine Kleinigkeit mehr. Regelmäßig lassen die Behörden Hoffnungsträger durchfallen und Börsenträume platzen. Künftig kommt es noch dicker.


Sanofi-Aventis ist fassungslos über die Ablehnung seiner Diätpille Acomplia bei der US-Behörde FDA. Begründung: psychische Nebenwirkungen.

GlaxoSmithKline fürchtet das Aus für das umsatzstarke Diabetesmittel Avandia. Risiko: Herzinfarkt.

Das neue Krebsmittel Vectibix vom weltgrößten Biotechkonzern Amgen findet nicht den Zuspruch der Kontrolleure bei der EU-Behörde Emea. Erklärung: Wirksamkeit zweifelhaft.

Drei Beispiele aus der jüngsten Vergangenheit - eine gemeinsame Wirkung: Aufruhr an der Börse. Die Aktienkurse der betreffenden Konzerne sackten nacheinander auf ein Zweijahrestief. Allen Beteiligten, den Managern, Analysten und Kontrolleuren steckt noch der Skandal um das Schmerzmittel Vioxx in den Knochen. Die Folge für den Hersteller Merck & Co. sowie die Branche waren Tausende Schadensersatzklagen, Imagekrisen und Milliardenverluste. Das mahnte zur Vorsicht. Im Jahr drei nach Vioxx zieht die Politik auf beiden Seiten des Atlantiks die Zügel nun noch fester an.

So feilten am Donnerstag in Washington US-Senatoren an letzten Details für ein Gesetz, das der FDA mehr Einfluss und Geld für zusätzliche Sicherheitskontrollen von Medikamenten gibt. Dazu zahlt die Industrie an die FDA Gebühren von rund 400 Mio. $ jährlich, weitere 225 Mio. $ bringt sie in den kommenden fünf Jahren für die FDA-Observierung von Neueinführungen auf. "Die Nation hat aus den Sicherheitsproblemen mit dem Diabetesmedikament Avandia gelernt", sagte der Vorsitzende des Kongressausschusses, John Dingell, vor wenigen Tagen. Zudem können Verstöße gegen Marketing- und Sicherheitsauflagen mit bis zu 100 Mio. $
Strafe geahndet werden.

Und auch die Emea kann nun härter durchgreifen. Die EU-Kommission hat am 15. Juni eine Verordnung in Kraft gesetzt die Verstöße gegen Emea-Regeln mit hohen Geldbußen ahndet - etwa, wenn Firmen Vorgaben ihrer Arzneimittelzulassungen nicht einhalten, Informationen zur Risikobewertung ihrer Produkte zurückhalten oder deren Nebenwirkungen gar nicht oder erst sehr spät melden.

"Sehr harte Sanktionen"

Die Höchstgrenze der Geldbußen liegt bei fünf Prozent des Jahresumsatzes des betroffenen Zulassungsinhabers. Zulassungsinhaber kann auch eine Konzerntochter sein. "Das dürfte zu ungerechten Bestrafungen führen", sagte Unternehmensanwalt Uwe Fröhlich vom Pharmakonzern Baxter. "Zufälligerweise oder sogar absichtlich kann ein besonders umsatzstarker oder umsatzschwacher Teil eines Konzerns Inhaber der Zulassung sein. Ein Schlupfloch könnten auch Vermarktungspartnerschaften unabhängiger Unternehmen bieten, von denen nur eines die Zulassung hält." Gerechter sei es, die Buße am EU-weiten Umsatz der Arznei festzumachen. "Das sind alles in allem sehr harte Sanktionen", sagt Anwalt Jörg Schickert von der Kanzlei Lovells in München. Er findet manches an der Verordnung unausgereift. "Es gibt noch Schwachstellen, darunter die Frage, wie die Abgrenzung zwischen einzelstaatlichen Strafmaßnahmen und EU-weiten Sanktionen geregelt werden soll."

Das für Zulassungen zuständige Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) habe in der jüngeren Vergangenheit einige Straf- und Bußgeldverfahren eingeleitet, mit unterschiedlichem Ausgang entsprechend der Beweislage, heißt es auf Anfrage. "Ob es in Zukunft wichtiger sein wird, derartige Instrumentarien zur Verfügung zu haben, lässt sich nur schwer einschätzen", so das BfArM. Die im Arzneimittelgesetz für Ordnungswidrigkeiten vorgesehenen Bußgelder von maximal 25.000 Euro seien vergleichsweise gering.

Die Verordnung (EG) 658/2007 zur Auferlegung von Geldbußen durch die Kommission ist ein neuartiges Sanktionsmittel, das es für von der Emea zugelassene Arzneimittel bislang noch nicht gab. "Die Industrie sollte schnellstmöglich alle Schwachstellen abklopfen und Verfahren aufsetzen, die zukünftig Verstöße vermeiden. Dies sollte auch dokumentiert werden", sagte der Anwalt Schickert.

Emea-Chef Thomas Lönngren zumindest will nie mehr einen Tag wie den 30. September 2004 erleben: Weder der Vioxx-Hersteller Merck & Co. noch die FDA-Kollegen hatten ihn frühzeitig über den geplanten Rückruf der Schmerzpille informiert. Die Börse wusste früher Bescheid als er. "Wir wollen von Konzernen so schnell wie möglich informiert werden", sagte er.



Autor/Autoren: Peter Kuchenbuch

http://www.finanztreff.de/ftreff/news.htm?sektion=topthemen&…

[freetibet]

Biomira files investigational new drug application for PX-478, a novel inhibitor of hypoxia-inducible factor-1 alpha
Tuesday July 3, 8:00 am ET


EDMONTON, July 3 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for PX-478. PX-478 has been shown in preclinical studies to inhibit hypoxia-inducible factor (HIF)-1 alpha, a protein that controls the transcription of a number of genes whose products are important for tumor growth and survival. In these preclinical studies, PX-478 has produced significant tumor regression and growth delay in multiple models of human cancers, including cancers of the lung, breast, prostate, colon, kidney, pancreas and ovary.

"HIF-1 alpha plays a critical role in the response of tumor cells to low oxygen, a situation seen in tumors where existing blood vessels are insufficient to supply needed oxygen," said Dr. Lynn Kirkpatrick, Chief Scientific Officer of Biomira. "In areas of low oxygen and as tumors grow, they adapt their metabolism due to decreased oxygen and nutrients and attract new blood vessels to bring in more oxygen, a process known as angiogenesis. Both the altered metabolism and angiogenesis are under the control of HIF-1 alpha. Consequently, HIF-1 alpha is a drug target that provides a multi-pronged approach for cancer therapy. We believe that PX-478 will be the first small molecule to enter clinical development that acts directly to lower HIF-1 alpha protein levels."

"With the filing of this IND for PX-478, we are advancing the development of another promising compound," said Dr. Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "Upon clearance of the IND, we intend to initiate a Phase 1 trial for this compound in the third quarter of 2007. We also are on track to advance our other pipeline programs, including initiating another Phase 2 trial for PX-12 and filing an IND for PX-866 by the end of the year. At that point we will have four programs in clinical development, reflecting the diversity and promise of our product pipeline."

About PX-478

PX-478 is a potent inhibitor of HIF-1 alpha, a protein target whose levels are elevated in a wide range of tumors. The protein is a key factor in the response of a cancer cell to hypoxia (lack of oxygen), including the angiogenic cascade that allows tumors to establish new blood vessels essential to their survival and growth. Inhibition of angiogenesis is a validated approach to treating cancer.

In preclinical studies, PX-478 demonstrated antitumor activity when delivered orally and has shown marked tumor regression and growth inhibition, both of which correlated to the HIF-1 alpha levels of the tumor models. These models included ovarian, renal, prostate, colon, pancreatic, lung and breast cancer, representing a large potential market for this product candidate. The ability to combine PX-478 with radiation therapy may further expand the opportunities for this novel compound.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the pre-clinical and clinical development of PX-478, PX-12 and PX-866; the therapeutic and commercial potential of PX-478, PX-12 and PX-866; the filing of an investigational new drug application for PX-478 and PX-866 and the timing thereof; the initiation of a Phase 1 trial for PX-478; the initiation of a Phase 2 trial for PX-12; and future clinical development plans. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes", "anticipates", "plans", "expects", "will", "intends", "potential", "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the clinical development of PX-478, PX-12 and PX-866; the therapeutic and commercial potential of PX-478, PX-12 and PX-866; the filing of an investigational new drug application for PX-478 and PX-866 and the timing thereof; the initiation of a Phase 1 trial for PX-478; the initiation of a Phase 2 trial for PX-12; and future clinical development plans. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[freetibet]

Biomira appoints industry veteran as Chief Operating Officer


EDMONTON, July 17 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today
announced the appointment of Gary Christianson to the newly created position
of Chief Operating Officer. Mr. Christianson brings to Biomira more than 20
years of operational expertise in diverse areas, including technical
development, manufacturing of pharmaceutical products, facilities design and
management, and personnel development.
"Gary's extensive operational expertise will be an important asset as we
work to realize the potential of our expanding pipeline," said Dr. Robert L.
Kirkman, M.D., President and Chief Executive Officer of Biomira. "Biomira is
responsible for all manufacturing activities for our Phase 3 vaccine,
Stimuvax(R), including process scale-up for commercialization, and Gary has
the background to lead this effort. With PX-12 in Phase 2, PX-478 expected to
enter Phase 1 this quarter, and an Investigational New Drug application
planned for PX-866 by year's end, there are also multiple technical
development and manufacturing activities for our small molecule pipeline. In
addition, I expect that Gary will play a significant role in developing
strategies to integrate our multi-site activities and to maximize our
efficiency, productivity and capabilities. We are pleased to welcome him to
the Biomira team."
Mr. Christianson said, "I am very excited to join Biomira and believe
that its development pipeline holds numerous opportunities to make a
difference in the lives of cancer patients. I look forward to working with the
rest of the Biomira management team to create value for patients and for the
Company's investors."
Mr. Christianson was, most recently, Site Director for GlaxoSmithKline's
(GSK) Biologics Unit in Hamilton, Montana. In this position, he oversaw
staffing and planning for a 250-person facility that manufactured a key
component of several GSK vaccines. Previously, he spent six years as Vice
President, Technical Operations at Corixa Corp., including two years as a
General Manager. In addition to facility and personnel responsibilities at
Corixa, Mr. Christianson also oversaw production of Bexxar(R) (Tositumomab and
Iodine I 131 Tositumomab), an approved cancer therapy. From 1987 to 1999, Mr.
Christianson held positions of increasing responsibility at RIBI ImmunoChem
Research, rising to Director, Production and Engineering. He received a B.S.
in Mechanical Engineering Technology from Montana State University and is a
Licensed and Board Certified Professional Engineer. He is a member of numerous
professional organizations, including the International Society for
Pharmaceutical Engineers and the Parenteral Drug Association.

About Biomira

Biomira is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Biomira's goal is
to develop and commercialize novel synthetic vaccines and targeted small
molecules that have the potential to improve the lives and outcomes of cancer
patients.

Forward-Looking Statements

This press release contains forward looking statements, including,
without limitation, statements related to drug candidates in Biomira's
pipeline; future clinical development plans; the details of the clinical
trials; and the anticipated manufacturing activities for Stimuvax and other
Biomira product candidates. Any statements contained in this press release
that are not statements of historical fact may be deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans," "expects,"
"will," "intends," "potential," "possible" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Biomira's current expectations. Forward-looking
statements involve risks and uncertainties. Various factors could cause actual
results to differ materially from those projected in forward-looking
statements, including those predicting the timing, duration and results of
clinical trials, the anticipated manufacturing activities for Biomira product
candidates, and the possibility of future commercialization of any Biomira
product. There can be no guarantee that the results of earlier trials will be
predictive of either safety or efficacy in future trials. Biomira expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any
change in the company's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.


For further information: Investor and Media Relations Contact: Robert Kirkman,
M.D., Chief Executive Officer, Biomira, [phone], [e-mail]

[philippf]

EDMONTON, Aug. 2 /PRNewswire-FirstCall/ - Biomira Inc. ("Biomira" or
the "Company") (NASDAQ:BIOM) (TSX:BRA) today reported a consolidated net
loss from operations of $6.3 million or $0.05 per basic and diluted share
for the three months ended June 30, 2006, compared to $4.0 million or $0.04
per basic and diluted share for the same period in 2006. Revenue was $0.7
million for the 2007 second quarter, compared with $1.2 million for the
year earlier quarter. Total operating expenses were $7.0 million for the
quarter ended June 30, 2007, compared with $5.4 million for the same
quarter in 2006. All results are in Canadian dollars.

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=…

[seppel]

Es gibt News...mal schauen, wann die deutsche Übersetzung kommt.

Vorbörslich schon mal +17%

[Brama]

Hat einer Ahnung, was hier passiert ist !

[seppel]

Antwort auf Beitrag Nr.: 31.101.901 von Brama am 09.08.07 20:02:44

Brama, was meinst du? Den Xetrakurs oder die News von gestern?

[Brama]

Antwort auf Beitrag Nr.: 31.102.013 von seppel am 09.08.07 20:07:42

Der Xetrakurs, sieht jetzt aber wieder "normal" aus.

[freetibet]

Biomira initiates Phase 1 trial of PX-478 in patients with advanced metastatic cancers


EDMONTON, Aug. 28 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today
announced that the first patient has been enrolled in a Phase 1 clinical trial
of PX-478 in patients with advanced metastatic cancer. PX-478 is a novel small
molecule compound designed to inhibit the activity of hypoxia inducible factor
(HIF)-1 alpha, a transcription factor that controls the expression of a number
of genes important for growth and survival of cancer cells. Genes regulated by
HIF-1 alpha contribute to diverse functions such as new blood vessel growth
(angiogenesis), use of glucose for energy, and protection against apoptosis
(programmed cell death).
"HIF-1 alpha plays a critical role in the response of cancer cells to low
oxygen levels, stimulating processes that increase oxygen concentrations and
allow tumors to grow and thrive," said Dr. Lynn Kirkpatrick, Ph.D., Chief
Scientific Officer of Biomira. "In our preclinical studies, PX-478 produced
significant tumor regression and growth delay in a wide variety of models of
human cancers, including lung, breast, prostate, colon, kidney, pancreas, and
ovarian cancers. We believe this is the first small molecule agent to enter
clinical trials that directly lowers levels of HIF-1 alpha protein in tumors."
The Phase 1 trial is expected to enroll up to 36 patients with advanced
solid tumors or lymphoma who have failed or are intolerant of standard
therapy. PX-478 will be administered orally on days 1 through 5 of a 21-day
cycle. Primary xobjectives of the study include establishment of a maximum
tolerated dose, evaluation of safety, and analyses of pharmacodynamic and
pharmacokinetic profiles of PX-478. Other xobjectives are to evaluate the
effects of PX-478 on tumor blood flow and vascular permeability as measured by
DCE-MRI, and to evaluate the anti-tumor activity of PX-478 in patients with
advanced malignancies.
"We are very excited about the potential for PX-478 as an anti-cancer
compound with broad potential application," said Dr. Robert L. Kirkman, MD,
President and Chief Executive Officer of Biomira. "We are also pleased with
the progress of our pipeline, as demonstrated by the initiation of this trial
on schedule. This is our second small molecule compound to enter clinical
development, and we expect to file an investigational new drug (IND)
application for PX-866, a third small molecule, by the end of 2007. Together
with PX-12, currently in Phase 2 development, the advancement of these
compounds reflects our significant progress in creating value from our
acquisition of ProlX Pharmaceuticals less than one year ago."

About PX-478

PX-478 is a potent inhibitor of HIF-1 alpha, a protein target whose
levels are elevated in a wide range of tumors. The protein is a key factor in
the response of a cancer cell to hypoxia (lack of oxygen), including the
angiogenic cascade that allows tumors to establish new blood vessels essential
to their survival and growth. Inhibition of angiogenesis is a validated
approach to treating cancer.
In preclinical studies, PX-478 demonstrated marked antitumor activity
when delivered orally, showing tumor regression and long growth delay, both of
which correlated to the HIF-1 alpha levels of the tumor models. The wide
variety of models that showed sensitivity to PX-478 presents a large potential
market for this product candidate. The ability to combine PX-478 with
radiation therapy may further expand the opportunities for this novel
compound. The PX-478 preclinical development work was partially supported by a
grant from the U.S National Institutes of Health Small Business Innovation
Research program.

About Biomira

Biomira is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Biomira's goal is
to develop and commercialize novel synthetic vaccines and targeted small
molecules that have the potential to improve the lives and outcomes of cancer
patients.

Forward Looking Statements

This press release contains forward-looking statements, including,
without limitation, statements related to the pre-clinical and clinical
development of PX-478, PX-12 and PX-866; the therapeutic and commercial
potential of PX-478, PX-12 and PX-866; the filing of an investigational new
drug application for PX-866 and the timing thereof; and future clinical
development plans. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Words such as "believes", "anticipates", "plans", "expects", "will",
"intends", "potential", "possible" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are
based upon Biomira's current expectations. Forward-looking statements involve
risks and uncertainties. Various factors could cause actual results to differ
materially from those projected in forward-looking statements, including those
predicting the clinical development of PX-478, PX-12 and PX-866; the
therapeutic and commercial potential of PX-478, PX-12 and PX-866; the filing
of an investigational new drug application for PX-866 and the timing thereof;
and future clinical development plans. There can be no guarantee that the
results of earlier trials will be predictive of either safety or efficacy in
future trials. Biomira expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the Company's expectations with
regard thereto or any change in events, conditions or circumstances on which
any such statements are based.

For further information: Investor and Media Relations Contact: Julie Rathbun,
Rathbun Communications, [phone], [e-mail]

[MasaRatti]

Merck: Positive Studiendaten mit Stimuvax
Mittwoch 5. September 2007, 09:41 Uhr


Darmstadt (aktiencheck.de AG) - Die Merck KGaA (ISIN DE0006599905/ WKN 659990) hat positive Drei-Jahres-Überlebensdaten einer randomisierten Phase-II-Studie mit dem MUC1-Tumorvakzin (Krebsimpfstoff) Stimuvax bei Patienten mit nicht-kleinzelligem Bronchialkarzinom (NSCLC) bekannt gegeben.

Wie der im DAX30 notierte Pharmakonzern am Mittwoch verkündete, lassen die Ergebnisse darauf schließen, dass Stimuvax in Kombination mit bester unterstützender Therapie (BSC = best supportive care) bei Patienten mit inoperablem NSCLC im Stadium IIIB, die nach Erstlinien-Radiochemotherapie entweder ein Ansprechen oder Krankheitsstabilisierung erreicht hatten,
ANZEIGE
Überlebensvorteile gegenüber einer alleinigen Behandlung mit BSC bieten kann.

Die neuesten Überlebensdaten zeigen, dass in der Stimuvax-Gruppe mehr als doppelt so viele Patienten nach drei Jahren noch am Leben waren als unter BSC allein. Die Mortalität konnte um 45 Prozent gesenkt werden. Aufgrund dieser Phase-II-Ergebnisse wird Stimuvax jetzt in der Studienphase III untersucht. Die Patientenaufnahme für die START (Stimulating Targeted Antigenic Responses to NSCLC)-Studie läuft bereits.

[psycho214]

Antwort auf Beitrag Nr.: 31.393.896 von MasaRatti am 05.09.07 09:47:47

kennt jemand den genauen termin wann die Phase 3 news kommen sollte? Ende September oder erst november???

oder ist das schon ein offizielles statement auch von seiten BIOM??

[freetibet]

Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer


EDMONTON, Sept. 5 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today
announced the presentation of three-year survival results from a randomized
Phase II trial of the Stimuvax(R) MUC-1 vaccine in non-small cell lung cancer
(NSCLC). The results suggest that Stimuvax combined with best supportive care
(BSC) may provide survival benefits to patients with unresectable stage IIIB
NSCLC who had either responded or had stable disease after initial
radio-chemotherapy, compared with patients receiving BSC alone. Dr. Charles
Butts, from the Department of Medical Oncology, Cross Cancer Institute,
Edmonton, Alberta and lead investigator of the Phase II study presented the
data yesterday (Abstract No. B1-01) at the International Association for the
Study of Lung Cancer (IASLC) Congress in Seoul, South Korea.
The updated survival results show that approximately twice as many
patients were still alive at three years in the Stimuvax arm compared with BSC
alone (49% (n=17) vs. 27% (n=8)), representing a
45% reduction in mortality. As previously reported, patients with stage IIIB
locoregional disease who received Stimuvax in this trial also experienced a
17.3 month difference in median survival compared with patients receiving BSC
alone (30.6 months vs. 13.3 months, respectively). Patients receiving Stimuvax
in this trial also reported mild to moderate side effects limited to flu-like
symptoms, gastro-intestinal disturbances and mild injection site reactions.
"The updated survival data are encouraging and support the need for
further investigation via the ongoing Phase III trial of Stimuvax as a
maintenance therapy for patients with advanced lung cancer," commented Dr.
Butts.
Based on the Phase II results, Stimuvax has entered its Phase III
development and the START (Stimulating Targeted Antigenic Responses to NSCLC)
trial is currently open for enrollment. The START trial is being conducted by
Merck KGaA of Darmstadt, Germany, which has licensed worldwide development and
commercialization rights to Stimuvax from Biomira. Stimuvax is being developed
in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono
Inc.
"Patients with unresectable stage III non-small cell lung cancer have
significant unmet medical need, and the START study is the first Phase III
program to evaluate a therapeutic cancer vaccine in this population," said Dr.
Robert L. Kirkman, MD, President and Chief Executive Officer of Biomira. "If
these survival results are statistically confirmed in the Phase III trial,
Stimuvax has the potential to become an important tool in the treatment of
lung cancer."
According to the American Cancer Society, lung cancer is the leading
cause of cancer-related deaths in both men and women worldwide, with
approximately 80% of cases classified as NSCLC. Current survival rates for
NSCLC are low, with only 16% of patients alive five years post-diagnosis.
Unfortunately for most patients, current treatments provide limited success.
Stimuvax is an innovative cancer vaccine designed to stimulate the body's
immune system to identify and destroy cancer cells expressing MUC1, a protein
antigen that is widely expressed on common cancers including lung, breast and
colorectal.

About the Phase II Trial

171 patients with ECOG 0-2 stage IIIB/IV NSCLC with stable or responding
disease after any first-line chemotherapy with or without radiotherapy were
randomized to receive Stimuvax plus BSC or BSC alone. Patients were stratified
by stage of disease (IIIB LR or stage IIIB with malignant pleural effusion,
and stage IV). Patients in the Stimuvax arm received a single intravenous dose
of cyclophosphamide 300mg/m2 followed by 8 weekly subcutaneous immunizations
with Stimuvax (1,000(micro)g). While the overall study results were not
statistically significant, in the randomization stratum of patients with stage
IIIB locoregional disease, Stimuvax showed a median survival of 30.6 months
versus 13.3 months in the control group - an improvement of 17.3 months. In
the Phase IIb study, side effects were primarily limited to flu-like symptoms,
GI disturbances and injection site reactions.

About START - Phase III Trial

START is a multi-center, randomized, double-blind, placebo-controlled
study that will evaluate patients with documented unresectable stage IIIA or
IIIB NSCLC who have had a response or stable disease after at least two cycles
of platinum-based chemo-radiotherapy. The study is expected involve more than
1,300 patients in approximately 30 countries. For more information on the
START study, or to find a participating center and eligibility criteria, go to
www.nsclcstudy.com. The study is also listed on www.clinicaltrials.gov.

About Stimuvax

Stimuvax is an innovative cancer vaccine designed to induce an immune
response to cancer cells that express MUC1, a protein antigen widely expressed
on common cancers. MUC1 is over expressed on many cancers such as lung cancer,
breast cancer and colorectal cancer. Stimuvax is thought to work by
stimulating the body's immune system to identify and destroy cancer cells
expressing MUC1.

About Biomira

Biomira is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Biomira's goal is
to develop and commercialize novel synthetic vaccines and targeted small
molecules that have the potential to improve the lives and outcomes of cancer
patients.

Forward Looking Statements

This press release contains forward looking statements, including,
without limitation, statements related to the therapeutic and commercial
potential of Stimuvax; future clinical development plans; the details of the
clinical trials; and the anticipated future size of the market for Stimuvax.
Any statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," "intends," "potential,"
"possible" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Biomira's current
expectations. Forward-looking statements involve risks and uncertainties.
Various factors could cause actual results to differ materially from those
projected in forward-looking statements, including those predicting the
timing, duration and results of clinical trials, the timing and results of
regulatory reviews, and the safety and efficacy of Stimuvax. There can be no
guarantee that the results of earlier trials will be predictive of either
safety or efficacy in future trials. Biomira expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in the
company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based.


For further information: Investor and Media Relations Contact: Julie Rathbun,
Rathbun Communications, [phone] [e-mail]

[donnerpower]

Antwort auf Beitrag Nr.: 31.393.896 von MasaRatti am 05.09.07 09:47:47

[psycho214]

Antwort auf Beitrag Nr.: 31.415.251 von donnerpower am 06.09.07 14:41:48

mann scheisse ,

wir können noch nicht starten...

ich möchte mit 50 k rein aber unter 1 $

also reisst euch zammen

[freetibet]

Der nächste Kongress steht an.

http://www.lifescienceworld.com/2007/wvcl/confprog.stm

[DausendUndMehr]

Bin auch noch dabei und am Warten ...

[yoppu]

Biomira Announces Plan to Reincorporate in the United States
Wednesday September 12, 9:04 am ET
COMPANY TO HOST CONFERENCE CALL AT 10:00AM EDT


EDMONTON, BELLEVUE, WASHINGTON, Sept. 12 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News; the "Company") today announced that the Company's Board of Directors has approved a proposal to change its jurisdiction of incorporation from the federal jurisdiction of Canada to the State of Delaware in the United States of America through a plan of arrangement. Under the plan of arrangement, which is subject to shareholder and court approval, Biomira will migrate to the United States by creating a holding corporation based in the State of Delaware, Biomira Corporation, which will be the ultimate parent corporation of a successor corporation of the current Biomira and its subsidiaries. Biomira Corporation intends to establish its headquarters in or near Seattle, Washington.
ADVERTISEMENT


"We believe that reincorporation in Delaware is the right strategic move to increase long-term shareholder value," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "This move is intended to raise our profile in the U.S. financial markets, with the goals of increasing the visibility of our exciting product pipeline among U.S. institutional investors and providing access to a larger pool of investment capital. Additionally, we believe that relocating to a major biotechnology center such as Seattle will provide greater opportunity to attract and retain key personnel."

Upon the completion of the proposed arrangement, holders of common shares of Biomira Inc. will receive one-sixth of a share of common stock of Biomira Corporation in exchange for each common share of Biomira Inc., which will have the effect of a 6 for 1 reverse stock split of Biomira Inc. common shares.

"We believe that this effective reverse stock split should result in a higher trading price for the shares of Biomira Corporation and ultimately result in increased shareholder value," continued Dr. Kirkman. "A higher share price may allow investment in Biomira Corporation by institutional investors whose policies preclude investing in stock with lower share prices. Many brokerage firms prohibit using lower priced stocks in margin accounts. A higher price also is expected to benefit shareholders by reducing the risk of a NASDAQ Global Market delisting proceeding based on the minimum $1 share price rule."

"The relocation of our headquarters to the Seattle area is not expected to result in a significant change in our operations in Edmonton, Alberta," continued Dr. Kirkman. "We have a highly skilled, productive and dedicated workforce in Edmonton that we intend to maintain. However, a significant portion of our operations, particularly related to our small molecule development programs, is already in the U.S., and we believe that our Seattle area location will help us to attract the additional staff we need to advance these programs as rapidly and successfully as possible."

The transaction will be completed through a plan of arrangement, which will require the approval of two-thirds of the common and preference shares represented at a special meeting of Biomira's shareholders, voting as a class. Such a meeting is expected to take place in Edmonton, Alberta following the distribution of a definitive proxy statement/prospectus contained as part of a registration statement filed with the United States Securities and Exchange Commission (the "SEC") and receipt of an interim order with respect to the proposed plan of arrangement from the Alberta Court of Queen's Bench. Biomira Corporation today filed a registration statement on Form S-4 with the SEC that includes a preliminary proxy statement/prospectus covering the proposed plan of arrangement and the shares to be issued to Biomira's shareholders in the plan of arrangement. Assuming that the SEC declares the registration statement effective, the shareholders approve of the plan of arrangement, and the Alberta Court of Queen's Bench issues a final order approving the plan of arrangement, Biomira currently estimates that the transactions contemplated by the plan of arrangement should be completed in early 2008.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Conference Call and Webcast

Biomira's management will hold a conference call beginning at 10:00 a.m. EDT today, September 12, 2007. To listen to a live webcast of the call, visit www.biomira.com. Biomira intends to make a recording of the webcast available on the Biomira website and via telephone replay. It is expected that the archive of the webcast will be available approximately 15 minutes after completion of the discussion and will be posted for 90 days. It is expected that a replay will be available by phone approximately one hour after completion of the discussion and will be accessible for 7 days. Access numbers for this replay are:


416-640-1917, passcode 21246399 followed by the pound sign or
877-289-8525, passcode 21246399 followed by the pound sign

Forward Looking Statements

In order to provide Biomira's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements relating to the anticipated benefits of the proposed reincorporation of Biomira from Canada to the United States. These forward-looking statements represent Biomira's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to the proposed reincorporation transaction, Biomira's business and the general economic environment. Many of these risks and uncertainties are beyond Biomira's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include the possibility that the proposed arrangement and reincorporation may not be completed as a result of failure to obtain shareholder, judicial and/or regulatory approvals or for other reasons; that the anticipated benefits of the reincorporation, including our ability to increase our profile among U.S. institutional investors and to attract and retain scientific and administrative personnel by locating in a larger biotechnology center, may not be realized; the anticipated benefits of the effective reverse stock split, including a higher trading price for the common stock of Biomira Corporation and the attraction of institutional investors may not be realized; and the other risks and uncertainties described in the reports and other documents, including the registration statement on Form S-4, filed by either Biomira Inc. or Biomira Corporation with the Securities and Exchange Commission and/or Canadian regulatory authorities.

Although Biomira believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Biomira, you are encouraged to review the official corporate documents filed with the securities regulators in Canada and the United States, including the risk factors described in the registration statement on Form S-4 filed by Biomira Corporation with the Securities and Exchange Commission and on SEDAR.

Additional Information About the Arrangement/Reincorporation and Where to Find It

On September 12, 2007, Biomira Corporation, a Delaware corporation that will, if the arrangement is approved, become the parent corporation of a successor to Biomira Inc., a Canadian corporation, filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) containing a preliminary proxy statement/prospectus regarding the proposed plan of arrangement. We have also filed this registration statement on SEDAR. Investors and security holders of Biomira Inc. are urged to read the preliminary proxy statement/prospectus, which has not been declared effective by the SEC, and when and if it is available, the definitive proxy statement/prospectus filed with the SEC and on SEDAR. These documents as well as Biomira Inc.'s other filings with the SEC and Canadian regulatory authorities contain, or will contain, important information about Biomira Inc., Biomira Corporation, and the proposed plan of arrangement. The preliminary proxy statement/prospectus filed with the SEC by Biomira Corporation on September 12, 2007 and any other filings by Biomira Inc. or Biomira Corporation with the SEC may be obtained free of charge at the SEC's website, www.sec.gov. Similarly, the documents filed on SEDAR may be obtained free of charge at the SEDAR website, www.sedar.com. In addition, investors and security holders may obtain free copies of the documents Biomira Inc. and Biomira Corporation have filed with the SEC and/or Canadian regulatory authorities by contacting Biomira's Investor Relations Department at Biomira, Inc., 2011 - 94 St. Edmonton, AB, Canada T6N 1H1. Attn: Investor Relations, telephone: [phone], ext. 818.

Biomira Inc., Biomira Corporation, Robert L. Kirkman, M.D., Chief Executive Officer of both Biomira Inc. and Biomira Corporation, Edward A. Taylor, Chief Financial Officer of both Biomira Inc. and Biomira Corporation, and certain of Biomira Inc. and Biomira Corporation's other executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of Biomira Inc. in favor of the arrangement. The other executive officers and directors of Biomira Inc. or Biomira Corporation who may be participants in the solicitation of proxies in connection with the arrangement have not been determined as of this date. A description of the interests of Dr. Kirkman, Mr. Taylor, and other executive officers of Biomira Inc. and Biomira Corporation is set forth in the preliminary proxy statement/prospectus filed as part of the registration statement on Form S-4 described above. Investors and security holders may obtain more detailed information regarding the direct and indirect interests of Dr. Kirkman, Mr. Taylor, and other executive officers and directors in the arrangement by reading the preliminary proxy statement/prospectus filed with the SEC on September 12, 2007 as part of the registration statement on Form S-4 and, when and if it becomes available, the definitive proxy statement/prospectus.




--------------------------------------------------------------------------------
Source: Biomira Inc.

[philippf]

Antwort auf Beitrag Nr.: 31.547.872 von yoppu am 12.09.07 16:01:05

In Kürze:
• Firma will nach Delaware umziehen (Amerikanische Ostküste)
• Aktien-Resplit 1:6 geplant
• Hat alles keinen signifikanten Einfluss auf Tagesgeschäft in Edmonton

[psycho214]

Biomira Announces Plan to Reincorporate in the United States
COMPANY TO HOST CONFERENCE CALL AT 10:00AM EDT
EDMONTON, BELLEVUE, WASHINGTON, Sept. 12 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) (the 'Company') today announced that the Company's Board of Directors has approved a proposal to change its jurisdiction of incorporation from the federal jurisdiction of Canada to the State of Delaware in the United States of America through a plan of arrangement. Under the plan of arrangement, which is subject to shareholder and court approval, Biomira will migrate to the United States by creating a holding corporation based in the State of Delaware, Biomira Corporation, which will be the ultimate parent corporation of a successor corporation of the current Biomira and its subsidiaries. Biomira Corporation intends to establish its headquarters in or near Seattle, Washington.

'We believe that reincorporation in Delaware is the right strategic move to increase long-term shareholder value,' said Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. 'This move is intended to raise our profile in the U.S. financial markets, with the goals of increasing the visibility of our exciting product pipeline among U.S. institutional investors and providing access to a larger pool of investment capital. Additionally, we believe that relocating to a major biotechnology center such as Seattle will provide greater opportunity to attract and retain key personnel.'

Upon the completion of the proposed arrangement, holders of common shares of Biomira Inc. will receive one-sixth of a share of common stock of Biomira Corporation in exchange for each common share of Biomira Inc., which will have the effect of a 6 for 1 reverse stock split of Biomira Inc. common shares.

'We believe that this effective reverse stock split should result in a higher trading price for the shares of Biomira Corporation and ultimately result in increased shareholder value,' continued Dr. Kirkman. 'A higher share price may allow investment in Biomira Corporation by institutional investors whose policies preclude investing in stock with lower share prices. Many brokerage firms prohibit using lower priced stocks in margin accounts. A higher price also is expected to benefit shareholders by reducing the risk of a NASDAQ Global Market delisting proceeding based on the minimum $1 share price rule.'

'The relocation of our headquarters to the Seattle area is not expected to result in a significant change in our operations in Edmonton, Alberta,' continued Dr. Kirkman. 'We have a highly skilled, productive and dedicated workforce in Edmonton that we intend to maintain. However, a significant portion of our operations, particularly related to our small molecule development programs, is already in the U.S., and we believe that our Seattle area location will help us to attract the additional staff we need to advance these programs as rapidly and successfully as possible.'

The transaction will be completed through a plan of arrangement, which will require the approval of two-thirds of the common and preference shares represented at a special meeting of Biomira's shareholders, voting as a class. Such a meeting is expected to take place in Edmonton, Alberta following the distribution of a definitive proxy statement/prospectus contained as part of a registration statement filed with the United States Securities and Exchange Commission (the 'SEC') and receipt of an interim order with respect to the proposed plan of arrangement from the Alberta Court of Queen's Bench. Biomira Corporation today filed a registration statement on Form S-4 with the SEC that includes a preliminary proxy statement/prospectus covering the proposed plan of arrangement and the shares to be issued to Biomira's shareholders in the plan of arrangement. Assuming that the SEC declares the registration statement effective, the shareholders approve of the plan of arrangement, and the Alberta Court of Queen's Bench issues a final order approving the plan of arrangement, Biomira currently estimates that the transactions contemplated by the plan of arrangement should be completed in early 2008.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Conference Call and Webcast

[psycho214]

Antwort auf Beitrag Nr.: 31.549.172 von psycho214 am 12.09.07 17:21:52

sorry doppelt!!

[donnerpower]

Wird vom Markt nicht gut aufgenommen..ein Resplit ist auch nie was gutes!

...und weiter warten angesagt bis Tag X !!!

[psycho214]

Antwort auf Beitrag Nr.: 31.553.815 von donnerpower am 12.09.07 22:34:48

tja aber wann ist tag x ...

vor oder nach dem splitt - dass ist hier die frage....

[DausendUndMehr]

Warten bis zum Tag "X"


oder bis zum Tag

[philippf]

NAMENSÄNDERUNG!!!!!!!
http://www.940news.com/nouvelles.php?cat=22&id=927165
Biomira will change name to Oncothyreon following move to relocate in to the U.S. at 18:30 on September 27, 2007, EST.

THE CANADIAN PRESS

EDMONTON - Cancer treatment developer Biomira Inc. (TSX:BRA) said Thursday it plans to change its name to Oncothyreon Inc. as part of a previously announced plan to move its headquarters to Seattle.

The relocation plan requires a complex process consisting of "two triangular mergers" with the net effect that common stock of the current Biomira will be exchanged for shares of a new U.S. company registered in Delaware, ending Canadian incorporation.

Shareholders will be asked to exchange six of the old Biomira Corp. shares in return for one share of the new U.S.-based Biomira Inc., resulting in a six-for-one stock consolidation.

The transaction requires approval by holders of two-thirds of the common and preference shares represented at a special meeting of Biomira stockholders.

"Over the past year, we have successfully executed a strategy to create and realize new opportunities to create sustainable value for our company, our shareholders and for patients," stated CEO Robert Kirkman.

"We are a different company today than we were just twelve months ago, and our decision to change our name to Oncothyreon reflects that transformation."

Oncothyreon is derived from the Greek words for "tumour" and "shield" and "appropriately describes our goal to develop new therapies that protect against the deadly effects of cancer," Kirkman said.

If the plan receives all the necessary approvals, Oncothyreon will trade on the Nasdaq under the symbol Nasdaq:ONTY and on the Toronto Stock Exchange under TSX:ONY.

On the TSX Thursday, Biomira shares closed at 95 cents, up two cents or two per cent.

[psycho214]

Antwort auf Beitrag Nr.: 31.557.627 von DausendUndMehr am 13.09.07 11:09:20

Ich hoffe der Tag x kommt noch.

die Newslage ist nicht berauschend und das die umziehen auch nicht so.

trau mich gar nicht so richtig rein in diese aktie.....

die frage ist , vor oder nach dem split kaufen???

[freetibet]

Biomira to present at the BIO InvestorForum 2007
Wednesday October 3, 10:30 am ET


EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the BIO InvestorForum 2007 in San Francisco at 2:45pm PDT/5:45pm EDT on Wednesday, October 10.

The presentation is planned for a live webcast and can be accessed at:


http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIO…

and at the Biomira website (www.biomira.com).

Biomira intends to make a recording of the webcast available on the Biomira website approximately one hour after completion of the presentation. The presentation will be archived for 90 days.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[psycho214]

oh oh oh

was iss passiert??

zulassung futsch??

[donnerpower]

Antwort auf Beitrag Nr.: 32.054.928 von psycho214 am 17.10.07 19:51:40

Ungeduldige steigen aus..vorm Split leider immer so

[psycho214]

October 24, 2007 - 8:02 AM EDT

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

BIOM 0.71 -0.03

Today 5d 1m 3m 1y 5y 10y



BRA:CA 0.70 -0.01

Today 5d 1m 3m 1y 5y 10y



New data may help guide the clinical development of Biomira's PX-478 and PX-866
EDMONTON, Oct. 24 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) announced today that preclinical data for its targeted anti-cancer drug candidates PX-478 and PX-866 were presented in a poster session yesterday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held October 22-26 in San Francisco. The data may help to guide future clinical studies of these innovative small molecule compounds. A Phase 1 trial of PX-478 in patients with advanced metastatic cancers is in progress. Biomira expects to file an Investigational New Drug application for PX-866 early in 2008.

The PX-478 data (Abstract #284) provide insight into how and under what conditions the compound inhibits the activity of its target, the transcription factor hypoxia-inducible factor-1alpha (HIF-1 alpha). PX-478 works by a unique mechanism, decreasing both HIF-1 alpha gene expression and protein synthesis. This leads to a significant reduction in the amount and activity of HIF-1 alpha in the tumor. The results show that PX-478 is highly specific for HIF-1 alpha and does not inhibit the levels of any of the other proteins tested. Additionally, this inhibitory effect is independent of the tumor suppressor genes VHL and p53, genes that may significantly impact how cancer cells respond to a variety of therapeutic interventions.

'Hypoxia is a feature of many solid tumors and HIF-1 alpha is the tumor's primary survival response to this stress,' said Dr. Garth Powis, Director, Center for Targeted Therapy, MD Anderson Cancer Center, Houston, Texas, and senior author of the abstract. 'Inhibiting both transcription and translation is a double hit that dramatically decreases the activity of HIF-1 alpha, which regulates numerous pro-cancer pathways. That this reduction in HIF-1a activity occurs in cells regardless of oxygenation, p53 and VHL status suggests that PX-478 may have clinical activity in diverse cancers. The elucidation of the mechanisms by which PX-478 inhibits HIF-1 alpha confirms the compound's specificity and may aid the direction of the clinical program with respect to identifying specific cancer indications and potential combination regimens for this promising agent.'

A second poster reported data from preclinical studies of PX-866, a small molecule inhibitor of phosphatidylinositol-3-kinase (PI-3 kinase) (Abstract #257). These studies evaluated mutations in several cancer-related genes that could be predictive of response to PX-866 in animal tumor models. In a range of different tumor types, response to PX-866 correlated with wildtype Ras, while mutations in Ras were associated with PX-866 resistance. These results suggest that selecting for patient Ras status could improve the clinical benefit of PX-866.

Dr. Powis noted, 'Biomarkers that are predictive of response to particular therapies are playing an increasingly significant role in optimizing cancer treatment for individual patients. The PX-866 biomarker data suggest that it may be possible to identify those patients most likely to respond to the agent. These data also provide insight into how we could combine PX-866 with other agents based on the molecular profiles of specific cancers. Together, this knowledge may help to speed the clinical development of this promising new PI-3 kinase inhibitor'

Both posters will be available later today on the Biomira website, www.biomira.com.

About PX-478

PX-478 is a potent inhibitor of HIF-1 alpha, a protein target whose levels are elevated in a wide range of tumors. The protein is a key factor in the response of a cancer cell to hypoxia (lack of oxygen), including the angiogenic cascade that allows tumors to establish new blood vessels essential to their survival and growth. Inhibition of angiogenesis is a validated approach to treating cancer.

In preclinical studies, PX-478 demonstrated marked antitumor activity when delivered orally, showing tumor regression and long growth delay, both of which correlated to the HIF-1 alpha levels of the tumor models. The wide variety of models that showed sensitivity to PX-478 presents a large potential market for this product candidate. The ability to combine PX-478 with radiation therapy may further expand the opportunities for this novel compound.

About PX-866

PX-866 is an irreversible inhibitor of the phosphatidylinositol-3-kinase (PI3 kinase)/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer especially ovarian, colon, head and neck, urinary tract, and cervical cancers, where it leads to increased proliferation, inhibition of apoptosis (programmed cell death) and resistance to antitumor therapy. In preclinical studies, PX-866 has been shown to induce prolonged inhibition of tumor PI3 kinase signaling following both oral and intravenous administration. The compound also has been shown to have good in vivo anti-tumor activity in tumor models of human colon, pancreatic, breast, ovarian, prostate and lung cancer, as well as intracranial glioblastoma.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the pre-clinical and clinical development of PX-478 and PX-866; the therapeutic and commercial potential of PX-478 and PX-866; the filing of an investigational new drug application for PX-866 and the timing thereof; and future clinical development plans. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believes', 'anticipates', 'plans', 'expects', 'will', 'intends', 'potential', 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements express Biomira's current expectations, intentions, plans and forecasts of future events based on our experience and our assessment. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting relevance of pre-clinical data to the subsequent clinical development of PX-478 and PX-866; the clinical development of PX-478 and PX-866; the therapeutic and commercial potential of PX-478 and PX-866; the filing of an investigational new drug application for PX-866 and the timing thereof; and future clinical development plans. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Biomira Inc.

[freetibet]

Biomira to present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
Tuesday October 30, 8:00 am ET


EDMONTON, Oct. 30 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News) today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference in New York at 11:15am ET/8:15am PT on Tuesday, November 6, 2007.

The presentation is planned for a live webcast and can be accessed at:

http://www.wsw.com/webcast/rrshq12/biom

and at the Biomira website (www.biomira.com).

Biomira intends to make a recording of the webcast available on the Biomira website approximately one hour after completion of the presentation. The presentation will be archived for 90 days.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[MasaRatti]

Biomira Announces Third Quarter 2007 Financial Results

EDMONTON, ALBERTA, CANADA — November 1, 2007 - Biomira Inc. ("Biomira" or the "Company") (NASDAQ:BIOM) (TSX:BRA) today reported a consolidated net loss of $6.8 million or $0.06 per basic and diluted share for the three months ended September 30, 2007, compared to $3.7 million or $0.04 per basic and diluted share for the same period in 2006. Revenue was $1.2 million for the 2007 third quarter, compared with $1.7 million for the year earlier quarter. Total operating expenses were $7.9 million for the quarter ended September 30, 2007, compared with $5.6 million for the same quarter in 2006. All results are in Canadian dollars.

The increase in net loss of $3.1 million primarily resulted from lower revenues of $0.5 million and increased operating expenses of $2.3 million. The lower revenues resulted from reduced contract research and development funding as a result of transitioning the responsibility for the clinical development and regulatory activities for Stimuvax to Merck KGaA of Darmstadt, Germany ("Merck KGaA") during 2006. The increase in operating expenses is primarily attributable to professional fees associated with the Company's proposed reincorporation into the United States. Also contributing to the increase in operating expenses is higher amortization expense related to intangible assets acquired as part of the ProlX acquisition in October 2006. Partially offsetting these variances is lower research and development expenses, once again resulting from transitioning the responsibility for the clinical development and regulatory activities for Stimuvax to Merck KGaA during 2006.

Financial results for the nine months ended September 30, 2007 reflect a consolidated net loss of $18.4 million or $0.16 per basic and diluted share compared to $13.5 million or $0.15 per basic and diluted share for the same period in 2006.

As at September 30, 2007, cash and cash equivalents and short-term investments were $20.5 million compared to $33.0 million at the end of 2006, a decrease of $12.5 million. Major contributors to the net change included $10.6 million used in operations, $0.5 million used in payment of accrued business acquisition and share issuance costs, and $1.1 million used in the purchase of capital and intangible assets. Included in cash used in operations is an increase in inventory of $3.5 million related to Stimuvax manufacturing activities, which resumed in the first quarter of 2007 as a result of the commencement of the Merck KGaA-led phase 3 trial of Stimuvax in non-small cell lung cancer. Also included in cash used in operations are proceeds from collaborative agreements of $5.6 million related to milestone payments received under the provisions of the collaboration between Biomira and Merck KGaA.

About Biomira
Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements
In order to provide our investors with an understanding of our current results and future prospects, this release may contain statements that are forward looking. These forward-looking statements represent Biomira's intentions, plans, expectations and beliefs and are based on our experience and our assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including those predicting adequacy of financing and reserves on hand; currency exchange rate fluctuations; changes in general accounting policies; and general economic factors. Although we believe that any forward-looking statements that may be contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in Canada and the United States, including the risk factors described in our 2006 Annual Report and in the amended registration statement on Form S-4 filed by Oncothyreon Inc.

[donnerpower]

Oncology dominates Merck Serono pipeline, more acquisitions wanted
by Vincent Landon

BERLIN, Oct 25 (APM) - Oncology dominates Merck Serono's pipeline, according to figures released at the company's R&D update on Wednesday. However the Merck group said it is not counting on this alone to drive growth and is seeking more acquisitions.

Overall, 41 pharma projects were announced, ranging from Phase I to III or submitted for regulatory approval.

Of these, 22 are in cancer - eight in Phase 1, seven in Phase II, six in Phase III and one submitted.

By contrast, Merck Serono has only seven projects in neurodegenerative diseases, four in autoimmune and inflammatory diseases, two in fertility and two in endocrinology.

In total, six projects were added to the clinical pipeline and 11 were de-prioritized or stopped, Darmstadt-based Merck said.

Among the late-stage projects added were two Erbitux studies – a Phase III for gastric cancer and a Phase II for breast cancer – and atacicept Phase II/III studies for lupus.

When Merck announced its takeover of Serono in September last year, the two companies' pipelines had 28 products in development of which 12 projects were dedicated to oncology and five to neurology. There were five projects in Phase III.

Merck is trying to get Erbitux, its second-best seller after Rebif, approved to fight lung cancer and other indications beyond its current use against tumours of the colon, head and neck.

The new Phase III portfolio incudes Erbitux in four additional indications (adjuvant colon cancer, SCCHN, NSCLC and gastric cancer, safinamide in both early and mid-to late stage Parkinson's and Rebif new formulation in CIS).

Erbitux third-quarter sales rose 36% to 118 million euros while Rebif sales rose 4.1% to 306 million euros. Rebif is set to face severe competition from about 2011.

"The goals of our review were to create as much value as possible from our current compounds by better managing risk across the portfolio and directing resources to our most promising projects," Elmar Schnee, the board member responsible for the pharmaceuticals business said in a statement.

Merck, which was driven for many years by Glucophage (metformin) also announced it will stop its diabetes research and partner out any current programmes.

The company has at least two other diabetes drug in its pipeline. The first is EMD387008, which is in Phase II trials in patients with Type II diabetes and the second is an unnamed Dipeptidyl Peptidase IV (DPP IV) inhibitor, which is also in Phase II clinical trials.

Over the coming years, Merck anticipates the following submissions:

2007: sapropterin for mild to moderate phenylketonuria and Erbitux for first line therapy in colorectral cancer (both EMEA)

2008: Erbitux first line NSCLC stage 3b/4, Erbitux first line SSCHN, recurrent and metastatic (both EMEA)

2009/10: Rebif new formulation for CIS, safinamide for early/late stage Parkinson, oral cladribine tablets for relapsing forms of multiple sclerosis (EMEA & FDA)

2011: Erbitux for gastric cancer (EMEA); Stimuvax for NSCLC & Atacicept for Lupus (EMEA & FDA)

2012: Erbitux for adjuvant colon cancer (EMEA) and Cilengitide for glioblastoma (EMEA & FDA)

ACQUISITIONS

Chief executive of the pharma and chemicals company Karl-Ludwig Kley told a conference call that Merck aims to reach sales of 10 billion euros by 2010, compared with the 6.26 billion euros it earned in 2006.

"We can only reach this goal through acquisitions," he said without elaborating on possible targets or whether they would be in the chemicals or pharma domain.

Merck said on Wednesday third-quarter profit fell 74.9% to 36.2 million euros on write downs from the purchase of Switzerland's Serono.

Total revenues leapt 60.6% to 1.74 billion euros and the pharmaceuticals business accounted for more than 70% of total revenues.

Its Merck Serono unit saw revenues almost double to 1.09 billion euros from 476 million euros in the third quarter last year.

[freetibet]

Biomira Inc. receives Nasdaq delisting notification
Monday November 5, 8:16 am ET


EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News; the "Company") today announced that on November 2, 2007, it received a letter from The Nasdaq Stock Market, Inc. ("Nasdaq") notifying the Company that for the 30 consecutive trading days preceding the date of the letter, the bid price of the Company's common stock had closed below the $1.00 per share minimum required for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Marketplace Rule 4450(a)(5). The letter further notified the Company that, in accordance with Nasdaq Marketplace Rule 4450(e)(2), the Company will be provided 180 calendar days, or until April 30, 2008, to regain compliance with the minimum bid price requirement. Compliance will be achieved if the bid price per share of the Company's common stock closes at $1.00 per share or greater for a minimum of ten (10) consecutive trading days prior to April 30, 2008.

"We expect that we will regain compliance with the minimum bid price rule as one result of the reverse stock split included in the plan of arrangement to be considered at the upcoming special meeting of our shareholders," said Robert L. Kirkman, M.D. President and CEO of Biomira. "Ensuring compliance with this rule was a major reason the Board of Directors of Biomira included the reverse split in the plan. We also believe that a higher trading price may allow investment in Biomira by institutional investors whose policies preclude investing in stock with lower share prices."

"The initiatives we have put in place over the last year are each part of a strategic plan to create long-term sustainable value for our shareholders," continued Dr. Kirkman. "These initiatives include the expansion of our clinical development pipeline with the acquisition of ProlX Pharmaceuticals Inc.; the advancement of Stimuvax® into a global Phase 3 trial; the signing of amended and restated collaboration and supply agreements with Merck KGaA, our partner for Stimuvax; and our plan to reincorporate in the United States and revise our capital structure. We are looking forward to the future we believe these steps will make possible, under our planned new name, Oncothyreon Inc."

The Company has previously announced a special meeting of shareholders to be held at 9:00 a.m. (Mountain Time) in Edmonton, Alberta on December 4, 2007. At the meeting, the Company's shareholders will consider a special resolution to approve a plan of arrangement under which the Company will migrate to the United States by creating a Delaware holding corporation, Oncothyreon Inc., which will become the ultimate parent corporation of a successor to Biomira and its subsidiaries. If the plan of arrangement is approved by shareholders of Biomira and other conditions are satisfied, including the issuance by the Alberta Court of Queen's Bench of a final order approving the plan of arrangement, each outstanding common share of Biomira Inc. will be exchanged for one-sixth of a share of common stock of Oncothyreon Inc., which will have the effect of a 6 for 1 reverse stock split of Biomira Inc. common shares.

If compliance with Nasdaq's Marketplace Rules is not achieved by April 30, 2008, and if the Company is not eligible for an additional compliance period, Nasdaq will provide notice that the Company's common stock will be delisted from the Nasdaq Global Market. In the event of such notification, the Company would have an opportunity to appeal Nasdaq's determination or to apply to transfer its common stock to the Nasdaq Capital Market.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws in the United States and Canada. Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to compliance by either Biomira or Oncothyreon with applicable Nasdaq listing requirements; the impact of the proposed effective reverse stock split on compliance with Nasdaq listing requirements; benefits currently anticipated to be derived from the proposed reincorporation transaction; and Biomira's business, including, without limitation, statements related to our agreements with Merck KGaA, the therapeutic and commercial potential of Stimuvax and other drug candidates in our clinical development pipeline, benefits anticipated from the acquisition of ProlX, future clinical development plans, the details of our planned clinical trials, the regulatory approval process and the general economic environment. A number of factors could cause actual results or events to differ materially from those anticipated by forward-looking statements. In particular, neither Biomira nor Oncothyreon can predict whether the conditions to completion of the reincorporation, including shareholder and judicial approvals, will be obtained. In addition, even if the reincorporation and the associated effective reverse stock split are approved and implemented, neither Biomira nor Oncothyreon can provide any assurances that they will continue to satisfy Nasdaq listing requirements. The business of Biomira and, assuming completion of the arrangement, the business of Oncothyreon are subject to numerous risks and uncertainties associated with biopharmaceutical development companies, including risks relating to the results of clinical development and regulatory approvals. For more information about the risks and uncertainties facing Biomira and Oncothyreon, please refer to the registration statement on Form S-4 filed by Oncothyreon with the Securities and Exchange Commission (SEC) and by Biomira with Canadian regulatory authorities as well as to the respective companies' other filings in the United States with the SEC and in Canada on SEDAR.

Additional Information About the Arrangement/Reincorporation and Where to

Find It

On October 29, 2007, Oncothyreon Inc., a Delaware corporation that will, if the arrangement is approved, become the parent corporation of a successor to Biomira Inc., a Canadian corporation, filed an amended registration statement on Form S-4 with the Securities and Exchange Commission containing a proxy statement/prospectus regarding the proposed plan of arrangement. Biomira has also filed this amended registration statement on SEDAR. Investors and security holders of Biomira Inc. are urged to read the proxy statement/prospectus filed with the SEC and on SEDAR. These documents as well as Biomira Inc.'s other filings with the SEC and Canadian regulatory authorities contain, or will contain, important information about Biomira Inc., Oncothyreon Inc., and the proposed plan of arrangement. The amended proxy statement/prospectus filed with the SEC by Oncothyreon Inc. on October 29, 2007 and any other filings by Biomira Inc. or Oncothyreon Inc. with the SEC may be obtained free of charge at the SEC's website, www.sec.gov. Similarly, the documents filed on SEDAR may be obtained free of charge at the SEDAR website, www.sedar.com. In addition, investors and security holders may obtain free copies of the documents Biomira Inc. and Oncothyreon Inc. have filed with the SEC and/or Canadian regulatory authorities by contacting Biomira's Investor Relations Department at Biomira, Inc., 2011 - 94 St. Edmonton, AB, Canada T6N 1H1. Attn: Investor Relations, telephone: [phone], ext. 818.

Biomira Inc., Oncothyreon Inc., Robert L. Kirkman, M.D., Chief Executive Officer of both Biomira Inc. and Oncothyreon Inc., Edward A. Taylor, Chief Financial Officer of both Biomira Inc. and Oncothyreon Inc., and certain of Biomira Inc. and Oncothyreon Inc.'s other executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of Biomira Inc. in favor of the arrangement. The other executive officers and directors of Biomira Inc. or Oncothyreon Inc. who may be participants in the solicitation of proxies in connection with the arrangement have not been determined as of this date. A description of the interests of Dr. Kirkman, Mr. Taylor, and other executive officers of Biomira Inc. and Oncothyreon Inc. is set forth in the preliminary proxy statement/prospectus filed as part of the registration statement on Form S-4 described above. Investors and security holders may obtain more detailed information regarding the direct and indirect interests of Dr. Kirkman, Mr. Taylor, and other executive officers and directors in the arrangement by reading the amended proxy statement/prospectus filed with the SEC on October 29, 2007 as part of the registration statement on Form S-4 and, when it becomes available, the definitive proxy statement/prospectus.

--------------------------------------------------------------------------------
Source: Biomira Inc.

[BULLE2004]

Antwort auf Beitrag Nr.: 32.292.039 von freetibet am 05.11.07 15:19:53

einfach nur eine schreckliche Entwicklung bei Biomira.
Ich glaube hier ist wirklich nichts mehr zu holen.
Oder gibt es doch noch ein Quentchen Hoffnung?

[donnerpower]

Antwort auf Beitrag Nr.: 32.298.973 von BULLE2004 am 05.11.07 20:44:10

Ich denke wenn wir von der dritten Phase reden, muss ich sagen da hat sich nigs geändert ..habe immer noch ein gutes Gefühl..solange keine News kommen kann es nur bedeuten die Droge wirkt!

Die aktuelle Lage dagegen sieht auf dem ersten Blick nicht so schön aus..aber das hätte man so sehen müssen..wenn Biomira noch keine Haupteinnahmequelle hat.

Das der Kurs heute weiter eingebrochen ist kann ich nur belächeln..eine Reserve Split ist doch schon längst veröffentlich somit wird ein delisting an der Nasdaq umgangen.

Zeigen wir weiter Geduld

[huetchen6]

Antwort auf Beitrag Nr.: 32.302.062 von donnerpower am 06.11.07 00:25:29

der kurs wird heute noch weiter fallen, dann können wir einsteigen, phase2 3 jahre leben....

[donnerpower]

Antwort auf Beitrag Nr.: 32.311.647 von huetchen6 am 06.11.07 17:30:11

Überlege mir ne Daytrader Posi aufzubauen...

[philippf]

Das habe ich auch schon überlegt, aber ich fürchte dafür ist der Handel zu gering... Da kann es schonmal sein, dass man die Dinger dann nicht mehr loswird...

[schmacki]

Wenns so weitergeht macht der Aktiensplit auch keinen Sinn.

[BIOMIRA]

so ich kauf jetzt FETT nach
aber nur drüben

[schmacki]

Antwort auf Beitrag Nr.: 32.497.955 von BIOMIRA am 20.11.07 17:38:35

Nachgekauft?:rolleyesas ist ja ein Fass ohne Boden!

[BULLE2004]

Antwort auf Beitrag Nr.: 32.497.955 von BIOMIRA am 20.11.07 17:38:35

Spende das Geld lieber Bedürftigen als das Geld zu verbrennen.

[BIOMIRA]

Antwort auf Beitrag Nr.: 32.514.770 von BULLE2004 am 21.11.07 18:40:24

setze auf eine technische gegenreaktion
dann kommt panik hinzu (shortsquezze)
evtl. nach dem taxselling(das ist voll im gange)

[BIOMIRA]

indikatoren total überverkauft

[BIOMIRA]

denke mal die 0,8 sehen wir schneller als hier jemand vermutet

[MasaRatti]

Antwort auf Beitrag Nr.: 32.574.083 von BIOMIRA am 26.11.07 20:01:46

Hi zusammen,
gerade weil der Kurs von Oncothyreon(Biomira) jetzt sooo
weit unten steht, bin ich noch immer der Meinung, das Merck-Serono
die Klitsche übernehmen sollte ... warum ... die Produktion von
Stimuvax liegt in den Händen von Biomira, es fallen immermal Meilensteinzahlungen an und die
anderen Produkte (wenn mögliche Zukunftsdaten aussichtsreich wären!)
wären auch passend für die Pipeline und Ausrichtung von Merck in der
Onkologie ! Was meint Ihr, alles sooo abwägig

[BIOMIRA]

feiner gewinn
denke es geht weiter

[BIOMIRA]

http://bigcharts.marketwatch.com/markets/screener.asp?exchan…
tagesgewinner
nun werden neue investoren neugierig
gut fürsteigende kurse
den shorties wird das lachen vergehen

[BIOMIRA]

und wieder bei den tagesgewinnern dabei
läuft supi
wann fällt wieder der dollar?
next week?

[BIOMIRA]

Antwort auf Beitrag Nr.: 32.686.088 von BIOMIRA am 06.12.07 17:15:16

0,69

[BIOMIRA]

Antwort auf Beitrag Nr.: 32.690.172 von BIOMIRA am 06.12.07 21:45:54

cool wenn man bei seiner aktie bleibt.
bin ab sofort mit allen positionen im gewinn.
denke mal die 1-dollar schwelle sehen wir next week

[MasaRatti]

Moin,
ja, jetzt sind die Umsätze auch endlich mal gestiegen von unter
100.000 auf fast 1.000.000 - das ist sicherlich kein Zufall !
Auch die Kaufpakete zu 250.000 Stück und mehr, machen doch
Hoffnung ! Mal sehen wie der Chart sich entwickelt, Rebound bei hohen
Umsätzen bis x,y Dollar

[huetchen6]

Antwort auf Beitrag Nr.: 32.692.316 von MasaRatti am 07.12.07 06:41:06

Der Weg für Oncothryon ist frei.Jetzt kommen neue Investoren.Biom.benötigt bis Freigabe noch viel Geld, woher nehmen wenn nicht stehlen.Tatsache ist, die wo jetzt einsteigen,bekommen die Aktie zugünstig, die muss jetzt rauf. Die wo bei ca.25 Cent gekauft haben können spielen, aber nur einmal,dann ist ihre Aktie fort, für nen Apfel u.nen Ei.

Glaube nicht wenn etwas daran ist mit Provenge(Dendr) u. FDA, das es Stimuvax auch so geht,hier läuft die Start - Studie mit 1300
Personen, wenn die Ergebnisse aus 30 Ländern u.300 Versuchsstadionen eingeflogen kommen, ist es fakt.
Die Aktie muss nach oben.

[Bullus]

Wird heute in USA oder Canada die Aktie nicht gehandelt, oder warum geht da kein Stück um......

[huetchen6]

Antwort auf Beitrag Nr.: 32.728.171 von Bullus am 11.12.07 16:34:38

in Amerika, unter ONTY, Kanada ist scheinbar noch nicht soweit.
(ONY)

[Bullus]

Antwort auf Beitrag Nr.: 32.728.312 von huetchen6 am 11.12.07 16:43:39

Tut mir leid, aber das verstehe ich nicht. Hab ich was verpaßt. Hat sich der Name geändert, oder wie....

[huetchen6]

Antwort auf Beitrag Nr.: 32.728.682 von Bullus am 11.12.07 17:07:40

ja, gehe auf Biomira suchen, in Google, Termin 05.12.07, da steht alles drin.

[Bullus]

Antwort auf Beitrag Nr.: 32.728.885 von huetchen6 am 11.12.07 17:22:51

ja jetzt hab ich was gefunden. Das da aber keiner was schreibt. Platz genug hier im Thread wäre ja sicherlich gewesen.
Ich verstehe das so, dass es für 6 Biomira 1 Aktie der neuen Firma gibt. Mal sehen wie das so weitergeht. Ach ja, gibt es da schon ein entsprechendes Forum

[huetchen6]

Antwort auf Beitrag Nr.: 32.729.329 von Bullus am 11.12.07 17:56:09

ja, 6:1 u. Oncothyreon die Umbenennung, in USA als Holding.

[freetibet]

Oncothyreon to begin trading today on NASDAQ and TSX
Tuesday December 11, 8:00 am ET


BELLEVUE, WA, Dec. 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY - News; TSX:ONY - News) today announced that its common stock will begin trading on the Nasdaq Global Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY at the opening of trading today. Oncothyreon Inc. is the new name for the former Biomira Inc., as the result of a plan of arrangement under which Biomira has moved its jurisdiction of incorporation from Canada to the state of Delaware in the United States. Shareholders of the former Biomira received one share of Oncothyreon common stock for each six shares of Biomira that they held, and the trading price today will reflect this effective reverse split.
ADVERTISEMENT


"Today represents a major milestone in our plan for Oncothyreon to become a leading developer of innovative therapeutic products in oncology," said Robert L. Kirkman, M.D. President and Chief Executive Officer of Oncothyreon. "Oncothyreon begins its new existence with a strong product pipeline of therapeutic vaccines and targeted small molecules for the treatment of cancer. We intend to focus on moving this pipeline forward as rapidly as possible, both through internal efforts and potential partnerships, while we continue to seek new product opportunities through in-licensing and acquisition."

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements relating to the clinical development of its products and future business plans. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the speed of clinical development of Oncothyreon's products and future business plans and the other risks and uncertainties described in the reports and other documents filed by either Biomira Inc. or Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed by either Biomira Inc. or Oncothyreon Inc. with the securities regulators in United States and Canada with the SEC and on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

--------------------------------------------------------------------------------
Source: Biomira Inc.